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Abstract 
 
Efforts made to improve the scope of palladium-catalyzed carboetherification 
and carboamination reactions are illustrated herein, and strategies for 
overcoming various limitations to the method are discussed. As described in this 
thesis, the synthesis of bis, fused and poly-substituted tetrahydrofurans, 1,3-
oxazolidines, benzopyrans and benzoxepines was achieved through the 
palladium-catalyzing coupling of γ-hydroxy alkenes, O-vinyl-1, 2-amino alcohols, 
homoallylphenols and 2-(pent-4-en-1-yl)phenols with aryl and alkenyl halides, 
respectively. The synthesis of the aforementioned heterocycles represents a 
significant advancement in the methodology toward the eventual application of 
natural product synthesis, especially the annonaceous acetogenins.  
In Chapter 2, a novel strategy for the synthesis of bis and fused 
tetrahydrofurans is described. Sequential Pd-catalyzed carboetherification 
reactions were performed to yield bis and fused THFs, which enabled access into 
biologically active compounds such as the annonaceous acetogenins. As 
described in Chapter 3, the diastereoselectivity of Pd-catalyzed 
carboetherification reactions of substrates bearing internal alkenes was improved 
by employing S-Phos, an electron-rich, bulky monodentate biaryl ligand, which 
promoted reductive elimination and suppressed β-hydride elimination. As a 
result, the synthesis of poly-substituted tetrahydrofurans was achieved in 
excellent diastereoselectivity, and biologically active compounds possessing this 
motif, such as Simplakidine A, a cytotoxic marine natural product, may be 
produced using the proposed methodology. In Chapter 4, the synthesis of 1,3-
oxazolidines using a catalyst system based on S-Phos is described. The use of 
S-Phos promoted reductive elimination, which was disfavored due to the 
presence of electron withdrawing substituents on the substrate. Through the 
  
xiii 
work described in this thesis, 1,3-oxazolidines, an important structural motif in 
organic synthesis, can now be obtained using Pd-catalyzed carboamination 
reactions. A catalyst system composed of Pd2(dba)3/S-Phos also proved to be 
useful for the production of benzopyrans, which are common in antioxidants and 
were previously inaccessible through our methodology. As outlined in Chapter 5, 
the scope of the methodology was effectively expanded to include 
homoallylphenols, highlighting the ability of the catalyst to overcome entropic 
effects and the low nucleophilicity of phenols. Heterocycles containing 6-
membered rings were produced in a convergent manner, allowing access into 
motifs common in biologically active materials. In Chapter 6, the methodology 
was further extended towards benzoxepines, enabling the synthesis of unique, 
biologically relevant materials. 
  
1 
Chapter 1: Background and Limitations of Palladium-
Catalyzed Carboamination and Carboetherification 
Reactions  
 
1.1 Background and Significance  
Saturated heterocycles are commonplace structural units in natural products 
and biologically active compounds. Significantly, natural products containing 
tetrahydrofurans and benzopyrans show unique activity, especially the 
annonaceous acetogenins1 and vitamin E derivatives2, which possess antitumor 
properties (Figure 1-1). Benzoxepines and 1,3-oxazolidines also show wide-
ranging biological activities, and the latter is used as a chiral auxiliary to effect 
stereoselective syntheses.3, 4 Due to the importance of the aforementioned 
saturated heterocycles in medicinal and synthetic chemistry, myriad methods 
have been developed for their synthesis. Nevertheless, convergent synthetic 
methods that effect carbon-heteroatom and carbon-carbon bond formation and 
are amenable to the rapid production of analog libraries are relatively rare.5 Thus, 
the research outlined in the present thesis is focused on the development of 
methodology for the stereoselective synthesis of saturated heterocycles, for the 
ultimate goal of the synthesis of biologically relevant molecules. 
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Figure 1.1. Examples of Heterocyclic Natural Products 
As previously mentioned, the annonaceous acetogenins are diverse natural 
products of marine origin that contain a mono-, bis-, or tris-tetrahydrofuran core 
with flanking hydroxyl substituents at the 1’ position.6 Previous studies have 
shown that this motif is essential for biological activity, and many methods have 
been developed to produce both bis- and 2,1’-substituted tetrahydrofurans.7 For 
instance, rhenium- and cobalt-catalyzed reactions have been used to transform 
γ-hydroxy alkenes into 1’-hydroxyl substituted tetrahydrofurans, as shown in 
Scheme 1-1.8 Although these methods produce the desired motif in excellent 
yield and diastereoselectivity, they are not amenable for analog synthesis and 
the production of heterocyclic libraries, which are useful for studying structure-
activity relationships. Moreover, these methods lack the ability to forge carbon-
carbons, which is fundamental for creating structural complexity from simple 
starting materials. 
O
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Scheme 1.1. Oxidative Cyclization Methods for the Synthesis of Bis-
Tetrahydrofurans 
Bis tetrahydrofurans are also synthesized via sequential ring-closing reactions 
(Scheme 1-2). Although ring closure is effected with these methods, carbon-
carbon bond formation is not achieved, and additional steps must be conducted 
to install alkyl groups, which increases the number of steps of the overall 
synthesis. Methods typically used in tandem ring forming approaches include 
SN2 reactions, radical cyclizations, and epoxide-opening reactions.9, 10, 11 Similar 
strategies have been evoked to produce fused tetrahydrofurans, which are 
structurally interesting compounds displayed in diverse natural products. 
Common methods adopted for the synthesis of fused tetrahydrofurans are shown 
in Scheme 1-3, which highlight various reactions such as SN1 and SN2 
reactions.12 Similar to bis-THFs, fused tetrahydrofurans can also be synthesized 
via metal-catalyzed oxidative cyclization reactions and ring-opening of 
epoxides.13 
OBz
OH
1. TFAReO3, TFAA
2. NaHCO3
O
BzO
OH
Co(modp)2,
TBHP, iPrOH
O
BzO
OH
O O OHBnO
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Scheme 1.2. Methods for the Synthesis of Bis-Tetrahydrofurans 
 
Scheme 1.3. Methods for the Synthesis of Fused-Tetrahydrofurans 
In contrast, substituents at the 1’ position are often installed prior to THF 
formation, as illustrated in Scheme 1-4. Methods previously employed for the 
production of 2,1’-polysubstituted tetrahydrofurans include [3+2] annulation, 
radical cyclizations, Prins cyclizations and haloetherification. 14, 15, 16 Despite the 
application of a wide variety of different procedures for the synthesis of 2,1’-
Br
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polysubstituted tetrahydrofurans, high diastereoselectivity is often difficult to 
achieve, and additional manipulations are often required to obtain the desired 
substitution pattern or to obtain the required functional group at the 1’ position. 
Thus, a method that can produce 2,1’-substituted tetrahydrofurans in high 
diastereoselectivity is desirable. 
 
Scheme 1.4. Methods Employed to Synthesize 2,1’-Polysubstituted 
Tetrahydrofurans 
Benzopyrans and benzoxepines are 6- and 7-membered ring oxygenated 
heterocycles that display unique biological properties. For instance, benzopyrans 
are common antioxidants, and benzoxepines have shown allelopathic activity, as 
observed in heliannuol C.17, 18 Although the synthesis of benzopyrans can be 
readily achieved via Freidel crafts or SN2 reactions, the reaction conditions are 
often harsh and sensitive functional groups are not well-tolerated (Scheme 1-5). 
Alternative approaches for the synthesis of benzopyrans include C-H activation, 
radical cyclization and Pd-catalyzed reactions.19, 20, 21 Nevertheless, these 
methods also suffer significant limitations, including the use of toxic reagents and 
SiMe2Ph
OTBS
Ph + OBnH
O BF3OEt2 O OBn
PhMe2Si
Ph
OTBS
78%, >20:1 dr
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S h!
C4F9I
80%, 2:1 dr O
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O
H
O
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OH61%, 10:1 dr
OH NCS, I2 O
I
83%, >20:1 dr
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poor substrate scope. As evidenced, novel methodologies must be developed in 
order to access benzopyrans in a diastereoselective manner. 
 
Scheme 1.5. Representative Methods for the Synthesis of Benzopyrans  
On the other hand, due to the difficulty in overcoming entropic effects for the 
generation of 7-membered rings, relatively few methods have been developed for 
the synthesis of benzoxepines. Nevertheless, several Pd-catalyzed methods 
have been proposed, including sequential alkylation-alkenylation reactions and [5 
+ 2] annulation reactions (Scheme 1-6).22, 23 More traditional approaches such as 
Grubb’s catalysis, SN2 reactions and iodination have also been employed; 
however, the yields of these reactions are often low or substrate-dependent.24, 25, 
26 As such, additional methodologies that can be used to synthesize 
+
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67% O OEt
O
O
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benzoxepines in an efficient and convergent manner would be useful tools for 
organic and medicinal chemists. 
 
Scheme 1.6. Methods for the Synthesis of Benzoxepines  
 Lastly, 1,3-oxazolidines are often employed as chiral auxiliaries in organic 
reactions and display unique biological activity in their own right. Therefore, 
myriad methods have been employed to synthesize diastereomerically pure 1,3-
oxazolidines, especially condensation reactions between 1,2 amino alcohols and 
ketones and cycloaddition reactions (Scheme 1-7).27, 28 However, 
stereoselectivity is often difficult to achieve, especially when the formation of 2,5-
cis-1,3-oxazolidines is desired. To this end, various Pd-catalyzed methods and 
tandem reactions based on Michael additions have been developed.29, 30 
Although the diastereoselectivity of these methods are high, carbon-carbon bond 
formation cannot be effected. Thus, a method that can achieve both high 
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diastereoselectivity and concomitant carbon-heteroatom and carbon-carbon bond 
formation is required to produce libraries of 1,3-oxazolidine chiral auxiliaries for 
stereoselective syntheses. 
 
Scheme 1.7. Representative Methods for the Synthesis of 1,3-Oxazolidines 
1.2 Introduction to Pd-Catalyzed Carboamination and Carboetherification 
Reactions  
To address the lack of convergent synthetic methods for the production of 
heterocycles such as those listed above, research in the Wolfe lab is focused on 
the development of methodology for the synthesis of various types of saturated 
heterocycles.31 In particular, palladium-catalyzed coupling reactions of γ-hydroxy 
alkenes and γ-amino alkenes with aryl and alkenyl halides have been developed 
to construct complex heterocycles in a stereoselective manner (Figure 1-2). For 
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instance, tetrahydrofurans, pyrrolidines, isoxazolidines,32 piperazines,33 
morpholines,34 imidazoldin-2-ones35 and pyrrazolidines36 have been synthesized 
using this methodology, which can effect carbon-heteroatom and carbon-carbon 
bond formation in a single step. 
 
Figure 1.2. Palladium-Catalyzed Carboetherification and Carboamination 
Reactions for the Synthesis of Various Heterocycles 
The mechanism of palladium-catalyzed carboetherification reactions has been 
studied in detail and is shown in Scheme 1-8.37 The reaction begins with a Pd (0) 
species, which undergoes oxidative addition into the aryl or alkenyl halide bond 
to afford complex I-5. Coordination and deprotonation of the heteroatom to the 
substrate leads to I-6, which can coordinate the pendant alkene to produce I-7.38 
Subsequently, the coordinated alkene inserts into the Pd-heteroatom bond, 
resulting in the formation of I-8. Lastly, reductive elimination of Pd (II) affords a 
Pd (0) species, along with the final heterocyclic product (I-9). 
O
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Scheme 1.8. Proposed Mechanism of Palladium-Catalyzed Carboetherification 
and Carboamination Reactions 
1.3 Limitations to the Method  
Although Pd-catalyzed carboetherification and carboamination reactions have 
been shown to be powerful tools for the rapid synthesis of heterocyclic libraries, 
several limitations remained to be addressed. For instance, in carboetherification 
reactions of substrates bearing internal alkenes, the desired product was formed 
as a mixture of diastereomers (Scheme 1-9) due to competing beta-hydride 
elimination and reinsertion processes. These processes reduced the 
diastereoselectivity of the reaction and prevented the use of the method for the 
synthesis of the annonaceous acetogenins, which often possess functional 
groups at the 1’ position.39 This diverse family of natural products also often 
contains a bis-tetrahydrofuran core, which our group had not previously 
demonstrated was accessible via palladium-catalyzed carboetherification 
reactions. 
 
Scheme 1.9. Pd-Catalyzed Carboetherification Reactions of Internal Alkene 
Substrates 
X
Ar
X
PdAr
Ln
X
Pd
Pd0Ln
Pd
PdLn
Br
Ar
X
NaOt-Bu
Olefin 
Coordination
Olefin 
Insertion
Ar-Br
Oxidative 
Addition
Ln
Ar
Ar
Ln
X
I-5
I-6
I-7
I-8
I-9
OH
PhBr
Pd2(dba)3/P(o-tol)3
NaOtBu, Tol, 110oC
OPh
  
11 
Previously, large-ring heterocycles such as benzopyrans and benzoxepines 
could not be synthesized using our methodology due to entropic effects and the 
poor nucleophilicity of phenol. In addition, 1,3-oxazolidines were also 
inaccessible due to the presence of electron-withdrawing substituents, which 
suppressed reductive elimination, and the electron-rich nature of the cyclizing 
alkene. Scheme 1-10 illustrates several biologically relevant motifs that could not 
be synthesized due to limitations in the methodology that were overcome through 
the work described in this thesis. 
 
Scheme 1.10. Heterocycles not Previously Accessible through Pd-Catalyzed 
Carboetherification and Carboamination Reactions 
Considerable extensions have been made toward the eventual application of 
our methodology to the synthesis of biologically active compounds such as the 
annonaceous acetogenins, as outlined in this thesis. For instance, as described 
in Chapter 2, palladium-catalyzed carboetherification reactions have been 
extended to the synthesis of bis and fused tetrahydrofurans, which represents a 
significant advancement in the scope of our method. Most importantly, novel 
reaction conditions have been developed to synthesize diastereomerically pure 
1’-substituted tetrahydrofurans from substrates bearing an internal alkene by 
effectively suppressing competing beta-hydride elimination and reinsertion 
processes, which lead to the production of the minor diastereomer. The 
optimized conditions and corresponding mechanistic implications are described 
in detail in Chapter 3, which outlines the use of a catalyst system containing S-
phos, an electron-rich biaryl ligand known to enhance reductive elimination. Due 
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to the achievements described in Chapter 3, natural products containing 
polysubstituted tetrahydrofurans such as Simplakidine A can potentially be 
synthesized via Pd-catalyzed carboetherification reactions. 
In addition to the limitations described above, Pd-catalyzed carboetherification 
reactions had not been applied to generate 6- or 7-membered rings, and 
electron-rich alkenes such as enol ethers had not been employed. Nevertheless, 
these constraints have been overcome using monodentate biaryl ligands. As 
described in Chapter 4, the synthesis of 1,3-oxazolidines through the palladium-
catalyzed carboamination of O-vinyl-1,2-aminoalcohols was achieved using S-
phos. This bulky monodentate ligand apparently enhanced reductive elimination, 
which was slowed due to the electronic effects of the heteroatom adjacent to the 
pendent alkene. As a result, the stereoselective synthesis of poly-substituted 1,3-
oxazolidines can be attained using Pd-catalyzed carbamination reactions, 
allowing the production of extensive libraries of these heterocycles. Thus, 
through the work described in Chapter 4 of this thesis, a significant limitation to 
our methodology was addressed, and a novel method for the synthesis of 1,3-
oxazolidines was developed. 
As outlined in Chapters 5 and 6, the synthesis of 6- and 7-membered 
heterocycles was attained by developing reaction conditions based on S-phos 
and Ru-phos, respectively. The aforementioned ligands overcame the low 
nucleophilicity of the phenol substrate and entropic effects to form the desired 
product. Therefore, access into a new arena of natural product synthesis was 
enabled through the expansion of the substrate scope of Pd-catalyzed 
carboetherification reactions, which can effect both carbon-carbon and carbon-
heteroatom bond formation in a single step, addressing the needs of the 
synthetic community for convergent and stereoselective methods. 
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Chapter 2: Palladium-Catalyzed Carboetherification 
Reactions for the Synthesis of Bis- and Fused-
Tetrahydrofurans 
 
2.1 Introduction  
A large number of interesting compounds contain attached-ring or fused-ring 
tetrahydrofuran scaffolds (Figure 2-1). The 2,6-dioxabicyclo[3.3.0]octane 
framework (II-1) is found in both naturally occurring1 and synthetic molecules that 
are relevant to human health (e.g., II-3; antitumor activity)2 and agriculture (e.g., 
II-4; herbicide).3 Attached-ring tetrahydrofurans (II-2) are displayed in a vast 
number of natural products, including the annonaceous acetogenins,4 of which 
asimicin (II-5) is a member. 
 
Figure 2.1. Examples of Biologically Active Bis-Tetrahydrofurans. 
A variety of different approaches have been developed for the construction of 
these useful compounds.5 Many of these strategies involve generation of the bis-
tetrahydrofuran framework via sequential (or tandem) ring-closing reactions of 
1,2-diols bearing pendant functional groups such as alkenes, epoxides, alcohols, 
or allylic acetates/halides.6 Although these methods effectively form the 
heterocyclic ring, they do not allow the simultaneous construction of a C-C bond. 
Thus, substituents attached to the tetrahydrofuran C-2 position, such as the side 
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chains present in II-3-II-5, must be installed in separate steps either prior to or 
following ring-closure. 
 
Scheme 2.1. Synthetic Strategy 
We felt that an alternative approach to the construction of substituted fused-ring 
tetrahydrofurans with general structure II-8 could be developed using sequential 
Pd-catalyzed carboetherification reactions7,8 of unsaturated 1,2-diols such as II-6. 
As shown in Scheme 2-1, treatment of II-6 with an aryl or alkenyl halide in the 
presence of NaOtBu and a palladium catalyst should provide II-7, which could be 
converted to II-8 in a second catalytic transformation. This strategy could also be 
applied to the synthesis of attached-ring tetrahydrofurans (e.g., II-9 to II-10) by 
simply extending the tether between the alcohols and the alkenes by one 
methylene unit. Importantly, each carboetherification reaction would generate 
both a C-O bond (to form the heterocylic ring) and a C-C bond, thus providing a 
more concise approach to substituted bis-tetrahydrofurans compared to currently 
available methods. 
 
Figure 2.2. Protection of 1,2-diols 
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2.2 Efforts Toward a One-pot Synthesis  
 To examine the feasibility of the strategy outlined above, we elected to 
examine the selective monocyclization of known diols II-6 and II-99 which can be 
generated by Cu-catalyzed addition of vinylmagnesium bromide or 
allylmagnesium bromide to commercially available butadiene diepoxide. We also 
prepared mono-TBS-protected10 derivatives II-12 and II-13 (Figure 2-2), as our 
prior studies indicated that carboetherification reactions of mono-protected 1,2-
diols are often more efficient than transformations of the corresponding 
unprotected diols. 
Preliminary attempts to effect selective monocyclization of unprotected diols II-
6 and II-9 provided unsatisfactory results (Figure 2-3). Treatment of II-6 with one 
equivalent of bromobenzene under our standard carboetherification conditions 
(NaOtBu, cat. Pd2(dba)3/Dpe-Phos)11 afforded mixtures of bis-cyclized product II-
14 and unreacted starting material. Treatment of II-6 with four equivalents of 
bromobenzene led to complete consumption of starting material and the 
formation of II-14 with >20:1 dr, albeit in only 30% yield. Efforts to achieve 
monocyclization of II-9 did lead to the formation of desired tetrahydrofuran II-15, 
but yields were low and isomerization of the second alkene was problematic. Use 
of excess aryl halide in this reaction failed to generate significant amounts of the 
bis-tetrahydrofuran target, and instead provided an 81% combined yield of II-15 
and inseparable alkene isomers. 
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Figure 2.3. Attempted Monocyclization of 1,2-Diols. 
2.3 Carboetherification Reactions of TBS-Protected Substrates 
Although carboetherification reactions of II-6 and II-9 were generally ineffective, 
transformations of TBS-protected substrates II-12 and II-13 proceeded smoothly. 
As shown in Table 2-1, treatment of II-12 with an aryl bromide in the presence of 
NaOtBu and a catalyst composed of Pd2(dba)3 and Dpe-Phos provided 
tetrahydrofurans II-16 in good yields with excellent diastereoselectivities. 
Cleavage of the silyl ether protecting group was achieved under standard 
conditions, and carboetherification of the resulting alcohols II-17 provided fused 
tetrahydrofurans (II-8) as single stereoisomers (>20:1 dr). Both cyclizations led to 
products that are trans-2,5-disubstituted around the tetrahydrofuran ring(s), 
which is consistent with our previously reported observations and stereochemical 
models for the conversion of γ-hydroxy alkenes to tetrahydrofurans. 
 
The first carboetherification reaction in this sequence (II-12 to II-16) was 
sensitive to the electronic properties of the aryl bromide, and the best yields were 
obtained with electron-neutral substrates (entries 1-6 of Table 2-1). However, the 
scope of the second carboetherification reaction (entries 16 to 8 of Table 2-1) 
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was much broader, and a number of different aryl bromides were effectively 
coupled. In addition, use of β-bromostyrene in the second transformation was 
also successful (entry 7 of Table 2-1). Diastereoselectivities were uniformly high 
in all of the carboetherification reactions (>20:1 dr), and in many cases the 
overall yield of II-8 exceeded 50% over the three-step sequence. 
 
Table 2.1. Stepwise Synthesis of Fused Tetrahydrofuransa 
The synthesis of attached-ring bis-tetrahydrofurans was achieved by subjecting 
protected diol II-13 to an analogous sequence of carboetherification (II-13 to II-
18), deprotection (II-18 to II-19), and carboetherification (II-19 to II-10). As 
observed in the transformations of II-12, the scope of the second 
carboetherification step is considerably broader than the first (with respect to the 
aryl bromide component). Yields of attached-ring tetrahydrofurans were slightly 
lower than the corresponding fused-ring products described above. However, 
entry R1 yield II-16 (%)b R
2
1 86
94
91
86 92
91 91
71 90 87
81
85
3
5
7 44 92 67
2
4
6
overall
yield (%)c
68
74
75
67
43
54
27
89 368
TBAF
O
PO H
H
R1
Pd2(dba)3
THF, 65 °C
THF O
HO H
H
R1
O
O
H H
R1
R2
OH
PO
II-12
II-16 II-17 II-8
NaOtBu
THF, 65 °C
NaOtBu
Dpe-Phos
Pd2(dba)3
Dpe-Phos
P = TBS
yield II-17
 (%)b
yield II-8
 (%)b
Ph
p-Tol
p-tBuPh
p-PhC(O)Ph
p-PhC(O)Ph
3-pyridyl
m-MeOPh
p-F3CPh
p-PhPh
2-naphthyl
(E)-!-styryl
6-MeO-2-naphthyl
R2BrR1Br
a Conditions: Steps 1 and 3: 1.0 equiv II-12 or II-17, 2.0 equiv ArBr, 2.0 
equiv NaOtBu, 2 mol % Pd2(dba)3, 4 mol % Dpe-Phos, THF, 65 oC. Step 2: 
1.0 equiv II-16, 10 equiv TBAF, THF, rt. b Isolated yields (average of two or 
more experiments). All products were obtained with >20:1 dr. c Yield 
obtained over the three step sequence from II-12 to II-8.
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diastereoselectivities were excellent, and all products were obtained with >20:1 
dr favoring 2,5-trans-stereochemistry around both tetrahydrofuran rings. 
 
Table 2.2. Stepwise Synthesis of Attached Tetrahydrofuransa 
To further probe the synthetic utility of these transformations, we sought to 
determine if nonracemic starting materials could be converted to bis-
tetrahydrofuran products without loss of enantiomeric purity. To this end, (-)-II-13 
was prepared in 96% ee via asymmetric dihydroxylation of commercially 
available trans-1,5,9-decatriene (II-20)12 followed by mono-TBS-protection of the 
resulting diol. This substrate was converted to (-)-II-10h using a sequence of 
reactions identical to that shown in Table 2-2, entry 8, and the product was 
obtained with >20:1 dr and 95% ee (Figure 2-4).  
entry R1 yield 18 (%)b R
2
1 64
63
54
73 89
72 91
64 91 75
61
72
3
5
7 55 96 71
2
4
6
overall
yield (%)c
42
41
35
40
44
42
37
53 288
TBAF
Pd2(dba)3
THF
II-13 II-18 II-19
II-10
NaOtBu
Toluene
NaOtBu
Dpe-Phos
Pd2(dba)3
Dpe-Phos
P = TBS
yield 19
 (%)b
yield 10
 (%)b
p-tBuPh
Ph
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p-MeOPh
p-PhPh
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R2BrR1Br
65 °C 110 °C
OH
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O
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H
H
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O
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H
H
H
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O
O
H
H
H
R1
R2
H
THF
a Conditions: Steps 1 and 3: 1.0 equiv II-13 or II-19, 2.0 equiv ArBr, 2.0 equiv 
NaOtBu, 2 mol % Pd2(dba)3, 4 mol % Dpe-Phos, Toluene or THF, 65 or 110 °C. 
Step 2: 1.0 equiv II-18, 10 equiv TBAF, THF, rt. b Isolated yields (average of two or 
more experiments). All products were obtained with >20:1 dr. c Yield obtained over 
the three step sequence from II-13 to II-10.
  
21 
 
Figure 2.4. Synthesis of an Enantioenriched Bis-Tetrahydrofuran. 
The synthesis of more elaborate tetrahydrofuran products is also feasible using 
this method. For example, protected tetraol derivative II-29 was generated from 
D-mannitol using standard transformations.13 Namely, D-mannitol was converted 
to triacetonide II-22, which was selectively cleaved to monoacetonide II-23 using 
an aqueous solution of acetic acid. Subsequent tosylation of the primary alcohol 
followed by base-catalyzed epoxide formation and Grignard addition afforded II-
26 in 41% overall yield. Next, benzyl protection, cleavage of the acetonide using 
TFA, and selective mono-TBS-protection of the resulting diol was performed to 
yield II-29. This substrate was converted to bis-tetrahydrofuran II-32 with >20:1 dr 
using the same reaction sequence described above (Scheme 2-2). 
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Scheme 2.2. Synthesis of a Highly Substituted Bis-Tetrahydrofuran 
2.4 Conclusions 
In conclusion, we have developed a concise approach to the construction of 
both attached-ring and fused-ring bis-tetrahydrofurans using sequential Pd-
catalyzed carboetherification reactions. This strategy allows for preparation of 
derivatives bearing different substituents at the 2-position of each tetrahydrofuran 
ring, and provides access to derivatives that could not be easily generated with 
existing methods.  
 
2.5 Experimental 
General.  All reactions were carried out under a nitrogen atmosphere in oven or 
flame dried glassware. Tris(dibenzylideneacetone)dipalladium (0) and all 
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phosphine ligands were purchased from Strem Chemical Co. and used without 
further purification. All aryl bromides and 1,3 butadiene diepoxide were obtained 
from commercial sources (Aldrich Chemical CO or Acros Chemical CO) and 
were used as obtained. (4R,5S,6S,7R)-4,7-bis(benzyloxy)deca-1,9-diene-5,6-
diol,14,15 (5R*,6R*)-deca-1,9-diene-5,6-diol,16 (+)-(5R,6R)-deca-1,9-diene-5,6-diol, 
and (4R*,5R*)-octa-1,7-diene-4,5-diol were prepared according to literature 
procedures. Toluene and THF were purified using a GlassContour solvent 
purification system. Yields refer to isolated yields of compounds estimated to be 
≥95% pure as determined by 1H NMR. The yields reported in the supporting 
information describe the result of a single experiment, whereas the yields 
reported in Tables 2-1 and 2-2 are average yields of two or more experiments. 
Thus, the yields reported in the supporting information may differ from those 
shown in Tables 2-1 and 2-2. 
 
Preparation of Substrates 
 
(±)-(4R*,5R*)-5-(tert-Butyldimethylsiloxy)octa-1,7-dien-4-ol II-12). A flame-
dried flask was cooled under a stream of nitrogen and charged with (4R*,5R*)-
octa-1,7-diene-4,5-diol (1.5 g, 10.6 mmol). THF (10.6 mL) was added, the 
resulting solution was cooled to –78 °C, and n-BuLi (5.6 ml, 10.6 mmol, 1.9 M in 
hexanes) was added dropwise with stirring. The reaction mixture was allowed to 
warm to rt over 1 h and then a solution of TBSCl (1.59 g, 10.6 mmol) in THF 
(10.6 mL) was added slowly. The resulting mixture was stirred at rt for 30 min, 
then imidazole (36 mg, 0.53 mmol) was added and the mixture was stirred 
overnight at rt. A solution of saturated aqueous NaHCO3 (5 mL) was added, and 
II-
OH
TBSO
11
II-12
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the resulting mixture was diluted with ethyl acetate (5 mL). The layers were 
separated and the aqueous layer was extracted with ethyl acetate (3 X 5 mL). 
The combined organic layers were dried over anhydrous sodium sulfate, filtered, 
and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel to afford the title compound as a pale yellow oil (1.8 
g, 66%). 1H NMR (400 MHz, CDCl3) δ 5.91–5.72 (m, 2 H), 5.13–5.04 (m, 4 H), 
3.65–3.59 (m, 2 H), 2.49–2.39 (m, 1 H), 2.26–2.15 (m, 4 H), 0.9 (s, 9 H), 0.01 (s, 
3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 135.1, 134.1, 117.5, 116.9, 
73.7, 71.7, 38.3, 25.7, 17.9, –4.2, –4.8; IR (film, cm–1) 3450, 2930; MS(ESI): 
279.1756 (279.1756 calcd for C13H28SiO2, M + Na+).  
 
(±)-(5R*,6R*)-6-(tert-Butyldimethylsiloxy)deca-1,9-dien-5-ol (II-13). The 
conversion of (5R*,6R*)-deca-1,9-diene-5,6-diol (2.93 g, 17.24 mmol) to the title 
compound was achieved using a procedure analogous to that described above 
for the preparation of II-12. This procedure afforded 2.65 g (54%) of the title 
compound as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 5.90–5.74 (m, 2 H), 
5.07–4.94 (m, 4 H), 3.58–3.53 (m, 1 H), 3.51–3.45 (m, 1 H), 2.30–2.20 (m, 1 H), 
2.18–2.00 (m, 4 H), 1.80–1.69 (m, 1 H), 1.59–1.45 (m, 3 H), 0.90 (s, 9 H), 0.04 
(s, 3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 138.4, 138.3, 114.7, 114.6, 
74.4, 71.8, 33.2, 32.8, 30.1, 29.2, 18.1, –4.2, –4.6; IR (film, cm–1): 3459, 2953; 
MS(ESI): 307.2063 (307.2069 calcd for C15H32SiO2, M + Na+). 
 
(–)-(5R,6R)-6-(tert-Butyldimethylsiloxy)deca-1,9-dien-5-ol (II-13). The 
conversion of (+)-(5R,6R)-deca-1,9-diene-5,6-diol (1.19 g, 7.0 mmol) to the title 
compound was achieved using a procedure analogous to that described above 
II-
OH
TBSO
12II-
II-13
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for the preparation of II-12. This procedure afforded 1.29 g (44%) of the title 
compound as a pale yellow oil, [α]D23 = –3.3° (c 0.42, CH2Cl2). The enantiopurity 
of this compound was judged to be 96% ee through 19F NMR analysis of the 
corresponding Mosher ester derivative (II-S1). 
 
(–)-(2S,4R,5R)-5-[(tert-Butyldimethylsilyloxy)nona-1,8-dien-4-yl]-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoate (II-S1). A flame-dried flask was 
cooled under a stream of nitrogen and charged with dimethylaminopyridine (4 
mg, 0.035 mmol), DCC (40 mg, 0.193 mmol), (S)-α-methoxytrifluorophenylacetic 
acid (45 mg, 0.193 mmol) and THF (1 mL). A solution of (5R,6R)-6-(tert-
butyldimethylsiloxy)deca-1,9-dien-5-ol (50 mg, 0.18 mmol) in THF (0.35 mL) was 
added dropwise, and the resulting mixture was stirred at rt until the starting 
material was consumed as judged by GC analysis. The reaction was diluted with 
cold pentane, filtered, and washed with brine. The layers were separated and the 
aqueous layer was extracted with ethyl acetate (3 X 5 mL). The combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel to afford the title compound as a clear oil (77 mg, 
87%), [α]D23 = –7.3° (c 0.70, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.53–7.46 (m, 
2 H), 7.39–7.34 (m, 3 H), 5.79–5.66 (m, 1 H), 5.65–5.53 (m, 1 H), 5.00–4.84 (m, 
5 H), 3.70–3.64 (m, 1 H), 3.54–3.51 (s, 3 H), 2.14–1.90 (m, 3 H), 1.87–1.74 (m, 2 
H), 1.70–1.59 (m, 1 H), 1.39–1.27 (m, 1 H), 1.26–1.16 (m, 1 H), 0.85 (s, 9 H), 
0.10 (s, 3 H), 0.04 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 166.3, 138.0, 137.2, 
132.1, 129.6, 128.4, 127.2, 119.4 (q, J = 186 Hz) 115.6, 114.8, 70.6, 55.7, 55.6, 
34.9, 30.4, 30.1, 26.6, 25.8 (q, J = 49.6 Hz), 17.9, -4.4, –4.7 (one signal is 
missing due to incidental equivalence); 19F NMR (376 MHz, CDCl3) –71.4; IR 
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(film, cm–1) 2930, 1746, 1170; MS(ESI): 523.2457 (523.2467 calcd for 
C26H39SiO4F3, M + Na+) 
 
(–)-(4R,5R,6S,7R)-4,7-Bis(benzyloxy)-6-(tert-butyldimethylsiloxy)deca-1,9-
dien-5-ol (II-29). The conversion of (4R,5S,6S,7R)-4,7-bis(benzyloxy)deca-1,9-
diene-5,6-diol (1.76 g, 4.7 mmol) to the title compound was achieved using a 
procedure analogous to that described above for the preparation of II-12. This 
procedure afforded 0.9 g (50%) of the title compound as a colorless oil, [α]D23 = –
4.2o (c 0.63, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.32–7.28 (m, 5 H), 7.27–
7.24 (m, 4 H), 7.24–7.20 (m, 1 H), 5.99–5.87 (m, 1 H), 5.86–5.74 (m, 1 H), 5.19–
4.95 (m, 4 H), 4.68 (d, J = 11.4 Hz, 1 H), 4.56 (d, J = 11.4 Hz, 1 H), 4.47 (d, J = 
11.7 Hz, 1 H), 4.36 (d, J = 11.4 Hz, 1 H), 4.16 (t, J = 2.0 Hz, 1 H), 3.59–3.54 (m, 
1 H), 3.48–3.40 (m, 2 H), 3.07 (d, J = 6.3 Hz, 1 H), 2.67–2.58 (m, 1 H), 2.54–2.45 
(m, 1 H), 2.41–2.25 (m, 2 H), 0.88 (s, 9 H), 0.05 (s, 3 H), 0.00 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 138.5, 138.4, 135.4, 128.3, 128.2, 127.7, 127.6, 127.57, 
125.5, 117.5, 117.0, 83.4, 78.9, 72.6, 71.4, 70.8, 70.4, 34.9, 33.6, 26.0, 18.3, –
3.7, –4.9; IR (film, cm–1) 3516, 3067; MS(ESI) 519.2907 (519.2921 calcd for 
C30H44SiO4, M + Na+). 
Synthesis of Bis-Tetrahydrofurans via Pd-Catalyzed Alkene 
Carboetherification 
 
General Procedure 1: Palladium-Catalyzed Carboetherification Reactions 
for the Formation of Tetrahydrofuran Derivatives. An oven or flame-dried 
OTBS
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Schlenk tube was cooled under a stream of nitrogen and charged with Pd2(dba)3 
(2 mol% complex, 4 mol % Pd), Dpe-phos (4 mol %), NaOtBu (2.0 equiv), and 
the aryl bromide (2.0 equiv). The tube was purged with nitrogen and the alcohol 
substrate (1.0 equiv), and THF or Toluene (0.25 M in substrate) were added. The 
mixture was heated to 65 °C or 110 °C with stirring until the starting material had 
been consumed as judged by GC or 1H NMR analysis. The mixture was cooled 
to room temperature, quenched with saturated aqueous NH4Cl (2 mL), and 
diluted with ethyl acetate (10 mL). The layers were separated and the aqueous 
layer was extracted with ethyl acetate (3 X 10 mL). The combined organic layers 
were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. 
The crude product was then purified by flash chromatography on silica gel. 
General Procedure 2: Cleavage of TBS Protecting Groups. An oven or flame-
dried round-bottomed flask was cooled under a stream of nitrogen and charged 
with the protected alcohol (1.0 equiv). The tube was purged with nitrogen, THF 
(0.1 M in protected alcohol) was added, and the reaction was cooled to 0 °C. 
TBAF (10 equiv, 1 M in THF) was added dropwise and the reaction was warmed 
to rt. The mixture was stirred at rt until the starting material had been consumed 
as judged by GC analysis. The mixture was then quenched with 1 M HCl (5 mL) 
and diluted with ethyl acetate (10 mL). The layers were separated and the 
aqueous layer was extracted with ethyl acetate (3 X 10 mL). The combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel. 
Synthesis of Fused-Ring Bis-Tetrahydrofurans (Table 2-1) 
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(±)-(2R*,3R*,5R*)-(2-Allyl-5-benzyltetrahydrofuran-3-yloxy)(tert-
butyl)dimethylsilane (II-16a, Table 2-1, Entries 1–2). The coupling of (±)-II-12 
(400 mg, 1.56 mmol) with bromobenzene (330 µL, 3.13 mmol) was achieved 
following general procedure 1 using THF as solvent and a reaction temperature 
of 65 °C. This procedure afforded 385 mg (74%) of the title compound as an 
orange oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.34–7.21 (m, 5 H), 
5.95–5.83 (m, 1 H), 5.19–5.06 (m, 2 H), 4.55–4.46 (m, 1 H), 4.24–4.20 (m, 1 H), 
3.90–3.85 (m, 1 H), 3.04–2.94 (dd, J = 5.5, 13.3 Hz, 1 H), 2.83–2.76 (dd, J = 7.1, 
13.7 Hz, 1 H), 1.92–1.85 (m, 2 H), 1.79–1.71 (m, 1 H), 1.68–1.62, (m, 1 H), 0.91 
(s, 9 H), 0.01 (s, 3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 138.4, 135.7, 
129.4, 128.2, 126.1, 116.3, 82.4, 73.3, 42.0, 41.0, 34.2, 25.7, 18.0, –4.5, –5.0; IR 
(film, cm–1) 3030, 1472; MS(ESI): 355.2060 (355.2069 calcd for C20H32SiO2, M + 
Na+). 
 
(±)-(2R*,3R*,5R*)-[2-Allyl-5-(4-methylbenzyl)tetrahydrofuran-3-yloxy](tert-
butyl)dimethylsilane (II-16b, Table 2-1, Entries 3–4). The coupling of (±)-II-12 
(200 mg, 0.78 mmol) with 4-bromotoluene (190 µL, 1.56 mmol) was achieved 
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following general procedure 1 using THF as solvent and a reaction temperature 
of 65 °C. This procedure afforded 230 mg (85%) of the title compound as a red 
oil. This material was obtained as a >20:1 mixture of diastereomers as judged by 
1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.13–7.07 (m, 4 H), 5.92–5.81 
(m, 1 H), 5.17–5.03 (m, 2 H), 4.50–4.43 (m, 1 H), 4.21–4.17 (m, 1 H), 3.87–3.82 
(m, 1 H), 2.94 (dd, J = 5.5, 8.1 Hz, 1 H), 2.74 (dd, J = 7.0, 13.7 Hz, 1 H), 2.76–
2.69 (m, 2 H), 2.33 (s, 3 H), 1.89–1.82 (m, 1 H), 1.76–1.67 (m, 1 H), 0.88 (s, 9 
H), 0.01 (s, 3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 135.7, 135.5, 
129.3, 128.9, 116.2, 82.3, 77.7, 73.3, 41.6, 41.0, 34.2, 25.7, 21.0, 18.0, –4.5, –
5.1; IR (film, cm–1) 2930, 1463. MS(ESI): 369.2213 (369.2226 calcd for 
C21H34SiO2, M + Na+). 
 
(±)-(2R*,3R*,5R*)-[2-Allyl-5-(4-tert-butylbenzyl)tetrahydrofuran-3-yloxy](tert-
butyl)dimethylsilane (II-16c, Table 2-1, Entries 5–6). The coupling of (±)-II-12 
(400 mg, 1.56 mmol) with 1-bromo-4-tert-butylbenzene (0.55 mL, 3.13 mmol) 
was achieved following general procedure 1 using THF as solvent and a reaction 
temperature of 65 °C. This procedure afforded 450 mg (74%) of the title 
compound as a red oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.34 
(d, J = 8.2 Hz, 2 H), 7.17 (d, J = 8.2 Hz, 2 H), 5.94–5.83 (m, 1 H), 5.18–5.05 (m, 
2 H), 4.53–4.45 (m, 1 H), 4.22–4.19 (m, 1 H), 3.90–3.85 (m, 1 H), 2.93 (dd, J = 
5.5, 16.0 Hz, 1 H), 2.75 (dd, J = 6.7, 12.0 Hz, 1 H), 2.45–2.29 (m, 2 H), 1.94–1.85 
(m, 1 H), 1.80–1.71 (m, 1 H) 1.33 (s, 9 H), 0.89 (s, 9 H), 0.01 (s, 3 H), 0.00 (s, 3 
H); 13C NMR (100 MHz, CDCl3) δ 153.9, 140.4, 134.1, 130.1, 121.3, 87.3, 78.3, 
O
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46.6, 46.1, 39.4, 39.2, 36.4, 30.8, 23.1, 6.0, 0.5, 0.0; IR (film, cm–1) 2957, 1471. 
MS(ESI): 411.2687 (411.2695 calc for C24H40SiO2, M + Na+). 
 
(±)-(2R*,4R*,5R*)-4-[5-Allyl-4-(tert-butyldimethylsilyloxy)tetrahydrofuran-2-
ylmethyl]phenyl(phenyl)methanone (II-16d, Table 2-1, Entries 7–8). The 
coupling of (±)-II-12 (500 mg, 1.95 mmol) with 4-bromobenzophenone (1.02 g, 
3.9 mmol) was achieved following general procedure 1 using THF as solvent and 
a reaction temperature of 65 °C. This procedure afforded 300 mg (42%) of the 
title compound as an amber oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.29–7.15 (m, 9 H); 5.91–5.79 (m, 1 H), 5.15–5.03 (m, 2 H), 4.56–4.46 (m, 1 H), 
4.23–4.19 (m, 1 H), 3.87–3.22 (m, 1 H), 2.99 (dd, J = 6.3, 13.7 Hz, 1 H), 2.88 (dd, 
J = 6.3, 13.7 Hz, 1 H), 2.44–2.27 (m, 1 H), 1.89 (dd, J = 1.6, 5.9 Hz, 1 H), 1.85 
(dd, J = 5.9, 7.0 Hz, 1 H), 1.77–1.69 (m, 1 H), 0.88 (s, 9 H), 0.05 (s, 3 H), (0.01 
(s, 3 H); 13C NMR (100 MHz, CDCl3) δ 196.5, 143.7, 137.8, 135.6, 132.2, 130.2, 
129.9, 129.4, 128.2, 116.4, 82.5, 73.2, 42.0, 41.3, 34.1, 25.7, 18.0, –4.5, –5.0 
(one carbon signal is absent due to incidental equivalence); IR (film, cm–1) 2928, 
1700, 1278. MS(ESI): 459.2330 (459.2331 calcd for C27H36SiO3,  M + Na+). 
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(±)-(2R*,3R*,5R*)-2-Allyl-5-benzyltetrahydrofuran-3-ol (II-17a, Table 2-1, 
Entries 1–2). Removal of the TBS protecting group from II-17a (198 mg, 0.593 
mmol) with TBAF (5.93 mL, 5.93 mmol) was achieved following general 
procedure 2. This procedure afforded 127 mg (97%) of the title compound as an 
orange oil. 1H NMR (400 MHz, CDCl3) δ 7.31–7.19 (m, 5 H), 5.92–5.81 (m, 1 H), 
5.21–5.07 (m, 2 H), 4.54–4.45 (m, 1 H), 4.25–4.20 (m, 1 H), 3.87 (dt, J = 2.7, 7.0 
Hz, 1 H), 2.97 (dd, J = 5.9, 13.7 Hz, 1 H), 2.78–2.63 (m, 1 H), 2.51–2.35 (m, 2 H), 
1.98 (dd, J = 6.3, 13.3 Hz, 1 H), 1.85–1.77 (m, 1 H), 1.68 (s, 1 H); 13C NMR (100 
MHz, CDCl3) δ 138.1, 134.8, 129.4, 128.3, 126.3, 117.0, 81.4, 77.8, 73.1, 42.0, 
40.8, 33.8; IR (film, cm–1) 3411, 2925, 1454. MS(ESI): 241.1201 (241.1204 calcd 
for C14H18O2, M + Na+). 
 
(±)-(2R*,3R*,5R*)-2-Allyl-5-(4-methylbenzyl)tetrahydrofuran-3-ol (II-17b, 
Table 2-1, Entries 3–4). Removal of the TBS protecting group from II-16b (181 
mg, 0.52 mmol) with TBAF (5.2 mL, 5.2 mmol) was achieved following general 
procedure 2. This procedure afforded 113 mg (93%) of the title compound as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.09 (s, 4 H), 5.92–5.81 (m, 1 H), 5.21–
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5.06 (m, 2 H), 4.51–4.43 (m, 1 H), 4.26–4.20 (m, 1 H), 3.86 (dt, J = 2.7, 7.1 Hz, 1 
H), 2.93 (dd, J = 5.9, 13.7 Hz, 1 H), 2.71 (dd, J = 7.0, 13.7 Hz, 1 H), 2.51–2.34 
(m, 2 H), 2.31 (s, 3 H), 2.01–1.95 (m, 1 H), 1.85–1.77 (m, 1 H), 1.61–1.53 (m, 1 
H); 13C NMR (100 MHz, CDCl3) δ 135.7, 135.0, 134.9, 129.3, 129.0, 117.0, 81.5, 
77.9, 72.9, 41.6, 40.7, 33.8, 21.0; IR (film, cm–1) 3451, 2985, 1422. MS(ESI): 
255.1352 (255.1361 calcd for C15H20O2, M + Na+). 
 
(±)-(2R*,3R*,5R*)-2-Allyl-5-(4-tert-butylbenzyl)tetrahydrofuran-3-ol (II-17c, 
Table 2-1, Entries 5–6). Removal of the TBS protecting group from II-16b (100 
mg, 0.287 mmol) with TBAF (2.87 mL, 2.87 mmol) was achieved following 
general procedure 2. This procedure afforded 65 mg (92%) of the title compound 
as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.82–7.32 (m, 2 H), 7.17–7.12 (m, 2 
H), 5.93–5.82 (m, 1 H), 5.22–5.07 (m, 2 H), 4.53–4.44 (m, 1 H), 4.24 (t, J = 3.5 
Hz, 1 H), 3.90 (dt, J = 6.7, 7.0 Hz, 1 H), 2.95 (dd, J = 5.9, 13.7 Hz, 1 H), 2.71 (dd, 
J = 7.0, 13.7 Hz, 1 H), 2.39–2.06 (m, 2 H), 2.05–1.97 (m, 1 H), 1.87–1.78, (m, 1 
H), 1.67 (s, 1 H), 1.31 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 149.0, 135.1, 
134.9, 129.0, 125.2, 117.0, 81.5, 77.9, 72.9, 41.6, 41.0, 34.4, 33.8, 31.4; IR (film, 
cm–1) 3418, 2963, 1363. MS(ESI): 297.1826 (297.1830 calcd for C18H26O2, M + 
Na+). 
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(±)-(2R*,4R*,5R*)-4-(5-Allyl-4-hydroxytetrahydrofuran-2-
ylmethyl)phenyl(phenyl)methanone (II-16d, Table 2-1, Entries 7–8). Removal 
of the TBS protecting group from II-156 (30 mg, 0.077 mmol) with TBAF (77 µL, 
0.77 mmol) was achieved following general procedure 2. This procedure afforded 
23 mg (92%) of the title compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 
7.79–7.71 (m, 4 H), 7.60–7.54 (m, 1 H), 7.49–7.43 (m, 2 H), 7.35–7.30 (m, 2 H), 
5.91–5.79 (m, 1 H), 5.19–5.05 (m, 2 H), 4.57–4.48 (m, 1 H), 4.24 (s, 1 H), 3.87 
(dt, J = 2.7, 7.0 Hz, 1 H), 2.99 (dd, J = 6.3, 13.7 Hz, 1 H), 2.85 (dd, J = 6.3, 13.7 
Hz, 1 H), 2.50–2.34 (m, 2 H), 2.02 (dd, J = 6.3, 13.7 Hz, 2 H), 1.85–1.77 (m, 1 H); 
13C NMR (100 MHz, CDCl3) δ 196.6; 143.5, 137.7, 135.6, 134.8, 132.3, 130.3, 
130.0, 129.4, 128.2, 117.1, 81.6, 72.9, 42.0, 40.9, 33.8 (one carbon signal is 
absent due to incidental equivalence; IR (film, cm–1) 3474, 2932, 1265. MS(ESI): 
345.1468 (345.1467 calcd for C21H22O3, M + Na+). 
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(±)-(2R*,3aR*,5R*,6aR*)-2-Benzyl-5-[4-
(trifluoromethyl)benzyl]hexahydrofuro[3,2-b]furan (II-8a, Table 2-1, Entry 1). 
The coupling of II-17a (31 mg, 0.14 mmol) with 4-bromobenzotrifluoride (60 µL, 
0.28 mmol) was achieved following general procedure 1 using THF as solvent 
and a reaction temperature of 65 °C. This procedure afforded 45 mg (87%) of the 
title compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.39–7.34 (d, J = 7.8 Hz, 2 H), 7.17–7.08 (m, 4 H), 7.06–7.01 (m, 3 H), 4.55–4.50 
(m, 2 H), 4.14–4.05 (m, 2 H), 2.77–2.70 (m, 2 H), 2.66 (dd, J = 5.5, 13.7 Hz, 1 H), 
2.57 (dd, J = 6.3, 13.7 Hz, 1 H), 1.94 (dt, J = 1.5, 12.5 Hz, 2 H), 1.54–1.40 (m, 2 
H); 13C NMR (100 MHz, CDCl3) δ 142.5, 138.2, 129.3 (q, J = 183 Hz, 1 C), 128.3, 
128.2, 125.2 (q, J = 60 Hz), 83.8, 83.7, 83.68, 83.52, 77.3, 41.7, 41.4, 40.7, 
40.66 (one signal is absent due to incidental equivalence); IR (film, cm–1) 2936, 
1325, 1113. MS(ESI): 385.1406 (385.1391 calcd for C21H21F3O2, M + Na+). 
 
(±)-(2R*,3aR*,5R*,6aR*)-4-(5-Benzylhexahydrofuro[3,2-b]furan-2-
ylmethyl)phenyl(phenyl)methanone (II-8b, Table 2-1, Entry 2). The coupling 
of II-17a (31 mg, 0.14 mmol) with 4-bromobenzophenone (74 mg, 0.28 mmol) 
was achieved following general procedure 1 using THF as solvent and a reaction 
temperature of 65 °C. This procedure afforded 55 mg (96%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.64–7.60 (m, 2 H), 7.59–7.55 (m, 2 H), 7.44–7.38 (m, 1 H), 7.34–7.28 (m, 2 H), 
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7.19–7.01 (m, 7 H), 4.56–4.51 (m, 2 H), 4.17–4.06 (m, 2 H), 2.81–2.71 (m, 2 H), 
2.67 (dd, J = 5.9, 7.8 Hz, 1 H), 2.57 (dd, J = 6.7, 13.7 Hz, 1 H), 2.01–1.90 (m, 2 
H), 1.55–1.46 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 196.3, 143.4, 138.1, 137.7, 
135.6, 132.2, 130.2, 130.0, 129.2, 129.1, 128.3, 128.2, 126.2, 83.7, 83.5, 80.6, 
80.0, 41.7, 41.6, 40.7, 40.6; IR (film, cm-1) 2993, 1759, 1246. MS(ESI): 421.1771 
(421.1780 calcd for C27H26O3, M + Na+). 
 
(±)-(2R*,3aR*,5R*,6aR*)-3-[5-(4-Methylbenzyl)hexahydrofuro[3,2-b]furan-2-
ylmethyl]pyridine (II-8c, Table 2-1, Entry 3). The coupling of II-17b (56 mg, 
0.24 mmol) with 3-bromopyridine (47 µL, 0.48 mmol) was achieved following 
general procedure 1 using THF as solvent and a reaction temperature of 65 °C. 
This procedure afforded 75 mg (92%) of the title compound as a yellow oil. This 
material was obtained as a >20:1 mixture of diastereomers as judged by 1H NMR 
analysis. 1H NMR (400 MHz, CDCl3) δ 8.47–8.40 (m, 2 H), 7.55–7.51 (m, 1 H), 
7.22–7.17 (m, 1 H), 7.08 (s, 4 H), 4.69–4.64 (m, 2 H), 4.28–4.18 (m, 2 H), 2.89–
2.74 (m, 3 H), 2.68 (dd, J = 6.4, 7.0 Hz, 1 H), 2.30 (s, 3 H), 2.14–2.03 (m, 2 H), 
1.69–1.58 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 150.4, 147.7, 136.7, 137.7, 
135.6, 134.9, 129.0, 128.9, 123.1, 83.7, 83.4, 80.7, 79.6, 41.2, 40.52, 40.5, 38.5, 
20.9; IR (film, cm–1) 3053, 1265. MS(ESI): 310.1810 (310.1807 calcd for 
C20H23O2 N, M + H+). 
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(±)-(2R*,3aR*,5R*,6aR*)-2-(3-Methoxybenzyl)-5-(4-
methylbenzyl)hexahydrofuro[3,2-b]furan (II-8d, Table 2-1, Entry 4). The 
coupling of II-17b (40 mg, 0.34 mmol) with 3-bromoanisole (43 µL, 0.34 mmol) 
was achieved following general procedure 1 using THF as solvent and a reaction 
temperature of 65 °C. This procedure afforded 48 mg (82%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.24–7.18 (m, 1 H), 7.10 (s, 4 H), 6.82–6.75 (m, 3 H), 4.72–4.68 (m, 2 H), 4.32–
4.22 (m, 2 H), 3.80 (s, 3 H), 2.94–2.85 (m, 2 H), 2.74–2.67 (m, 2 H), 2.33 (s, 3 
H), 2.13 (q, J = 2.4 Hz, 1 H), 2.09 (q, J = 2.3 Hz, 1 H), 1.71–1.62 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 160.0, 139.9, 135.7, 135.1, 129.3, 129.1, 129.0, 121.7, 
115.1, 111.5, 83.7, 83.6, 80.7, 80.4, 55.1, 41.8, 41.3, 40.8, 40.7, 21.0; IR (film, 
cm–1) 2920, 1259. MS(ESI): 361.1788 (361.1780 calcd for C22H26O3, M + Na+). 
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(±)-(2R*,3aR*,5R*,6aR*)-2-(Biphenyl-4-ylmethyl)-5-(4-tert-
butylbenzyl)hexahydrofuro[3,2-b]furan (II-8e, Table 2-1, Entry 5). The 
coupling of II-17c (46 mg, 0.2 mmol) with 4-bromobiphenyl (46 mg, 0.2 mmol) 
was achieved following general procedure 1 using THF as solvent and a reaction 
temperature of 65 °C. This procedure afforded 35 mg (83%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.62–7.58 (m, 2 H), 7.56–7.52, (m, 2 H), 7.49–7.43 (m, 2 H), 7.38–7.28 (m, 5 H), 
7.16 (d, J = 8.2 Hz, 2 H), 4.75 (d, J = 4.9 Hz, 2 H), 4.37–4.26 (m, 2 H), 2.94 (dt, J 
= 6.3, 14.0 Hz, 2 H), 2.81 (dd, J = 6.3, 13.9 Hz, 1 H), 2.72 (dd, J = 6.4, 13.7 Hz, 1 
H), 2.20–2.12 (m, 2 H), 1.77–1.64 (m, 2 H), 1.34 (s, 9 H);13C NMR (100 MHz, 
CDCl3) δ 149.0, 141.0, 139.2, 137.4, 135.2, 129.7, 129.0, 128.7, 127.1, 127.0, 
125.2, 83.7, 83.6, 80.7, 80.5, 41.4, 41.3, 40.9, 40.8, 34.4, 31.4 (one carbon 
signal is missing due to incidental equivalence); IR (film, cm-1) 2900, 1091. 
MS(ESI): 427.2628 (427.2637 calcd for C30H34O2, M + H+). 
 
(±)-(2R*,3aR*,5R*,6aR*)-2-(4-tert-Butylbenzyl)-5-(naphthalen-2-
ylmethyl)hexahydrofuro[3,2-b]furan (II-8f, Table 2-1, Entry 6). The coupling of 
II-17c (41 mg, 0.2 mmol) with 2-bromonapthalene (41 mg, 0.2 mmol) was 
achieved following the general procedure 1 using THF as solvent and a reaction 
temperature of 65 °C. This procedure afforded 36 mg (90%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR (400 MHz, CDCl3) δ 7.84–7.76 (m, 3 H), 
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7.66 (s, 1 H), 7.50–7.41 (m, 2 H), 7.38–7.34 (m, 1 H), 7.33–7.29 (m, 2 H), 7.17–
7.12 (m, 2 H), 4.74–4.71 (m, 2 H), 4.43–4.34 (m, 1 H), 4.33–4.24 (m, 1 H), 3.07 
(dd, J = 5.9, 13.7 Hz, 1 H), 2.96–2.87 (m, 2 H), 2.17–2.09 (m, 2 H), 1.77–1.64 (m, 
3 H), 1.32 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 149.0, 135.9, 135.2, 133.5, 
132.2, 128.8, 127.9, 127.8, 127.6, 127.6, 127.5, 125.9, 125.3, 125.2, 83.7, 83.6, 
80.7, 80.5, 41.8, 41.3, 40.9, 40.8, 34.4, 31.4 (two carbon signals are missing due 
to incidental equivalence; IR (film, cm–1) 2960, 1091. MS(ESI): 423.2292 
(423.2300 calcd for C28H32O2, M + Na+). 
 
(±)-4-(2R*,3aR*,5R*,6aR*)-4-(5-Cinnamylhexahydrofuro[3,2-b]furan-2-
ylmethyl)phenyl(phenyl)methanone (II-8g, Table 2-1, Entry 7). The coupling 
of II-17d (70 mg, 0.23 mmol) with β-bromostyrene (58 µL, 0.45 mmol) was 
achieved following general procedure 1 using THF as solvent and a reaction 
temperature of 65 °C. This procedure afforded 68 mg (70%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis1H NMR (400 MHz, CDCl3) 7.79–
7.21 (m, 3 H), 7.59–7.54 (m, 1 H), 7.49–7.43 (m, 2 H), 7.34–7.30 (m, 4 H), 7.29–
7.24 (m, 2 H), 7.24–7.16 (m, 2 H), 6.43 (d, J = 16.0 Hz, 1 H), 6.22–6.13 (m, 1 H), 
4.74–4.69 (m, 2 H), 4.36–4.29 (m, 1 H), 4.19–4.12 (m, 1 H), 2.95 (dd, J = 6.3, 
13.7 Hz, 1 H), 2.85 (dd, J = 5.9, 7.8 Hz, 1 H), 2.51–2.35 (m, 2 H), 2.20–2.11 (m, 
2 H), 1.73–1.64 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 196.3, 143.4, 137.7, 
137.3, 135.6, 132.2, 132.1, 130.2, 130.0, 129.1, 128.4, 128.1, 127.0, 126.0, 83.8, 
83.5, 80.0, 79.5, 41.6, 40.7, 40.5, 38.8 (one signal is absent due to incidental 
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equivalence); IR (film, cm–1) 2920, 1700, 1278. MS(ESI): 447.1938 (447.193 
calcd for C29H28O3, M + Na+). 
 
(±)-(2R*,3aR*,5R*,6aR*)-4-[5-(6-Methoxynaphthalen-2-
ylmethyl)hexahydrofuro[3,2-b]furan-2-ylmethyl]phenyl(phenyl)methanone 
(II-8h, Table 2-1, Entry 8). The coupling of II-17d (50 mg, 0.16 mmol) with 2-
bromo-6-methoxynaphthalene (70 mg, 0.32 mmol) was achieved following 
general procedure 1 using THF as solvent and a reaction temperature of 65 °C. 
This procedure afforded 70 mg (91%) of the title compound as an orange oil. 
This material was obtained as a >20:1 mixture of diastereomers as judged by 1H 
NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.81–7.77 (m, 3 H), 7.75–7.71 (m, 3 
H), 7.67 (q, J = 5.5 Hz, 2 H), 7.50–7.44 (m, 2 H), 7.31 (d, J = 8.2 Hz, 3 H), 7.14–
7.09 (m, 2 H), 4.73–4.68 (m, 2 H), 4.39–4.27 (m, 2 H), 3.90 (s, 3 H), 3.03 (dd, J = 
5.9, 13.7 Hz, 1 H), 2.98–2.81 (m, 3 H), 2.17–2.08 (m, 2 H), 1.76–1.63 (m, 2 H); 
13C NMR (100 MHz, CDCl3) δ 196.3, 157.2, 143.4, 137.7, 135.6, 133.3, 133.1, 
132.1, 130.2, 129.9, 129.1, 129.0, 128.2, 128.1, 127.3, 126.6, 118.6, 105.4, 83.7, 
83.5, 80.7, 79.9, 55.2, 41.6, 40.7, 40.6 (two carbons signals are absent due to 
incidental equivalence); IR (film, cm–1) 2935, 1657, 1278. MS(ESI): 501.2053 
(501.2042 calcd for C32H30O4, M + Na+). 
 
Synthesis of Attached-Ring Bis-Tetrahydrofurans (Table 2) 
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(±)-(1R*,2R*,5R*)-tert-Butyl 1-[5-(4-tert-butylbenzyl)tetrahydrofuran-2-
yl]pent-4-enyloxy)dimethylsilane (II-18a, Table 2-2, Entries 1–2). The 
coupling of (±)-II-13 (400 mg, 1.4 mmol) with 1-bromo-4-tert-butylbenzene (0.5 
mL, 2.8 mmol) was achieved following general procedure 1 using THF as solvent 
and a reaction temperature of 65 °C. This procedure afforded 460 mg (79%) of 
the title compound as an amber oil. This material was obtained as a >20:1 
mixture of diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, 
CDCl3) δ 7.31–7.27 (m, 2 H), 7.17–7.13 (m, 2 H), 5.88–5.76 (m, 1 H), 5.05–4.92 
(m, 2 H), 4.17–4.09 (m, 1 H), 3.96 (dd, J = 6.3, 18.0 Hz, 1 H), 3.63–3.57 (m, 1 H), 
2.91 (dd, J = 6.1, 13.7 Hz, 1 H), 2.69 (dd, J = 7.0, 13.5 Hz, 1 H), 2.26–2.15 (m, 1 
H), 2.13–2.02 (m, 1 H), 1.95–1.84 (m, 2 H), 1.70–1.49 (m, 3 H) 1.46–1.39 (m, 1 
H), 1.31 (s, 9 H), 0.88 (s, 9 H), 0.05 (s, 3 H), 0.01 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 148.8, 139.0, 129.0, 125.1, 114.3, 81.5, 80.1, 74.4, 41.4, 34.3, 32.0, 
31.9, 31.4, 30.0, 27.4, 26.0, 25.9, –4.2, –4.7; IR (film, cm–1) 2930, 1089. 
MS(ESI): 439.3005 (439.3008 calcd for C26H44SiO2, M + Na+). 
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(±)-(1R*,2R*,5R*)-1-[(5-Benzyltetrahydrofuran-2-yl)pent-4-enyloxy](tert-
butyl)dimethylsilane (II-18b, Table 2-2, Entries 3–4), The coupling of (±)-II-13 
(400 mg, 1.4 mmol) with bromobenzene (0.3 mL, 2.8 mmol) was achieved 
following general procedure 1 using THF as solvent and a reaction temperature 
of 65 °C. This procedure afforded 350 mg (68%) of the title compound as a 
yellow oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.28–7.15 (m, 5 H), 
5.86–5.75 (m, 1 H), 5.03–4.90 (m, 2 H), 3.94 (q, J = 13.9 Hz, 1 H), 3.61–3.55 (m, 
1 H), 2.92 (dd, J = 5.9, 13.5 Hz, 1 H), 2.69 (dd, J = 7.0, 13.5 Hz, 1 H), 2.24–2.13 
(m, 1 H), 2.11–2.00 (m, 1 H), 1.91–1.77 (m, 2 H), 1.68–1.48 (m, 4 H), 1.46–1.36 
(m, 1 H), 0.87 (s, 9 H), 0.04 (s, 3 H), 0.00 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
139.0, 138.8, 129.2, 128.1, 126.0, 114.3, 81.5, 80.0, 74.4, 41.9, 32.1, 31.7, 29.9, 
27.4, 26.0, –4.2, –4.7; IR (film, cm–1) 2930, 1078. MS(ESI): 383.2373 (383.2382 
calcd for C22H36SiO2, M + Na+). 
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(±)-(1R*,2R*,5R*)-tert-Butyl 1-{[5-(3-methoxybenzyl)tetrahydrofuran-2-
yl]pent-4-enyloxy}dimethylsilane (II-18c, Table 2-2, Entries 5–6). The 
coupling of (±)-II-13 (400 mg, 1.4 mmol) with 3-bromoanisole (0.36 mL, 2.8 
mmol) was achieved following the general procedure 1 using THF solvent and a 
reaction temperature of 65 °C. This procedure afforded 360 mg (65%) of the title 
compound as an orange oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.19 
(t, J = 7.8 Hz, 1 H), 6.82–6.73 (m, 3 H), 5.88–5.76 (m, 1 H), 5.05–4.92 (m, 2 H), 
4.19–4.11 (m, 1 H), 3.96 (q, J = 6.2 Hz, 1 H), 3.79 (s, 3 H), 3.63–3.57 (m, 1 H), 
2.81 (dd, J = 5.9, 13.5 Hz, 1 H), 2.70 (dd, J = 7.0, 13.5 Hz, 1 H), 2.25–2.14 (m, 1 
H), 1.94–1.83 (m, 2 H) 1.71–1.49 (m, 4 H), 1.49–1.37 (m, 1 H), 0.88 (s, 9 H), 
0.05 (s, 3 H), 0.01 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 159.5, 140.4, 139.0, 
129.1, 121.8, 115.0, 114.4, 111.5, 81.6, 80.0, 74.4, 55.1, 42.0, 32.1, 31.8, 30.0, 
27.4, 26.0, –4.2, –4.7; IR (film, cm–1) 2928, 1062. MS(ESI): 413.2482 (413.2488 
calcd for C23H38SiO3, M + Na+). 
 
(±)-(1R*,2R*,5R*)-1-{[5-(4-Methoxybenzyl)tetrahydrofuran-2-yl]pent-4-
enyloxy}dimethylsilane (II-18d, Table 2-2, Entries 7–8). The coupling of (±)-II-
13 (400 mg, 1.4 mmol) with 4-bromoanisole (0.36 mL, 2.8 mmol) was achieved 
following general procedure 1 using THF as solvent and a reaction temperature 
of 65 °C. This procedure afforded 310 mg (56%) of the title compound as an 
orange oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.14–7.10 (m, 2 H), 
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6.84–6.79 (m, 2 H), 5.88–5.75 (m, 1 H), 5.05–4.89 (m, 2 H), 4.14–4.05 (m, 1 H), 
3.98–3.90 (m, 1 H), 3.78 (d, J = 4.1 Hz, 1 H), 3.58 (s, 3 H), 3.48–3.39 (m, 1 H), 
2.91–2.84 (m, 1 H), 2.69–2.61 (m, 1 H), 2.12–2.00 (m, 1 H), 1.92–1.81 (m, 2 H), 
1.70–1.49 (m, 3 H), 1.49–1.33 (m, 1 H), 0.88 (s, 9 H), 0.05 (s, 3 H), 0.00 (s, 3 H); 
13C NMR (100 MHz, CDCl3) δ 157.9, 138.9, 130.8, 130.2, 114.3, 113.6, 81.4, 
80.1, 74.3, 55.1, 40.9, 32.0, 31.6, 30.0, 27.3, 25.9, –4.2, –4.8; IR (film, cm–1) 
2929, 1040. MS(ESI): 413.2474 (413.2488 calcd for C23H38SiO3, M + Na+). 
 
(±)-(1R*,2R*,5R*)-1-[5-(4-tert-Butylbenzyl)tetrahydrofuran-2-yl]pent-4-en-1-ol 
(II-19a, Table 2-2, Entries 1–2). Removal of the TBS protecting group from II-
18a (26 mg, 0.067 mmol) with TBAF (0.67 mL, 0.67 mmol) was achieved 
following general procedure 2. This procedure afforded 18 mg (96%) of the title 
compound as an orange oil. 1H NMR (400 MHz, CDCl3) δ 7.33–7.29 (m, 2 H), 
7.17–7.13, (m, 2 H), 5.90–5.73 (m, 1 H), 5.09–4.94 (m, 2 H), 4.19–4.10 (m, 1 H), 
3.89–3.82 (q, J = 7.0 Hz, 1 H), 3.44–3.36 (m, 1 H), 2.93 (dd, J = 6.3, 13.7 Hz, 1 
H), 2.69, (dd, J = 8.0, 13.7 Hz, 1 H), 2.40–2.34 (d, J = 3.7 Hz, 1 H), 2.31–2.20 
(m, 1 H), 2.18–2.06 (m, 1 H), 1.99–1.87 (m, 2 H), 1.65–1.40 (m, 4 H), 1.27 (s, 9 
H); 13C NMR (100 MHz, CDCl3) δ 149.0, 138.5, 135.5, 128.9, 114.7, 82.1, 80.0, 
77.3, 73.4, 41.3, 34.3, 32.5, 32.0, 31.3, 29.8, 28.2; IR (film, cm–1) 3436, 2964, 
1060. MS(ESI): 325.2141 (325.2144 calcd for C20H30O2, M + Na+). 
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(±)-(1R*,2R*,5R*)-1-(5-Benzyltetrahydrofuran-2-yl)pent-4-en-1-ol (II-19b, 
Table 2-2, Entries 3–4). Removal of the TBS protecting group from II-18a (36 
mg, 0.1 mmol) with TBAF (1.0 mL, 1.0 mmol) was achieved following general 
procedure 2. This procedure afforded 22 mg (92%) of the title compound as an 
amber oil. 1H NMR (400 MHz, CDCl3) δ 7.37–7.31 (m, 3 H), 7.29–7.24 (m, 2 H), 
5.95–5.83 (m, 1 H), 5.14–5.00 (m, 2 H), 4.25–4.17 (m, 1 H), 3.90 (q, J = 7.0 Hz, 1 
H), 3.49–3.43 (m, 1 H), 3.01 (dd, J = 6.3, 13.7 Hz, 1 H), 2.78 (dd, J = 7.0, 13.7 
Hz 1 H), 2.45 (s, 1 H), 2.40–2.30 (m, 1 H), 2.27–2.16 (m, 1 H), 2.07–1.95 (m, 2 
H), 1.74–1.62 (m, 2 H), 1.59–1.51 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 138.6, 
138.5, 129.3, 128.3, 126.2, 114.7, 82.2, 79.9, 73.4, 41.8, 32.5, 31.9, 29.8, 28.2; 
IR (film, cm–1) 3449, 2964, 1073. MS(ESI): 269.1514 (269.1517 calcd for 
C16H22O2, M + Na+). 
 
(±)-(1R*,2R*,5R*)-1-[5-(3-Methoxybenzyl)tetrahydrofuran-2-yl]pent-4-en-1-ol 
(II-19c, Table 2-2, Entries 5–6). Removal of the TBS protecting group from II-
18c (250 mg, 0.64 mmol) with TBAF (6.4 mL, 6.4 mmol) was achieved following 
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general procedure 2. This procedure afforded 170 mg (97%) of the title 
compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.21–7.17 (m, 2 H), 
6.82–6.74 (m, 2 H), 5.89–5.77 (m, 1 H), 5.08–4.94 (m, 2 H), 4.19–4.10 (m, 1 H), 
3.87–3.80 (m, 1 H), 3.79 (s, 3 H), 3.43–3.38 (m, 1 H), 2.93 (dd, J = 6.3, 13.7 Hz, 
1 H), 2.70 (dd, J = 6.7, 13.7 Hz, 1 H), 2.35–2.24 (m, 1 H), 2.21–2.10 (m, 1 H), 
2.02–1.90 (m, 2 H), 1.68–1.57 (m, 2 H), 1.54–1.45 (m, 2 H) (the OH proton signal 
was not detected due to broadening); 13C NMR (100 MHz, CDCl3) δ 159.5, 
140.2, 138.5, 129.2, 121.7, 115.0, 114.7, 111.5, 82.2, 79.9, 73.4, 55.1, 41.9, 
32.6, 32.0, 30.0, 28.2; IR (film, cm-1) 3453, 2937, 1046. MS(ESI): 299.1617 
(299.1623 calcd for C17H24O3, M + Na+). 
 
(±)-(1R*,2R*,5R*)-1-[5-(4-Methoxybenzyl)tetrahydrofuran-2-yl]pent-4-en-1-ol 
(II-19d, Table 2-2, Entries 7–8). Removal of the TBS protecting group from II-
18d (290 mg, 0.74 mmol) with TBAF (7.4 mL, 7.4 mmol) was achieved following 
general procedure 2. This procedure afforded 190 mg (94%) of the title 
compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.15–7.11 (m, 2 H), 
6.85–6.81 (m, 2 H), 5.89–5.77 (m, 1 H), 5.08–4.94 (m, 2 H), 4.15–4.07 (m, 1 H), 
3.86–3.80 (m, 1 H), 3,79 (s, 3 H), 3.43–3.36 (m, 1 H), 2.88 (dd, J = 5.9, 13.7 Hz, 
1 H), 2.67 (dd, J = 6.7, 13.7 Hz, 1 H), 2.37 (s, 1 H), 2.36–2.24 (m, 1 H), 2.21–
2.12 (m, 1 H), 2.00–1.89 (m, 2 H), 1.66–1.56 (m, 2 H), 1.54–1.46 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 158.0, 138.4, 130.6, 130.2, 114.7, 113.7, 82.1, 80.1, 
73.4, 55.1, 40.8, 32.5, 31.7, 29.8, 28.2; IR (film, cm–1) 3469, 2918, 1036. 
MS(ESI): 299.1622 (299.1623 calcd for C17H24O3, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-5-(4-tert-Butylbenzyl)-5'-(4-methylbenzyl)octahydro-
2,2'-bifuran (II-10a, Table 2-2, Entry 1). The coupling of II-19a (30 mg, 0.11 
mmol) with 4-bromotoluene (28 µL, 0.22 mmol) was achieved following general 
procedure 1 using toluene as solvent and a reaction temperature of 110 °C. This 
procedure afforded 30 mg (67%) of the title compound as an amber oil. This 
material was obtained as a >20:1 mixture of diastereomers as judged by 1H NMR 
analysis. 1H NMR (400 MHz, CDCl3) δ 7.23–7.20 (m, 2 H), 7.19 (s, 1 H), 7.08–
7.04 (m, 2 H), 7.01 (s, 3 H), 4.16–4.08 (m, 2 H), 3.90–3.84 (m, 2 H), 3.02–2.95 
(m, 2 H), 2.56 (dd, J = 8.2, 13.3 Hz, 2 H), 2.24 (s, 3 H), 1.90–1.78 (m, 4 H), 1.56–
1.44 (m, 4 H), 1.23 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 148.9, 135.7, 135.6, 
135.5, 129.2, 129.0, 128.9, 125.1, 81.7, 81.6, 80.5, 80.4, 41.5, 41.5, 34.3, 31.6, 
31.4, 31.39, 29.8, 28.3, 21.0; IR (film, cm–1) 2900, 1051. MS(ESI): 415.2594 
(415.2613 calcd for C27H36O2, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-5-(Biphenyl-4-ylmethyl)-5'-(4-tert-
butylbenzyl)octahydro-2,2'-bifuran (II-10b, Table 2-2, Entry 2). The coupling 
of II-19a (50 mg, 0.17 mmol) with 4-bromobiphenyl (80 mg, 0.34 mmol) was 
achieved following general procedure 1 using toluene as solvent and a reaction 
temperature of 110 °C. This procedure afforded 46 mg (61%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.62–7.58 (m, 2 H), 7.55–7.50 (m, 2 H), 7.44 (t, J = 7.4 Hz, 2 H), 7.37–7.28, (m, 5 
H), 7.15 (d, J = 8.2 Hz, 2 H), 4.31–4.17 (m, 2 H), 4.02–3.94 (m, 2 H), 3.11 (dt, J = 
5.1, 13.9 Hz, 2 H), 2.75 (dd, J = 8.0, 13.5 Hz, 1 H), 2.65 (dd, J = 8.4, 13.3 Hz, 1 
H), 2.00–1.89 (m, 4 H), 1.69–1.55 (m, 4 H), 1.32 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 148.8, 141.0, 139.0, 137.9, 135.6, 129.7, 128.9, 128.7, 127.0, 126.9, 
125.1, 81.7, 81.6, 80.5, 80.3, 41.6, 41.4, 34.3, 31.5, 29.8, 28.3 (three carbon 
signals are absent due to incidental equivalence); IR (film, cm–1) 2910, 1049. 
MS(ESI): 477.2776 (477.2770 calcd for C32H38O2, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-3-[5'-Benzyloctahydro-2,2'-bifuran-5-
yl)methyl]pyridine (II-10c, Table 2-2, Entry 3). The coupling of II-19b (25 mg, 
0.1 mmol) with 3-bromopyridine (20 µL, 0.2 mmol) was achieved following 
general procedure 1 using toluene as solvent and a reaction temperature of 110 
°C. This procedure afforded 20 mg (61%) of the title compound as an amber oil. 
This material was obtained as a >20:1 mixture of diastereomers as judged by 1H 
NMR analysis. 1H NMR (400 MHz, CDCl3) δ 8.43 (s, 2 H), 7.55 (d, J = 7.6, 1 H), 
7.26–7.13 (m, 6 H), 4.19–4.08 (m, 2 H), 3.92–3.84 (m, 2 H), 3.01 (dd, J = 5.1, 
13.0 Hz, 2 H), 2.93 (dd, J = 5.7, 13.9 Hz, 2 H), 1.94–1.81 (m, 4 H), 1.64–1.44 (m, 
4 H); 13C NMR (100 MHz, CDCl3) δ 150.5, 147.6, 138.7, 136.9, 134.2, 129.3, 
128.2, 126.1, 123.2, 81.8, 81.5, 80.5, 79.6, 41.9, 38.9, 31.4, 31.3, 29.7, 28.3; IR 
(film, cm–1) 2917, 1068. MS(ESI): 324.1960 (324.1964 calcd for C21H25O2N, M + 
H+). 
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(±)-(2R*,2'R*,5R*,5'R*)-5-Benzyl-5'-(naphthalen-2-ylmethyl)octahydro-2,2'-
bifuran (II-10d, Table 2-2, Entry 4). The coupling of II-19b (50 mg, 0.17 mmol) 
with 2-bromonaphthalene (36 mg, 0.34 mmol) was achieved following general 
procedure 1 using toluene as solvent and a reaction temperature of 110 °C. This 
procedure afforded 40 mg (65%) of the title compound as an orange oil. This 
material was obtained as a >20:1 mixture of diastereomers as judged by 1H NMR 
analysis. 1H NMR (400 MHz, CD3CF2OD) δ 8.48–8.39 (m, 3 H), 8.33–8.27 (m, 1 
H), 8.15–8.04 (m, 2 H), 8.04–7.82 (m, 6 H), 5.01–4.83 (m, 2 H), 4.69–4.60 (m, 2 
H), 3.86–3.83 (m, 1 H), 3.69–3.60 (m, 1 H), 3.48–3.38 (m, 1 H), 3.31–3.23 (m, 1 
H), 2.70–2.45 (m, 4 H), 2.35–2.20 (m, 2 H), 2.18–2.05 (m, 2 H); 13C NMR (100 
MHz, CDCl3) δ 138.7, 136.3, 133.4, 132.0, 129.2, 128.2, 128.0, 127.7, 127.5, 
127.48, 127.4, 126.0, 125.8, 125.2, 81.7, 81.68, 80.4, 80.3, 42.0, 41.9, 31.4, 
31.39, 28.3, 28.26; IR (film, cm–1) 3057, 1058. MS(ESI): 395.1994 (395.1987 
calcd for C26H28O2, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-5-(3-Methoxybenzyl)-5'-[4-
(trifluoromethyl)benzyl]octahydro-2,2'-bifuran (II-10e, Table 2-2, Entry 5). 
The coupling of II-19c (40 mg, 0.15 mmol) with 4-brombenzotrifluoride (40 µL, 
0.30 mmol) was achieved following general procedure 1 using toluene as solvent 
and a reaction temperature of 110 °C. This procedure afforded 40 mg (67%) of 
the title compound as an orange oil. This material was obtained as a >20:1 
mixture of diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, 
CDCl3) δ 7.49–7.44 (m, 2 H), 7.43–7.35 (m, 2 H), 7.18 (t, J = 7.4 Hz, 1 H), 6.81–
6.73 (m, 3 H), 4.24–4.15 (m, 2 H), 3.97–3.89 (m, 2 H), 3.78 (s, 3 H), 3.09–3.00 
(m, 2 H), 2.78 (dd, J = 7.1, 13.7 Hz, 1 H), 2.65 (dd, J = 8.2, 13.3 Hz, 1 H), 1.96–
1.85 (m, 4 H), 1.68–1.49 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 159.5, 140.3, 
139.7, 132.7, 129.2, 126.2 (q, J = 222.8 Hz), 125.9, 123.0, 121.7, 115.0, 111.4, 
81.7, 81.5, 80.3, 79.8, 55.1, 42.0, 41.6, 31.5, 31.4, 28.3, 28.26; IR (film, cm–1) 
2918, 1331, 1125. MS(ESI): 443.1815 (443.1810 calcd for C24H27O3F3, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-4-[5'-(3-Methoxybenzyl)octahydro-2,2'-bifuran-5-
ylmethyl]phenyl(phenyl)methanone (II-10f, Table 2-2, Entry 6). The coupling 
of II-19c (40 mg, 0.15 mmol) with 4-bromobenzophenone (80 mg, 0.30 mmol) 
was achieved following general procedure 1 using toluene as solvent and a 
reaction temperature of 110 °C. This procedure afforded 46 mg (65%) of the title 
compound as an amber oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 
7.81–7.77 (m, 2 H), 7.61–7.55 (m, 2 H), 7.51–7.45 (m, 2 H), 7.32 (d, J = 8.2 Hz, 2 
H), 7.18 (t, J = 7.8 Hz, 2 H), 6.81–6.72 (m, 3 H), 4.29–4.16 (m, 2 H), 3.98–3.92 
(m, 2 H), 3.78 (s, 3 H), 3.14–3.02 (m, 2 H), 2.81 (dd, J = 7.0, 13.3 Hz, 1 H), 2.66 
(dd, J = 5.1, 8.2 Hz, 1 H), 1.97–1.86 (m, 4 H), 1.68–1.52 (m, 4 H); 13C NMR (100 
MHz, CDCl3) δ 196.5, 159.5, 144.0, 140.3, 137.8, 135.5, 132.2, 130.2, 130.0, 
129.3, 129.2, 128.2, 121.7, 115.0, 111.4, 81.8, 81.6, 80.4, 79.9, 55.1, 42.0, 41.9, 
31.6, 31.5, 28.3, 28.3; IR (film, cm–1) 2918, 1603, 1315. MS(ESI): 479.2190 
(479.2198 calcd for C30H32O4, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-5-(3,5-Dichlorobenzyl)-5'-(4-
methoxybenzyl)octahydro-2,2'-bifuran (II-10g, Table 2-2, Entry 7). The 
coupling of II-19d (30 mg, 0.10 mmol) with 1-bromo-3,5-dichlorobenzene (47 mg, 
0.20 mmol) was achieved following general procedure 1 using toluene as solvent 
and a reaction temperature of 110 °C. This procedure afforded 30 mg (69%) of 
the title compound as an amber oil. This material was obtained as a >20:1 
mixture of diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, 
CDCl3) δ 7.21–7.19 (m, 1 H), 7.14–7.08 (m, 4 H), 6.85–6.79 (m, 2 H), 4.20–4.10 
(m, 2 H), 3.95–3.88 (m, 2 H), 3.78 (s, 3 H), 3.01–2.90 (m, 2 H), 2.71–2.59 (m, 2 
H), 1.98–1.85 (m, 4 H), 1.69–1.45 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 158.0, 
142.3, 134.6, 130.8, 130.2, 127.8, 126.3, 113.7, 81.8, 81.5, 80.6, 79.4, 55.2, 
41.2, 41.0, 31.5, 31.4, 28.3, 28.2; IR (film, cm–1) 2931, 1038, 795. MS(ESI): 
443.1162 (443.1157 calcd for C22H26O3Cl2, M + Na+). 
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(±)-(2R*,2'R*,5R*,5'R*)-5-(4-Methoxybenzyl)-5'-(6-methoxynaphthalen-2-
ylmethyl)octahydro-2,2'-bifuran (II-10h, Table 2-2, Entry 8). The coupling of II-
19d (30 mg, 0.10 mmol) with 2-bromo-6-methoxynaphthalene (48 mg, 0.20 
mmol) was achieved following general procedure 1 using toluene as solvent and 
a reaction temperature of 110 °C. This procedure afforded 21 mg (52%) of the 
title compound as an amber oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, ((CF3)2CDOD) 
δ 8.32 (t, J = 8.4 Hz, 2 H), 8.21 (s, 1 H), 7.95 (d, J = 8.4 Hz, 1 H), 7.85 (s, 2 H), 
7.79–7.72 (m, 2 H), 7.50 (d, J = 8.2 Hz, 2 H), 4.98–4.89 (m, 1 H), 4.87–4.78 (m, 1 
H), 4.64–4.56 (m, 2 H), 4.45 (s, 3 H), 4.41 (s, 3 H), 3.75 (dd, J = 5.5, 13.1 Hz, 1 
H), 3.57 (dd, J = 5.5, 13.3 Hz, 1 H), 3.38 (dd, J = 8.0, 13.1 Hz, 1 H), 3.21 (dd, J = 
8.0, 13.3 Hz, 1 H), 2.66–2.46 (m, 4 H), 2.35–2.16 (m, 2 H), 2.15–2.05 (m, 2 H); 
13C NMR (100 MHz, CDCl3) δ 157.9, 157.1, 133.9, 133.0, 130.7, 130.1, 128.9, 
128.4, 127.3, 126.5, 118.5, 113.5, 105.5, 81.6, 81.58, 80.5, 80.3, 55.2, 55.1, 
41.7, 40.9, 31.4, 31.3, 28.2 (two carbon signals are absent due to incidental 
equivalence); IR (film, cm–1) 2933, 1035. MS(ESI): 592.3429 (593.3427 calcd for 
C28H32O4, M + Na+). 
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(–)-(2R,2'R,5R,5'R)-5-(4-Methoxybenzyl)-5'-(6-methoxynaphthalen-2-
ylmethyl)octahydro-2,2'-bifuran (II-10h, eq 2-4). The title compound was 
prepared from (–)-II-13 using a sequence identical to that described above for the 
conversion of (±)-II-13 to (±)-II-18d, (±)-II-18d to (±)-II-19d, and (±)-II-19d to (±)-
II-10h. The yield of (+)-II-18d was 65%; [α]D23 = +0.6° (c 0.43, CH2Cl2). The yield 
of (–)-II-19d was 88%; [α]D23 = –3.3° (c 0.11, CH2Cl2). The yield of (–)-II-10h was 
61%; [α]D23 = –14.2° (c 0.12, CH2Cl2). NMR data for these compounds were 
identical to those reported above. 
 
(–)-(1’R,2’S,2R,3R,5S)-2’-(Benzyloxy)-1’-[3-(benzyloxy)-5-(4-tert-
butylbenzyl)tetrahydrofuran-2-yl]pent-4-enyloxy(tert-butyl)dimethylsilane 
(II-30). The coupling of II-29 (40 mg, 0.8 mmol) with 4-bromo-tert-butylbenzene 
(280 µL, 1.6 mmol) was achieved following general procedure 1 using THF as 
solvent and a reaction temperature of 65 °C. This procedure afforded 170 mg 
(35%) of the title compound as an orange oil. This material was obtained as a 
>20:1 mixture of diastereomers as judged by 1H NMR analysis, [α]D23 = –12.2o (c 
0.37, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.41–7.26 (m, 12 H), 7.21–7.16 (m, 2 
H), 6.00–5.89 (m, 1 H), 5.12–5.02 (m, 2 H), 4.61–4.54 (m, 2 H), 4.44 (d, J = 11.0 
Hz, 1 H), 4.37 (d, J = 11.7 Hz, 1 H), 4.34–4.25 (m, 1 H), 4.08–4.01 (m, 2 H), 3.85 
(q, J = 2.7 Hz, 1 H), 3.39–3.32 (m, 1 H), 3.03 (dd, J = 6.3, 13.3 Hz, 1 H), 2.85 
(dd, J = 7.0, 13.7 Hz, 1 H), 2.45–2.39 (m, 2 H), 2.29–2.21 (m, 1 H), 1.84–1.74 (m, 
1 H), 1.36 (s, 9 H), 0.92 (s, 9 H), 0.08 (s, 3 H), 0.01 (s, 3 H);13C NMR (100 MHz, 
CDCl3) δ 148.9, 138.7, 137.9, 136.5, 135.5, 128.9, 128.3, 128.1, 127.8, 127.6, 
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127.3, 125.1, 116.1, 84.2, 80.6, 80.3, 79.3, 74.6, 71.9, 71.4, 41.5, 37.6, 35.1, 
34.3, 31.3, 26.0, 18.3, –4.3, –4.7; IR (film, cm–1) 2955, 1092. MS(ESI): 651.3848 
(651.3846 calcd for C40H56SiO4, M + Na+). 
 
(–)-(1’R,2’S,2S,3R,5S)-2’-(Benzyloxy)-1’-[3-(benzyloxy)-5-(4-tert-
butylbenzyl)tetrahydrofuran-2-yl]pent-4-en-1-ol (II-31). Removal of the TBS 
protecting group from II-30 (160 mg, 0.25 mmol) with TBAF (2.5 mL, 2.5 mmol) 
was achieved following general procedure 2. This procedure afforded 106 mg 
(81%) of the title compound as an orange oil, [α]D23 = –70.4° (c 0.1, CH2Cl2). 1H 
NMR (400 MHz, CDCl3) δ 7.38–7.26 (m, 12 H), 7.17–7.13 (m, 2 H), 6.01–5.88 
(m, 1 H), 5.20–5.07 (m, 2 H), 4.66–4.44 (m, 4 H), 4.40–4.29 (m, 2 H), 4.21–4.15 
(m, 1 H), 3.64–3.56 (m, 1 H), 3.51–3.45 (m, 1 H), 3.06 (dd, J = 6.6, 13.5 Hz, 1 H), 
2.83 (dd, J = 6.5, 13.5 Hz, 1 H), 2.61–2.54 (m, 1 H), 2.48–2.39 (m, 1 H), 2.23–
2.14 (m, 2 H), 1.91–1.84 (m, 1 H), 1.32 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 
149.0, 138.4, 138.1, 135.5, 134.9, 129.0, 128.4, 128.3, 127.9, 127.7, 127.6, 
127.59, 125.3, 117.3, 82.0, 80.9, 80.4, 79.4, 72.4, 72.2, 71.8, 41.7, 37.3, 35.2, 
34.4, 31.4; IR (film, cm–1) 3468, 2961, 1100. MS(ESI): 537.2988 (537.2981 calcd 
for C34H42O4, M + Na+). 
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(–)-(2R,2'R,3R,3'R,5S,5'S)-3-[3,3'-Bis(benzyloxy)-5'-(4-tert-
butylbenzyl)octahydro-2,2'-bifuran-5-ylmethyl]pyridine (II-32). The coupling 
of II-31 (110 mg, 0.20 mmol) with 3-bromopyridine (40 µL, 0.40 mmol) was 
achieved following general procedure 1 using toluene as solvent and a reaction 
temperature of 110 °C. This procedure afforded 120 mg (57%) of the title 
compound as an amber oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis, [α]D23 = –43.7o (c 0.83, CH2Cl2). 1H 
NMR (400 MHz, CDCl3) δ 8.43–8.36 (m, 1 H), 7.46–7.41 (m, 1 H), 7.31–7.20 (m, 
11 H). 7.15–7.09 (m, 2 H), 7.07–7.02 (m, 3 H), 4.50–4.34 (m, 4 H), 4.20–4.09 (m, 
3 H), 4.07–4.00 (m, 3 H), 3.00–2.89 (m, 2 H), 2.80–2.66 (m, 2 H), 2.19–2.04 (m, 
2 H), 1.78–1.64 (m, 2 H), 1.25 (s, 9 H);13C NMR (100 MHz, CDCl3) δ 150.5, 
148.9, 147.6, 138.1, 138.0, 136.8, 135.5, 134.3, 128.9, 128.44, 128.4, 127.7, 
127.67, 127.6, 125.2, 123.2, 84.4, 84.2, 81.0, 80.9, 80.3, 79.6, 71.7, 41.7, 39.3, 
37.3, 37.2, 34.4, 31.4 (two signals are absent due to incidental equivalence); IR 
(film, cm–1) 2918, 1648, 1185. MS(ESI): 592.3429 (593.3427 calcd for 
C39H45NO4, M + Na+). 
Assignment of Stereochemistry 
2,3,5 Substituted Tetrahydrofurans (Table 2-1) 
The relative stereochemistry of II-16c was assigned on the basis of signals 
observed in 1H NMR nOe experiments. Relevant nOe data is shown below.  
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The stereochemistry of the related compounds II-16a, II-16b, and II-16d was 
assigned based on analogy to II-16c. 
 
Fused Bis-Tetrahydrofurans (Table 2-1) 
The relative stereochemistry of II-8f was assigned on the basis of signals 
observed in 1H NMR nOe experiments. Relevant nOe data is shown below.  
 
The stereochemistry of the related compounds II-8a–e and II-8g–h was assigned 
based on analogy to II-8f. 
 
2,5 Substituted Tetrahydrofurans (Table 2-2 and Scheme 2-2) 
The relative stereochemistry of II-30 was assigned on the basis of signals 
observed in 1H NMR nOe experiments. Relevant nOe data is shown below. 
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The stereochemistry of the related compounds II-19a–d and was assigned based 
on analogy to II-30. 
Attached-Ring Bis-Tetrahydrofurans 
The relative stereochemistry of II-32 was assigned on the basis of signals 
observed in 1H NMR nOe experiments. Relevant nOe data is shown below.  
 
The stereochemistry of the related compounds II-10a–h was assigned based on 
analogy to II-32. 
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Chapter 3: Palladium-Catalyzed Carboetherification 
Reactions of Internal Alkene Substrates 
 
3.1 Introduction 
The prevalence of tetrahydrofuran units in natural products and other 
biologically active molecules has inspired the invention of numerous methods for 
the construction of these heterocycles.1 For the past several years, our group 
has investigated a new approach to the stereoselective synthesis of 
tetrahydrofurans via Pd-catalyzed cross-coupling reactions between γ-hydroxy 
alkenes and aryl or alkenyl halides.2 These reactions exhibit several attractive, 
synthetically useful features: simple starting materials are employed, both a C-O 
and a C-C bond are generated, and control of relative stereochemistry around 
the tetrahydrofuran ring is generally high. For example, the coupling of III-1 with 
1-bromo-4-tert-butylbenzene afforded III-2 in 69% yield with >20:1 dr (Scheme 3-
1).3 Although Pd-catalyzed carboetherifications have considerable utility, at the 
time I joined the group, the method suffered from a significant limitation: 
transformations of substrates such as III-3 that contain acyclic internal alkenes 
afford products bearing stereocenters adjacent to the ring (e.g., III-4) with only 
modest stereoselectivity (ca. 3-5:1 dr). 
 
Scheme 3-1. Prior Studies 
O
Ar
H
1 mol % Pd2(dba)3
2 mol % Dpe-Phos
III-2
NaOtBu, THF, 65 °C
O
Ar
H
OH
III-4
Ph
H
Ar = p-t-BuPh
Ar–Br
69%, >20:1 dr
+
1 mol % Pd2(dba)3
4 mol % P(o-tol)3
NaOtBu, Toluene, 110 °C
Ar = p-PhPh73%, 5:1 dr
OH
Ar–Br+
Ph
III-1
III-3
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3.2 Mechanism of Diastereomer Formation  
Through a series of deuterium labeling experiments, Dr. Mike Hay found that 
both diastereomers (e.g., III-4 and III-11) formed in carboetherification reactions 
of substrates such as III-3 arise from a common intermediate (III-6) (Scheme 3-
2).4,5 The mechanism of these transformations involves oxidative addition of the 
aryl halide to Pd(0) followed by substitution of alkoxide for bromide to provide III-
5. A key syn-oxypalladation of III-5 generates intermediate III-6, which can 
undergo C-C bond-forming reductive elimination to afford tetrahydrofuran product 
III-4. However, the reductive elimination from complex III-6 is not fast enough to 
avoid competing β-hydride elimination. Thus, partial isomerization of III-6 occurs 
via β-hydride elimination/hydridopalladation to provide III-8, which undergoes σ-
bond rotation followed by a second β-hydride elimination/hydridopalladation to 
yield III-10. Reductive elimination from III-10 affords the minor stereoisomer III-
11, leading to the modest diastereoselectivity observed with substrates such as 
III-3.  
 
Scheme 3-2. Mechanism 
3.3 Ligand Optimization  
In recent years, a number of new phosphine ligands have been developed for 
Pd-catalyzed carbon-carbon and carbon-heteroatom bond-forming reactions that 
accelerate reductive elimination.6 It seemed that one of these ligands could 
potentially improve the diastereoselectivity in Pd-catalyzed carboetherifications of 
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internal alkenes by increasing the rate of reductive elimination from intermediate 
III-6. In order to probe this hypothesis, we investigated the Pd-catalyzed coupling 
of (Z)-2-methylhept-5-en-2-ol (III-12) with bromobenzene using a number of 
different ligands known to promote rapid reductive elimination.7 As shown in 
Table 3-1, P(o-tol)3, which was employed in our initial studies, provided III-13 in 
good yield but only 4:1 dr. Chelating ligands with wide bite angles, such as Dpe-
Phos and xantphos, failed to provide satisfactory results. However, considerably 
improved diastereoselectivity was obtained using Buchwald’s S-Phos ligand 
(entry 9, 9:1 dr). In addition, the Pd/S-Phos catalyst transformed E-alcohol 
stereoisomer III-3 to tetrahydrofuran III-14 in good yield and excellent 
diastereoselectivity (entry 10, 20:1 dr).8,9 
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Table 3-1. Ligand Optimizationa 
3.3 Substrate Scope  
O
Ph
H
2 mol % Pd2(dba)3
4 mol % Ligand
ligand yield (%)bIII-13:III-14
P(o-tol)3
RuPhos
764:1
689:1
III-12: R1 = H, R2 = Me
III-3: R1 = Me, R2 = H
III-14
entry
1
5
Ph–Br
NaOtBu, Toluene
140 °C
O
Ph
H
OH
R1
R2
+
III-13
substrate
S-Phos
X-Phos
Xantphos
861:20
403:1
172:1
10
4
3
III-12
III-3
III-12
III-12
S-Phos 849:19 III-12
Dpe-Phos 551:12 III-12
III-12
6
7
III-12
III-12
Dave-phos
John-phos 2:1 18
2:1 49
8 III-12 Brett-phos – 0
a Conditions: 1.0 equiv of alcohol, 2.0 equiv of ArBr, 2.0 equiv of NaOtBu, 2 mol % 
of Pd2(dba)3, 4 mol % of ligand, xylenes, 140 °C. b Isolated yields (average of two or 
more experiments).
O
Ph2P PPh2
O
Ph2P PPh2
Cy2P
iPr
iPr
Cy2P
iPrO
OiPr
Cy2P
Me2N
tBu2P
Cy2P
iPr
iPr
iPr
MeO
MeO
Cy2P
MeO
OMe
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With a much more effective catalyst system in hand, we investigated Pd-
catalyzed carboetherification reactions between a range of aryl or alkenyl 
bromides and several different γ-hydroxyalkene substrates, which were 
synthesized according to the general route shown in Scheme 3-3.10  
 
Scheme 3-3. General Method for the Synthesis of Various Substrates 
As shown in Table 3-2, both electron-donating and electron-withdrawing groups 
on the aryl bromide were tolerated. In all cases examined, the major 
diastereomer resulted from syn-addition of the arene and the oxygen atom 
across the double bond, which is consistent with our prior results. 
R
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p-CF3Ph
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81%
94%
NaHMDS
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ROH
p-CF3PhOH C6H12OH C9H19OH
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III-16
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O
Ph
H
749:1
yield (%)bdrsubstrate product
89>20:1
82>20:1
87>20:1
III-15
III-27
III-15
III-28
III-16
III-29
III-17 III-30
O
Ph
H
O
Ph
H
O
C6H4-p-CF3
H
CF3
CF3
entry
1
2
3
4
OH
Ph
OH
OH
C6H4-p-CF3
Ph
96>20:1
III-18 III-32
O
C6H4-p-CF3
H
6
OH
C6H4-p-CF3
51>20:1
III-19
III-33
O
C6H4-p-OMe
H7 OH
C6H4-p-OMe
60>20:1
III-20
III-34
O
C6H4-p-OMe
H8
OH
C6H4-p-OMe
Cl
Cl
Cl
Cl
55>20:1III-17
III-31
O
C6H4-p-CF3
H
5
Ph
  
66 
 
Table 3-2. Synthesis of Tetrahydrofuransa 
 In most instances, E-alkene substrates bearing aryl or alkyl substituents were 
converted to the desired products with high diastereoselectivities (entries 1, 2, 4, 
5, 7, and 11). In addition, the coupling reaction of a sterically hindered 
cyclohexyl-substituted alkene was also efficient (entry 9). An E-alkene bearing an 
acetal was transformed into the desired tetrahydrofuran III-39 with good 
diastereoselectivity, but only modest yield (entry 13). In contrast, the conversion 
60>20:1
III-20
III-34
O
C6H4-p-OMe
H8
OH
C6H4-p-OMe
Cl
Cl
90>20:1
III-21 III-35
O
Cy
H
9 OH
Cy
23c,d2:1
III-22 III-36
O
Cy
H
10
OH
Cy
94>20:1
III-23 III-37
O
C9H19
H
11 OH
C9H19
43d4:1
III-24 III-38
O
C9H19
H
12
OH
C9H19
OMe
OMe
42>20:1
III-25 III-39
O
H
13 OH
OMe
OO
OO
O
H
OTBS
OH
OTBS
14 8612:1
PhIII-26
III-4018:1 E:Z
a Conditions: 1.0 equiv of alcohol, 2.0 equiv of ArBr, 2.0 equiv of NaOtBu, 2 mol % of 
Pd2(dba)3, 4 mol % of S-Phos, xylenes, 140 °C. b Isolated yields (average of two or 
more experiments). c NMR yield. This material was contaminated with ca. 15% of an 
inseparable unidentified side product. d Formation of a side product tentatively assigned 
as a regioisomer was also observed.
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of cyclohexanol derivative III-26 to spirocyclic tetrahydrofuran III-40 proceeded 
with good yield (entry 14), but slightly lower stereoselectivity (12:1).  
Although reactions of Z-alkenes substituted with methyl or phenyl groups 
proceeded with only 9:1 dr (Table 3-1, entry 9, and Table 3-2, entry 3), 
substrates bearing either electron-rich or electron-poor aryl substituents on the 
alkene were converted to products with excellent diastereoselectivity (Table 3-2, 
entries 6 and 8). However, chemical yields were lower with the electron-donating 
aryl substituent (entry 8). Unfortunately, Z-alkene substrates bearing either a long 
alkyl chain (entry 12) or a bulky substituent (entry 10) were transformed with poor 
diastereoselectivity, and the formation of side products tentatively assigned as 
regioisomers was also observed.11  
 
Figure 3.1. Improvement in dr with S-phos. 
Prior efforts to effect carboetherification reactions of internal alkene substrates 
bearing stereocenters led to the formation of complicated mixtures of 
stereoisomers. For example, Dr. Mike Hay had previously shown the Pd/P(o-
tol)3-catalyzed coupling of III-41 with β-bromostyrene proceeded in 60% yield and 
afforded an inseparable mixture of four diastereomers (eq 1). However, I found 
that the use of the S-Phos ligand provided III-42 in 80% yield with 12:1 dr.12 As 
shown in Table 3-3, E-alkene substrates bearing stereocenters at C1 (entry 1) or 
C3 (entry 3) were efficiently converted to polysubstituted tetrahydrofurans with 
good to excellent stereocontrol. The conversion of Z-alkene III-44 to 
tetrahydrofuran III-47 proceeded with 7:1 syn/anti addition selectivity, which is 
similar to results obtained for carboetherification of (Z)-2-methylhept-5-en-2-ol III-
12 (Table 3-1, entry 9).13 Although the coupling of III-45 with 4-bromotoluene 
provided a 4:1 mixture of tetrahydrofuran diastereomers epimeric at C4, 
Ligand = P(o-tol)3: 60%, 79:9:5:4 dr
Ligand = S-Phos: 80%, 12:1 dr
42
O
H Ph
H
OH
41
(1)1–2 mol % Pd2(dba)3
4 mol % ligand
NaOtBu, Xylenes
110–140 °C
+
Br
Ph
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complete selectivity for syn-addition was observed.14 Nonetheless, all four 
transformations illustrated in Table 3-3 afforded products with significantly better 
diastereoselectivities than were obtained in related transformations with P(o-tol)3 
as ligand. Although this method is very effective with tertiary alcohol substrates 
bearing internal alkenes, efforts to employ secondary alcohols failed to generate 
tetrahydrofuran products. Instead, oxidation of the secondary alcohol to the 
corresponding ketone was observed, as shown in Figure 3-2.15  
 
Table 3-3. Synthesis of Polysubstituted Tetrahydrofuransa 
 
 
Figure 3.2. Attempted Pd-Catalyzed Carboetherification Reactions of Secondary 
Alcohols. 
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H
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III-41
III-48
III-45 III-49
O
H
Ph
O
H
H
O
H
H
C(O)Ph
CF3
CF3
entry
1
2
3
4
OHPh
OHPh
OH
OH
a Conditions: 1.0 equiv of alcohol, 2.0 equiv of ArBr, 2.0 equiv of NaOtBu, 2 mol % of Pd2(dba)3, 
4 mol % of S-Phos, Xylenes, 140 °C. b Isolated yields (average of two or more experiments). c 
The two diaster- eomers are epimeric at C1!. d The two diastereomers are epimeric at C4.
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OH
Ph
O
Ph
2 mol % Pd2(dba)3
2 mol % S-Phos
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140 °C
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3.4 A Model System of Simplakidine A  
The results illustrated in Table 3-3 prompted us to model the feasibility of 
applying our method to the synthesis of simplakidine A (III-52).16 This 
polysubstituted tetrahydrofuran natural product exhibits cytotoxic activity and has 
not previously been synthesized. As shown in Scheme 3-3, the tetrahydrofuran 
core of this molecule could potentially be generated through a Pd-catalyzed 
carboetherification between a tertiary alcohol bearing a pendant E-alkene (III-53) 
and a suitably substituted 4-bromopyridine derivative (III-54). The ring-closing 
reaction would form the C9 and C10 stereo-centers with concomitant installation 
of the heteroaryl group.  
  
Scheme 3-4. Strategy for the Synthesis of Simplakidine A 
The two substituents on C6 of the natural product are fairly close in size 
(approximately Me vs i-Bu), which suggests the diastereotopic face selectivity of 
the alkene carboetherification reaction will likely be controlled by the 
stereochemical configuration at C8 of substrate III-53 rather than C6. Thus, the 
simple tertiary alcohol III-41 seemed to be a reasonable approximation to III-53 
for an initial model study. As such, we examined the Pd/S-Phos-catalyzed 
coupling of III-41 with 4-bromopyridine hydrochloride. We were gratified to find 
that this transformation provided III-55 with 15:1 dr in 67% yield.  
To determine if the assumption that tertiary alcohol III-41 could be used to 
approximate III-53 was reasonable, III-56 was synthesized according to a 
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Et
EtHMe
Et
HO
HO2C N
Me
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+
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R
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+
N
Br
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OOH
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4 mol % PdCl2(CH3CN)2
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+
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literature procedure17 and was transformed into substrate III-57 in 2:1 dr via 
Grignard addition. Subsequently, III-57 was coupled under the optimized 
conditions to 4-bromopyridine, and the desired product III-58 was obtained as a 
mixture of 4 diastereomers in a 25:15:6:2 ratio (Scheme 3-5). Based on analogy 
to known compounds III-60 and III-61, in which the proton at the 2 position of the 
tetrahydrofuran ring of the minor 2,5-cis isomer is shifted upfield with respect to 
the 2,5-trans isomer, and III-62 and III-63, in which the proton at the 3 position of 
the tetrahydrofuran ring of the 2,3-cis isomer is shifted upfield with respect to the 
2,3-trans isomer, we tentatively assigned the major isomer (III-58) as the 2,3-
trans, 2,5-cis product and the minor isomer (III-59) as the 2,3-trans, 2,5-trans 
product. Thus, the stereocenter at C4 of III-57 likely controlled the 
diastereoselectivity of the reaction, indicating that simplakidine, which possesses 
a 2,3-trans, 2,5-cis configuration, may be accessed using our methodology. 
However, in order to more accurately determine the diastereoselectivity of the 
reaction, III-57 must be synthesized as a single diastereomer and subjected to 
the optimized conditions, and nOe analysis must be performed on the final 
product. 
 
Scheme 3-5. Pd-Catalyzed Carboetherification Reactions of a Model System 
Containing a Stereocenter at the Cyclizing Alcohol 
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Figure 3-3. Known Compounds Used to Assign the Stereochemistry of III-58 and 
III-59 
Although we had demonstrated that polysubstituted natural products such as 
simplakidine could be accessed with our methodology, we desired to develop a 
general strategy for biologically active tetrahydrofurans, especially the 
annoaceous acetogenins, which possess a hydroxyl substituent at the 1’ position. 
To this end, we evaluated the carboetherification of enol ether substrate III-70. 
This substrate was synthesized from commercially available hex-5-en-2-one (III-
64) via methyl Grignard addition, TMS protection of the resulting alcohol, and 
ozonolysis to afford aldehyde III-67. Subsequently, III-67 was transformed to III-
70 using the corresponding Wittig reagent followed by removal of the TMS group.  
 
Scheme 3-6. Synthesis of Enol Ether Substrate III-70 
Using a catalyst system composed of S-phos and Pd2dba3, a complex mixture 
of starting material and various unidentified products were obtained. In contrast, 
when chelating ligand xantphos was employed, III-72, a compound derived from 
alkoxy elimination, was detected in the crude HNMR spectrum. A variety of other 
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ligands were also used to effect the desired transformation; however, in all 
cases, the reaction conditions failed to produce polysubstituted tetrahydrofurans 
in appreciable yield. Thus, further optimization is necessary in order to access 
these biologically relevant motifs. 
 
 
 
Table 3-4. Attempted Pd-Catalyzed Carboetherification of III-70 
3.5 Conclusions  
In conclusion, we have developed significantly improved conditions for the 
synthesis of tetrahydrofurans bearing stereocenters at C2 and C1′ via Pd-
OH
MeO
III-70
O
Ph
2 mol % Pd2(dba)3
4 mol % Ligand
ligand Result
P(o-tol)3
RuPhos
III-72
entry
1
5
Ph–Br
NaOtBu, Toluene 110 °C
O
Ph
III-71
X-Phos
Xantphos
4
3
S-Phos6
Dpe-Phos2
O
Ph2P PPh2
O
Ph2P PPh2
Cy2P
iPr
iPr
Cy2P
iPrO
iPrO
Cy2P
MeO
MeO
OMe
III-72 Yield not obtained
III-70 Recollected
III-72 Yield not obtained
III-70 Recollected, complex mixture
III-70 Recollected, complex mixture
III-70 Recollected, complex mixture
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catalyzed carboetherification. The Pd/S-Phos catalyst system minimizes isomer- 
ization after the key syn-oxypalladation event in the catalytic cycle by facilitating 
rapid C-C bond-forming reductive elimination. This significantly expands the 
range of tetrahydrofuran products that can be generated efficiently by coupling 
aryl or alkenyl halides with unsaturated alcohol substrates. In addition, the 
experiments illustrated in Table 3-1 provide a measure of the relative facility of 
sp3C-CAr bond-forming reductive elimination with a series of different ligands, 
which may be useful in the development of other metal-catalyzed reactions.  
3.6 Experimental 
General. All reactions were carried out under a nitrogen atmosphere in oven or 
flame dried glassware. Tris(dibenzylideneacetone)dipalladium (0) and all 
phosphine ligands were purchased from Strem Chemical Co. and used without 
further purification. All aryl bromides were obtained from commercial sources 
(Aldrich Chemical CO or Acros Chemical CO) and were used as obtained. [3-
(Ethoxycarbonyl)propyl]triphenylphosphonium bromide,18 (E)-ethyl 5-phenylpent-
4- enoate,19 (Z)-ethyl 5-phenylpent-4-enoate,20 (E)-ethyl 5-(4-
methoxyphenyl)pent-4-enoate,21 1-[4-(trifluoromethyl)phenyl]prop-2-en-1-ol,22 1-
cyclohexylprop-2-en-1-ol,6 dodec-1-en-3-ol,23 1-(but- 3-enyl)cyclohexanol,8 (E)-
2-methylhept-5-en-2-ol,24 (Z)-2-methylhept-5-en-2-ol,25 and (E)-2,4- 
dimethylhept-5-en-2-ol26 were prepared according to literature procedures. 
Stereochemistry of tetrahydrofuran products was assigned by analogy to related 
compounds previously reported by our group through comparison of NMR 
spectra.27 Toluene and THF were purified using a GlassContour solvent 
purification system. Yields refer to isolated yields of compounds estimated to be 
95% pure as determined by 1H NMR. The yields reported in the supporting 
information describe the result of a single experiment, whereas the yields 
reported in Tables 3-1–3-2 and eq 3-3–3-5 are average yields of two or more 
experiments. Thus, the yields reported in the supporting information may differ 
from those shown in Tables 3-1–3-2 and eq 3-3–3-5. 
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Preparation of Substrates 
General Procedure 1: Synthesis of (E)-!,"-Unsaturated Esters via Johnson 
Orthoester 
Claisen Rearrangements of Allylic Alcohols.28 A round bottom flask 
equipped with a short path distillation head and a recovery flask was charged 
with an appropriate allylic alcohol (1.0 equiv), triethyl orthoacetate (5 equiv), and 
pivalic acid (0.05 equiv). The mixture was heated to 140 °C with stirring until the 
starting material had been completely consumed as judged by GC analysis. The 
reaction mixture was cooled to room temperature and diluted with ethyl acetate 
(1:1 v:v). A solution of 1 M HCl (1:1 v:v) was slowly added and the resulting 
biphasic mixture was stirred for 1 h at rt. The layers were separated and the 
organic layer was washed with water (2 x 50 mL) and saturated NaHCO3 (1 x 50 
mL). The organic layer was then dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography 
on silica gel. 
General Procedure 2: Synthesis of (Z)-γ ,δ-Unsaturated Esters via Wittig 
Olefinations of Aldehydes With [3-
(Ethoxycarbonyl)propyl]triphenylphosphonium Bromide.29 An oven-dried 
flask equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with [3-(ethoxycarbonyl)propyl]triphenylphosphonium bromide (1 equiv) 
and THF (1 M). The resulting suspension was cooled to –78 °C then a solution of 
NaHMDS (1 equiv) in THF (1 M) was added dropwise. The resulting mixture was 
stirred at –78 °C for one h, then a solution of the appropriate aldehyde (1 equiv) 
in THF (3 M) was added dropwise. The reaction mixture was stirred at –78 °C for 
2 h then was warmed to rt, and stirred overnight (ca 12 h). A solution of brine (5 
mL) was added, followed by with EtOAc (5 mL), and the mixture was transferred 
to a separatory funnel. The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were then dried 
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over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude material 
was purified by flash chromatography on silica gel. 
 
(E)-Ethyl 5-[4-(trifluoromethyl)phenyl]pent-4-enoate (III-S1). General 
procedure 1 was used for conversion of 1-[4-(trifluoromethyl)phenyl]prop-2-en-1-
ol (1.74 g, 0.86 mmol) to the title compound. This procedure afforded 2.6 g (92%) 
of the title compound as a colorless oil. This material was obtained with >20:1 
E:Z selectivity as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.47 
(d, J = 8.2 Hz, 2 H), 7.34 (d, J = 8.2 Hz, 2 H), 6.40 (d, J = 15.8 Hz, 1 H), 6.26 (dt, 
J =6.2, 15.8 Hz, 1 H), 4.10 (q, J = 7.0 Hz, 2 H), 2.54–2.47 (m, 2 H), 2.46–2.41 
(m, 2 H), 1.20 (t, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 172.6, 140.8, 
131.33 (q, J = 234.2 Hz), 129.0 (q, J = 32.1 Hz), 128.8, 125.3 (q, J = 3.8 Hz), 
122.9, 60.3, 33.6, 28.2, 14.1; IR (film, cm–1) 2984, 1734, 1327; MS(ESI): 
272.1026 (272.1024 calcd for C14H15F3O2, M+). 
 
 (Z)-Ethyl 5-[4-(trifluoromethyl)phenyl]pent-4-enoate (III-S2). General 
Procedure 2 was used for conversion of 4-(trifluoromethyl)benzaldehyde (0.35 
mL, 3.28 mmol) to the title compound. This procedure to afforded 0.70 g (70%) of 
the title compound as a colorless oil. This material was obtained as a 20:1 
mixture of Z:E isomers as judged by 1H NMR analysis. Data are for the major 
isomer. 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.3 Hz, 2 H), 7.34 (d, J = 8.3 
Hz, 2 H), 6.44 (d, J = 11.7 Hz, 1 H), 5.72 (dt, J = 7.3, 11.7 Hz, 1 H), 4.10 (q, J = 
O
O
F3C III-S1
O
O
CF3
III-S2
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7.1 Hz, 2 H), 2.65–2.59 (m, 2 H), 2.43–2.38 (m, 2 H), 1.20 (t, J = 7.1 Hz, 3 H); 
13C NMR (100 MHz, CDCl3) δ 172.5, 140.9, 131.4 (q, J = 218.9), 129.0 (q, J = 
47.2 Hz), 128.9, 125.1 (q, J = 3.7 Hz), 123.2, 60.3, 34.0, 23.9, 14.0; IR (film, cm–
1) 2984, 1734; MS(ESI): 272.1026 (272.1024 calcd for C14H17F3O, M+). 
 
(Z)-Ethyl 5-(4-methoxyphenyl)pent-4-enoate (III-S3). General Procedure 2 
was used for the conversion of 4-methoxybenzaldehyde (0.4 g, 3.28 mmol) to the 
title compound. This procedure afforded 0.46 g (59%) of the title compound as a 
colorless oil. This material was obtained as a 10:1 mixture of Z:E isomers as 
judged by 1H NMR analysis. Data are for the major isomer. 1H NMR (400 MHz, 
CDCl3) δ 7.25–7.22 (m, 2 H), 6.90–6.87 (m, 2 H), 6.41 (d, J = 11.7 Hz, 1 H), 5.54 
(dt, J = 7.1, 11.7 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.80 (s, 3H), 2.70–2.64 (m, 
2H), 2.46–2.42 (m, 2 H), 1.25 (t, J = 7.1 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
172.9, 158.4, 129.9, 129.5, 128.8, 113.6, 60.4, 55.2, 34.5, 24.1, 14.2 (one carbon 
signal is absent due to incidental equivalence); IR (film, cm–1) 2981, 1732; 
MS(ESI): 257.1152 (257.1154 calcd for C14H18O3, M + Na+). 
 
(E)-Ethyl 5-cyclohexylpent-4-enoate (III-S4). General Procedure 1 was used 
for the conversion of 1- cyclohexylprop-2-en-1-ol (1.28 g, 9.13 mmol) to the title 
compound. This procedure afforded 1.92 g (81%) of the title compound as a 
colorless oil. This material was obtained with >20:1 E:Z selectivity as judged by 
1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 5.45–5.32 (m, 2 H), 4.13 (q, J = 
O
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7.3 Hz, 2 H), 2.38–2.26 (m, 4 H), 1.94–1.85 (m, 1 H), 1.74–1.60 (m, 5 H), 1.30–
1.21 (m, 5 H), 1.19–1.10 (m, 1 H), 1.09–0.98 (m, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 173.1, 137.6,125.3, 60.1, 40.5, 34.4, 33.0, 28.0, 26.1, 25.9, 14.2; IR 
(film, cm–1) 2924, 1738; MS(ESI): 233.1520 (233.1517 calcd for C14H18O2, M + 
Na+). 
 
(Z)-Ethyl 5-cyclohexylpent-4-enoate (III-S5). General Procedure 2 was used 
for the conversion of 1-cyclohexylprop-2-en-1-ol (1.70 g, 3.70 mmol) to the title 
compound. This procedure afforded 0.65 g (51%) of the title compound as a 
colorless oil. This material was obtained with 20:1 E:Z selectivity as judged by 1H 
NMR analysis. 1H NMR (400 MHz, CDCl3) δ 5.21–5.12 (m, 2 H), 4.06 (q, J = 7.0 
Hz, 2 H), 2.34–2.24 (m, 4 H), 2.23–2.17 (m, 1 H), 1.66–1.50 (m, 5 H), 1.27–1.17 
(m, 5 H), 1.13–1.05 (m, 1 H), 1.03–0.94 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 
173.0, 137.3, 125.4, 60.1, 36.2, 34.6, 33.2, 26.0, 25.8, 23.0, 14.2; IR (film, cm–1) 
2923, 1739; MS(ESI): 233.1521 (233.152 calcd for C14H18O2, M + Na+). 
 
(E)-Ethyl tetradec-4-enoate (III-S6). General Procedure 1 was used for the 
conversion of dodec-1-en-3-ol (1.3 g, 7.06 mmol) to the title compound. This 
procedure afforded 1.17 g (69%) of the title compound as a colorless oil. This 
material was obtained with >20:1 E:Z selectivity as judged by 1H NMR analysis. 
1H NMR (400 MHz, CDCl3) δ 5.50–5.35 (m, 2 H), 4.12 (q, J = 6.8 Hz, 2 H), 2.37–
2.26 (m, 4 H), 1.96 (q, J = 6.6 Hz, 2H), 1.35–1.19 (m, 17 H), 0.88 (t, J = 6.8 Hz, 3 
H); 13C NMR (100 MHz, CDCl3) δ 173.2, 131.8, 127.9, 60.2, 34.4, 32.5, 32.0, 
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29.6, 29.5, 29.4, 29.3, 29.1, 27.9, 22.7, 14.2, 14.1; IR (film, cm–1) 2924, 1739; 
MS(ESI): 277.2140 (277.2144 calcd for C16H30O2, M + Na+). 
 
(Z)-Ethyl tetradec-4-enoate (III-S7). General Procedure 2 was used for the 
conversion of dodec-1-en-3-ol (1.50 g, 3.28 mmol) to the title compound. This 
procedure afforded 0.83 g (54%) of the title compound as a colorless oil. This 
material was obtained with 20:1 E:Z selectivity as judged by 1H NMR analysis. 1H 
NMR (400 MHz, CDCl3) δ 5.40–5.20 (m, 2 H), 4.05 (q, J = 7.0 Hz, 2 H), 2.33–
2.20 (m, 4 H), 2.00–1.92 (m, 2 H), 1.29–1.15 (m, 17 H), 0.80 (t, J = 7.0 Hz, 3 H); 
13C NMR (100 MHz, CDCl3) δ 173.0, 131.4, 127.2, 60.1, 34.3, 31.8, 29.6, 29.5, 
29.4, 29.3, 29.2, 27.1, 22.7, 22.6, 14.1, 14.0; IR (film, cm–1) 2924, 1739; 
MS(ESI): 277.2135 (277.2144 calcd for C16H30O2, M + Na+). 
General Procedure 3: Addition of MeMgBr to Esters. An oven or flame dried 
flask equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with MeMgBr (3 equiv, 3.0 M in diethyl ether). Additional ether was 
added to provide a 1.0 M solution of MeMgBr, which was then cooled to 0 °C. 
The appropriate ester (1.0 equiv) was added dropwise via syringe and the 
resulting mixture was warmed to rt and stirred for 2–4 h until the starting material 
was completely consumed as judged by TLC analysis. A saturated solution of 
aqueous NH4Cl (1:1 by volume with the reaction mixture) was added dropwise 
and the resulting mixture was then diluted with ethyl acetate (40 mL). The layers 
were separated and the aqueous layer was extracted with ethyl acetate (2 x 20 
mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel. 
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(E)-2-Methyl-6-phenylhex-5-en-2-ol (III-15). General Procedure 3 was used 
for the conversion of (E)-ethyl 5-phenylpent-4-enoate (1.16 g, 5.6 mmol) to the 
title compound. This procedure afforded 0.76 g (71%) of the title compound as a 
white solid, m.p. 42 °C. This material was obtained as a >20:1 mixture of E:Z 
isomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.32–7.22 
(m, 4 H), 7.18–7.13 (m, 1 H), 6.38 (d, J = 15.8 Hz, 1 H), 6.21 (dt, J = 6.8 Hz, 15.8 
Hz, 1 H), 2.31–2.24 (m, 2 H), 1.65–1.59 (m, 3 H), 1.21 (s, 6 H); 13C NMR (100 
MHz, CDCl3) δ 137.7, 130.8, 129.8, 128.4, 126.9, 125.9, 70.9, 43.2, 29.2, 28.0; 
IR (film, cm–1) 3362, 2970; MS(ESI): 190.1355 (190.1358 calcd for C13H18O, M+). 
 
(Z)-2-Methyl-6-phenylhex-5-en-2-ol (III-16). General Procedure 3 was used 
for the conversion of (Z)-ethyl 5-phenylpent-4-enoate (0.47 g, 2.3 mmol) to the 
title compound. This procedure afforded 0.39 g (90%) of the title compound as a 
colorless oil. This material was obtained as a >20:1 mixture of Z:E isomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.35–7.26 (m, 4 H), 
7.23–7.17 (m, 1 H), 6.44–6.40 (m, 1 H), 5.65 (dt, J = 7.2, 11.7 Hz, 1 H), 2.44–
2.37 (m, 2 H), 1.64–1.58 (m, 3 H), 1.20 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
137.6, 132.8, 129.0, 128.7, 128.2, 126.6, 70.8, 43.8, 29.2, 23.7; IR (film, cm–1) 
3370, 2970; MS(ESI): 190.1360 (190.1358 calcd for C13H18O, M+). 
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(E)-2-Methyl-6-[4-(trifluoromethyl)phenyl]hex-5-en-2-ol (III-17). General 
Procedure 3 was used for the conversion of (E)-ethyl5-[4-
(trifluoromethyl)phenyl]pent-4-enoate (0.75 g, 2.75 mmol) to the title compound. 
This procedure afforded 0.71 g (96%) of the title compound as a white solid m.p. 
58oC. This material was obtained as a >20:1 mixture of E:Z isomers as judged by 
1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.1 Hz, 2 H), 7.34 (d, 
J = 8.1 Hz, 2 H), 6.40 (d, J = 11.5 Hz, 1 H), 5.74 (dt, J = 7.4, 11.5 Hz, 1 H), 2.41–
2.32 (m, 2 H), 1.62–1.56 (m, 3 H), 1.18 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
141.1, 134.9, 128.8, 128.6 (q, J = 32.0 Hz), 127.7 (q, J = 225.2 Hz), 125.1 (q, J = 
3.8 Hz), 70.8, 43.4, 29.2, 23.6; IR (film, cm–1) 3370, 2972, 1327). MS(EI): 
240.1132 (240.1126 calcd for C14H17F3O, M – H2O). 
 
(Z)-2-Methyl-6-[4-(trifluoromethyl)phenyl]hex-5-en-2-ol (III-18). General 
Procedure 3 was used for the conversion of (Z)-ethyl 5-[4-
(trifluoromethyl)phenyl]pent-4-enoate (0.52 g, 1.91 mmol) to the title compound. 
This procedure afforded 0.49 g (80%) of the title compound as a colorless oil. 
This material was obtained as a >20:1 mixture of Z:E isomers as judged by 1H 
NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.1 Hz, 2 H), 7.43 (d, J = 
8.1 Hz, 2 H), 6.46 (d, J = 15.9 Hz, 1 H), 6.36 (dt, J = 6.6, 15.9 Hz, 1 H), 2.39–
2.33 (m, 2 H), 1.70–1.66 (m, 3 H), 1.28 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
141.2, 133.8, 128.8, 128.7 (q, J = 32.5 Hz), 126.0 (q, J = 220.2 Hz), 125.4 (q, J = 
3.7 Hz), 70.8, 42.9, 29.3, 28.1 (one signal is missing due to incidental 
equivalence); IR (film, cm–1) 3470, 2972; MS(EI): 240.1134 (240.1126 calcd for 
C14H17F3O, M – H2O). 
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(E)-6-(4-Methoxyphenyl)-2-methylhex-5-en-2-ol (III-19). General Procedure 3 
was used for the conversion of (E)-ethyl 5-(4-methoxyphenyl)pent-4-enoate 
(0.095 g, 0.04 mmol) to the title compound. This procedure afforded 0.059 g 
(66%) of the title compound as a white solid, m.p. 48 °C. This material was 
obtained as a >20:1 mixture of E:Z isomers as judged by 1H NMR analysis. 1H 
NMR (400 MHz, CDCl3) δ 7.24–7.21 (m, 2 H), 6.81–6.78 (m, 2 H), 6.32 (d, J = 
15.8 Hz, 1 H), 6.06 (dt, J = 6.8, 15.8 Hz, 1 H), 3.76 (s, 3 H), 2.29–2.21 (m, 2 H), 
1.63–1.57 (m, 2 H), 1.35 (s, 1 H), 1.22 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
158.7, 130.5, 129.2, 128.6, 126.9, 113.9, 70.9, 55.2, 43.3, 29.3, 27.9; IR (film, 
cm–1) 3297, 2966, 1250; MS(ESI): 243.1372 (243.1361 calcd for C14H20O2, M + 
Na+). 
 
(Z)-6-(4-Methoxyphenyl)-2-methylhex-5-en-2-ol (III-20). General Procedure 3 
was used for the conversion of (Z)-ethyl 5-(4-methoxyphenyl)pent-4-enoate (0.45 
g, 1.92 mmol) to the title compound. A second chromoatographic purification 
using silver impregnated silica gel provided the product as a >20:1 mixture of Z:E 
isomers as judged by 1H NMR analysis. This procedure afforded 0.42 g (86%) of 
the title compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.22–7.17 (m, 
2 H), 6.85–6.82 (m, 2 H), 6.34–6.30 (m, 1 H), 5.53 (dt, J = 7.2, 11.5 Hz, 1 H), 
3.77 (s, 3 H), 2.42–2.34 (m, 2 H), 1.64–1.57 (m, 2 H), 1.41 (s, 1 H), 1.19 (s, 6 H); 
13C NMR (100 MHz, CDCl3) δ 158.2, 131.0, 130.2, 129.8, 128.4, 113.6, 70.9, 
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55.2, 43.8, 29.2, 23.7; IR (film, cm–1) 3364, 2968, 1250; MS(ESI): 243.1361 
(243.1361 calcd for C14H20O2, M + Na+). 
 
(E)-6-Cyclohexyl-2-methylhex-5-en-2-ol (III-21). General Procedure 3 was 
used for the conversion of (E)-ethyl 5-cyclohexylpent-4-enoate (0.26 g, 1.25 
mmol) to the title compound. This procedure afforded 0.25 g (93%) of the title 
compound as a colorless oil. This material was obtained as a 20:1 mixture of E:Z 
isomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 5.30–5.19 
(m, 2 H), 2.32–2.24 (m, 1 H), 2.17–2.11 (m, 2 H), 1.74–1.59 (m, 6 H), 1.56– 1.51 
(m, 2 H), 1.35–1.12 (m, 9 H), 1.11–1.03 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 
136.4, 127.7, 71.1, 44.0, 36.3, 33.3, 29.2, 26.0, 25.9, 22.5, 19.2; IR (film, cm–1) 
3362, 2923; MS(EI): 178.1729 (178.1722 calcd for C13H24O, M – H2O). 
 
(Z)-6-Cyclohexyl-2-methylhex-5-en-2-ol (III-22). General Procedure 3 was 
used for the conversion of (Z)-ethyl 5-cyclohexylpent-4-enoate (1.46 g, 6.94 
mmol) to the title compound. This procedure afforded 1.36 g (81%) of the title 
compound as a colorless oil. This material was obtained as a >20:1 mixture of 
E:Z isomers as judged by 1H NMR analysis. 1H NMR (400 MHz CDCl3) δ 5.37–
5.34 (m, 2 H), 2.07–2.00 (m, 2 H), 1.90–1.80 (m, 1 H), 1.71–1.59 (m, 5 H), 1.59– 
1.55 (m, 1 H), 1.52 (s, 1 H), 1.51–1.47 (m, 2 H), 1.28 (s, 1 H), 1.27–0.91 (m, 9 
H); 13C NMR (100 MHz, CDCl3) δ 136.7, 127.5, 71.1, 43.4, 40.6, 33.1, 29.2, 27.6, 
27.5 26.2, 26.0; IR (film, cm–1) 3358, 2924; MS(ESI): 197.1903 (197.1905 calcd 
for C13H24O, M + H+). 
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(E)-2-Methylpentadec-5-en-2-ol (III-23). General Procedure 3 was used for 
the conversion of (E)-ethyl tetradec-4-enoate (0.63 g, 2.46 mmol) to the title 
compound. This procedure afforded 0.44 g (75%) of the title compound as a 
colorless oil. This material was obtained as a >20:1 mixture of E:Z isomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 5.41–5.37 (m, 2 H), 
2.08–2.01 (m, 2 H), 1.97–1.90 (m, 2 H), 1.66 (s, 1 H), 1.53–1.47 (m, 2 H), 1.34–
1.20 (m, 14 H), 1.17 (s, 6 H), 0.85 (t, J = 6.6 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 130.6, 130.1, 70.9, 43.5, 32.5, 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 27.6, 
22.6, 14.1 (one signal is missing due to incidental equivalence); IR (film, cm–1) 
3364, 2960; MS(ESI): 241.2521 (241.2531 calcd for C16H32O, M + H+). 
 
 (Z)-2-Methylpentadec-5-en-2-ol (III-24). General Procedure 3 was used for 
the conversion of (Z)-ethyl tetradec-4-enoate (0.29 g, 1.12 mmol) to the title 
compound. This procedure afforded 0.27 g (70%) of the title compound as a 
colorless oil. This material was obtained as a 20:1 mixture of E:Z isomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 5.36–5.28 (m, 2 H), 
2.11–2.04 (m, 2 H), 2.03–1.94 (m, 2 H), 1.66 (s, br, 1 H), 1.50–1.44 (m, 2 H), 
1.33–1.20 (m, 14 H), 1.18 (s, 6 H), 0.83 (t, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 130.3, 129.4, 71.0, 43.6, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 27.1, 
22.6, 22.3, 14.0; IR (film, cm–1) 3367, 2924; MS(EI): 222.2344 (222.2348 calcd 
for C16H32O, M – H2O). 
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(E)-[6-(1,3-Dioxolan-2-yl)-2-methylhex-5-en-2-yloxy]trimethylsilane (III-S8). 
An oven-dried flask equipped with a magnetic stirbar was cooled under a stream 
of nitrogen and charged with 2-vinyl-1,3-dioxolane (0.1 mL, 0.99 mmol), 
trimethyl(2-methylhex-5-en-2-yloxy)silane (0.186 g, 0.99 mmol), and CH2Cl2 (2.5 
mL) was added. Solid 1,3-Bis(2,4,6-trimethylphenyl)-2- 
(imidazolidinylidene)(dichlorophenylmethylene)(tricyclohexylphosphine)ruthenium 
(Grubbs 2nd generation catalyst) (0.042 g, 0.05 mmol) was added and the 
mixture was heated to reflux overnight. The mixture was then cooled to rt and 
concentrated in vacuo. The crude product was purified by flash chromatography 
on silica gel to afford 0.23 g (90%) of a yellow oil. This material was obtained as 
a 15:1 mixture of E:Z. isomers as judged by 1H NMR analysis. Data are for the 
major isomer. 1H NMR (400 MHz, CDCl3) δ 5.93 (dt, J = 6.7, 15.5 Hz, 1 H), 5.45 
(tq, J = 1.6, 6.7 Hz, 1 H), 5.14 (d, J = 6.7 Hz, 1 H), 4.00–3.91 (m, 2 H), 3.89–3.83 
(m, 2 H), 2.15–2.07 (m, 2 H), 1.52–1.45 (m, 2 H), 1.18 (s, 6 H), 0.05 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 138.3, 125.8, 104.2, 73.5, 64.9, 43.4, 30.0, 27.0, 2.5; 
IR (film, cm–1) 2970, 1249; MS(ESI): 281.1535 (281.1549 calcd for C13H26O3Si, M 
+ Na+). 
 
(E)-6-(1,3-Dioxolan-2-yl)-2-methylhex-5-en-2-ol (III-25). A flask equipped with 
a magnetic stirbar was purged with nitrogen and charged with (E)-[6-(1,3-
dioxolan-2-yl)-2-methylhex-5-en-2- yloxy]trimethylsilane (0.27 g, 1 mmol) and 
THF (1 mL). The resulting solution was cooled to 0 °C then TBAF (3.18 mL, 3.18 
mmol, 1 M in THF) was added dropwise. The mixture was warmed to rt and 
stirred until the starting material had been completely consumed as judged by 
TLC analysis. The mixture was diluted with water (x mL) then extracted with ethyl 
acetate (2 x 20 mL). The combined organic layers were dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by 
flash chromatography on basic alumina to afford 0.197 g (81%) of the title 
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compound as a colorless oil. This material was obtained as a 15:1 mixture of E:Z 
isomers as judged by 1H NMR analysis. Data are for the major isomer. 1H NMR 
(400 MHz, CDCl3) δ 5.89 (dt, J = 6.7, 13.3 Hz, 1 H), 5.43 (tq, J = 0.4, 6.7 Hz, 1 
H), 5.11 (d, J = 6.7 Hz, 1 H), 3.95–3.89 (m, 2 H), 3.85–3.77 (m, 2 H), 2.14–2.07 
(m, 2 H), 1.54–1.47 (m, 4 H), 1.14 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 137.7, 
126.1, 104.0, 70.5, 64.8, 42.4, 29.2, 26.9; IR (film, cm–1) 3391, 22968; MS(ESI): 
209.1149 (209.1154 calcd for C10H18O3, M + Na+). 
 
(E)-Methyl 5-(1-hydroxycyclohexyl)pent-2-enoate (III-S9). An oven-dried 
flask equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with methyl acrylate (0.29 mL, 3.24 mmol), 1-(but-3-enyl)cyclohexanol8 
(0.1 g, 0.65 mmol), and CH2Cl2 (3.25 mL). Solid 1,3-Bis(2,4,6-trimethylphenyl)-2-
(imidazolidinylidene)(dichlorophenylmethylene) 
(tricyclohexylphosphine)ruthenium (Grubbs 2nd generation catalyst) (28 mg, 
0.032 mmol) was added and the reaction mixture was heated to reflux for 4 
hours. The mixture was then cooled to rt and concentrated in vacuo. The crude 
product was purified by flash chromatography on silica gel to afford 0.11 g (78%) 
of the title compound as a tan oil. This material was obtained as a 15:1 mixture of 
E:Z isomers as judged by 1H NMR analysis. Data are for the major isomer. 1H 
NMR (400 MHz, CDCl3) δ 6.93 (dt, J = 6.9, 15.7 Hz, 1 H), 5.76 (dt, J = 1.6, 15.7 
Hz, 1 H), 3.64 (s, 3 H), 2.27–2.20 (m, 2 H), 1.69–1.10 (m, 13 H); 13C NMR (100 
MHz, CDCl3) δ 167.1, 150.1, 120.5, 51.3, 40.3, 37.3, 26.0, 25.9, 25.7, 22.1; IR 
(film, cm–1) 3482, 2931, 1725; MS(ESI): 235.1303 (235.1310 calcd for C12H20O3, 
M + Na+). 
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(E)-1-(5-Hydroxypent-3-en-1yl)cyclohexanol (III-S10). An oven-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with (E)-methyl 4-(1-hydroxycyclohexyl)pent-2-enoate (100 mg, 0.47 
mmol) and THF (0.5 mL). The resulting solution was cooled to –78 °C, then 
DIBAL-H (1.97 mL, 1.97 mmol, 1 M in THF) was added dropwise. The reaction 
mixture was stirred at –78 °C for one h, at which time TLC analysis indicated the 
starting material had been completely consumed. The reaction was quenched 
with 1M NaOH, and the solid precipitate was washed with EtOAc. The organic 
solutions were combined and washed with brine (1 x 5 mL), then dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product was 
purified by flash chromatography on silica gel to yield 86 mg (73%) of the title 
compound as a colorless oil. This material was obtained as a 15:1 mixture of E:Z 
isomers. Data are for the major isomer. 1H NMR (400 MHz, CDCl3) δ 5.72–5.52 
(m, 2 H), 4.02 (d, J = 5.5 Hz, 2 H), 2.14–2.05 (m, 2 H), 1.60–1.29 (m, 13 H), 
1.27–1.15 (m, 1 H). 13C NMR (100 MHz, CDCl3) δ 133.4, 128.9, 71.3, 63.6, 41.5, 
37.4, 25.8, 25.7, 22.1; IR (film, cm–1) 3350, 1456; MS(ESI): 207.1352 (207.1361 
calcd for C11H20O2, M + Na+). 
 
(E)-1-[5-(tert-Butyldimethylsilyloxy)pent-3-en-1yl]cyclohexanol (III-26). An 
oven-dried flask equipped with a magnetic stirbar was cooled under a stream of 
nitrogen and charged with (E)-1-(4-hydroxybut-2-enyl)cyclohexanol (56 mg, 0.3 
mmol) and DMF (0.3 mL). The solution was cooled to 0 °C then imidazole was 
added (25 mg, 0.3 mmol), followed by a solution of TBSCl (40 mg, 0.3 mmol) in 
DMF (0.3 mL). The mixture was warmed to rt and stirred overnight (ca 12 h). 
Water (x mL) was added to the reaction mixture, which was then extracted with 
ethyl acetate (2 x 20 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The product was then 
purified by flash chromatography on silica gel to yield 69 mg (79%) of the title 
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compound as a colorless oil. This material was obtained as an 18:1 mixture of 
E:Z. isomers. Data are for the major isomer. 1H NMR (400 MHz, CDCl3) δ 5.66–
5.57 (m, 1 H), 5.56–5.44 (m, 1 H), 4.09–4.05 (m, 2 H), 2.12–2.04 (m, 2 H), 1.60–
1.33 (m, 11 H), 1.28–1.15 (m, 2 H), 0.85 (s, 9 H), 0.02 (s, 6 H); 13C NMR (100 
MHz, CDCl3) δ 131.4, 129.2, 71.3, 63.9, 42.6, 37.4, 25.9, 25.8, 22.2, 18.4, –5.1, 
(one signal is missing due to incidental equivalence); IR (film, cm–1) 3392, 2930; 
MS(ESI): 321.2213 (321.2226 calcd for C17H34O2Si, M + Na+). 
 
(E)-7-ethyl-5-methylundec-8-en-5-ol An oven or flame dried flask equipped 
with a magnetic stirbar was cooled under a stream of nitrogen, charged with 
BuMgBr (3 equiv, 3.0 M in diethyl ether, 3.25 mL) and cooled to 0 °C. (E)-4-
ethyloct-5-en-2-one (1.0 equiv, 0.5 mL) was added dropwise via syringe and the 
resulting mixture was warmed to rt and stirred for 2–4 h until the starting material 
was completely consumed as judged by TLC analysis. A saturated solution of 
aqueous NH4Cl (1:1 by volume with the reaction mixture) was added dropwise 
and the resulting mixture was then diluted with ethyl acetate (10 mL). The layers 
were separated and the aqueous layer was extracted with ethyl acetate (2 x 10 
mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel to obtain 0.63 g of the product as a clear oil in 98% 
yield. 1H NMR (400 MHz, CDCl3) δ 5.46–5.36 (m, 1 H), 5.18–5.09 (m, 1 H), 2.06–
1.86 (m, 4 H), 1.46–1.33 (m, 3 H), 1.32–1.15 (m, 4 H), 1.13–1.07 (m, 2 H), 1.00 
(s, 3 H), 0.87 (t, J = 7.4 Hz, 3 H), 0.83-0.77 (m, 2 H), 0.72 (t, J = 7.4 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 135.0, 132.9, 73.2, 46.4, 41.6, 40.8, 29.7, 27.6, 26.4, 
25.4, 23.2, 13.9, 13.7. 
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2-methylhex-5-en-2-ol An oven or flame dried flask equipped with a magnetic 
stirbar was cooled under a stream of nitrogen, charged with a 3 M solution of 
methylgrignard in THF (2 equiv, 68 mL) and cooled to 0 °C. A 1 M solution of 
hex-5-en-2-one in THF (1.0 equiv, 10 g) was added dropwise via syringe and the 
resulting mixture was warmed to rt and stirred for 5 h until the starting material 
was completely consumed as judged by TLC analysis. A 1 M solution of HCl (1:1 
by volume with the reaction mixture) was added and the resulting mixture was 
diluted with ethyl acetate. The layers were separated and the aqueous layer was 
extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product 
was then purified by flash chromatography on silica gel to obtain 10.12 g of the 
product as a clear oil in 87% yield. 1H NMR (400 MHz, CDCl3) δ 5.80-5.91 (m, 1 
H), 5.05 (dq, J=17.39, 1.53 Hz, 1 H), 4.96 (dq, J=11.29, 1.83, 1.22 Hz, 1 H), 
2.11-2.19 (m, 2 H), 1.54-1.62 (m, 2H), 1.23 (s, 6H). 
 
trimethyl((2-methylhex-5-en-2-yl)oxy)silane An oven or flame dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with 2-methylhex-5-en-2-ol (1 equiv, 3.23 g) and trimethylsilylimidazole 
(1.5 equiv, 5.95 mL) and the resulting neat mixture was heated to 60 oC until the 
starting material was completely consumed as judged by TLC analysis. The 
crude product was then purified by flash chromatography on silica gel to obtain 
4.95 g of the product as a clear oil in 94% yield. 1H NMR (400 MHz, CDCl3) δ 
5.90-5.78 (m, 1 H), 5.04-4.89 (m, 2 H), 2.15-2.07 (m, 2 H), 1.55-1.48 (m, 3 H), 
1.21 (s, 6 H), 0.08 (s, 9 H). 
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4-methyl-4-((trimethylsilyl)oxy)pentanal An oven or flame dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen, charged 
with a solution of  trimethyl((2-methylhex-5-en-2-yl)oxy)silane in CH2Cl2 (1 equiv, 
1.0 M, 0.68 g) and cooled to -78 °C. Ozone was bubbled through the solution 
until the reaction mixture turned a pale blue color. Next, triphenylphosphine was 
added (2 equiv, 1.78 g), and the reaction was warmed to rt and stirred overnight. 
Upon completion, a saturated solution of aqueous NaCl (1:1 by volume with the 
reaction mixture) was added and the resulting mixture was diluted with ethyl 
acetate (10 mL). The layers were separated and the aqueous layer was 
extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product 
was then purified by flash chromatography on silica gel to obtain 0.46 g of the 
product as a clear oil in 67% yield. 
 
((6-methoxy-2-methylhex-5-en-2-yl)oxy)trimethylsilane An oven or flame 
dried flask equipped with a magnetic stirbar was cooled under a stream of 
nitrogen, charged with a solution of  (methoxymethyl)-triphenylphosphonium 
chloride in THF (1.2 equiv, 0.1 M, 1.71 g) and cooled to -78 °C. Potassium tert-
butoxide was added portionwise (1.2 equiv, 0.59 g), and the reaction was 
allowed to stir for 1 hr at -78 °C. Next, a 1 M solution of 4-methyl-4-
((trimethylsilyl)oxy)pentanal in THF (1 equiv, 0.84 g) was added dropwise, and 
the reaction was warmed to rt and stirred until the starting material was 
consumed, as indicated by GC analysis. A saturated solution of aqueous NaCl 
(1:1 by volume with the reaction mixture) was added and the resulting mixture 
was diluted with ethyl acetate (10 mL). The layers were separated and the 
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aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in 
vacuo. The crude product was then purified by flash chromatography on silica gel 
to obtain 0.90 g of the product as a clear oil in 99% yield. 1H NMR (400 MHz, 
CDCl3) δ 6.22-6.20 (m, 1 H), 4.69-4.62 (m, 1 H), 3.40 (s, 1 H), 2.00-1.86 (m, 2 H), 
1.51-1.44 (m, 3 H), 1.09 (s, 6 H), 0.08 (s, 9 H). 
 
6-methoxy-2-methylhex-5-en-2-ol An oven or flame dried flask equipped with 
a magnetic stirbar was cooled under a stream of nitrogen, charged with ((6-
methoxy-2-methylhex-5-en-2-yl)oxy)trimethylsilane (1 equiv, 1.0 M in THF, 0.86 
g) and cooled to 0 °C. A 1 M solution of TBAF in THF (3.0 equiv, 12 mL) was 
added dropwise via syringe and the resulting mixture was warmed to rt and 
stirred for 3 h until the starting material was completely consumed as judged by 
TLC analysis. A saturated solution of aqueous NH4Cl (1:1 by volume with the 
reaction mixture) was added and the resulting mixture was diluted with ethyl 
acetate (10 mL). The layers were separated and the aqueous layer was 
extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude product 
was then purified by flash chromatography on silica gel to obtain 0.58 g of the 
product as a clear oil in 62% yield and 2.4:1 dr. Data are for the major 
diastereomer. 1H NMR (400 MHz, CDCl3) δ 6.32-6.25 (m, 1 H), 4.76-4.66 (m, 1 
H), 3.47 (s, 1 H), 2.03-1.94 (m, 2 H), 1.55-1.47 (m, 3 H), 1.19 (s, 6 H). 
Synthesis of Tetrahydrofurans via Pd-Catalyzed Alkene 
Carboetherification General Procedure 4: Palladium-Catalyzed 
Carboetherification Reactions for the Formation of Tetrahydrofurans. An 
oven or flame-dried Schlenk tube was cooled under a stream of nitrogen and 
charged with Pd2(dba)3 (2 mol% complex, 4 mol % Pd), S-Phos (4 mol %), 
OH
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NaOtBu (2.0 equiv), and the aryl bromide (2.0 equiv). The tube was purged with 
nitrogen and the alcohol substrate (1.0 equiv), and xylenes (0.25 M in substrate) 
were added. The mixture was heated to 140 °C with stirring until the starting 
material had been consumed as judged by GC or 1H NMR analysis. The mixture 
was cooled to room temperature, quenched with saturated aqueous NH4Cl (2 
mL), and diluted with ethyl acetate (10 mL). The layers were separated and the 
aqueous layer was extracted with ethyl acetate (3 X 10 mL). The combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel. 
 
(1’S*,5S*)-2,2-Dimethyl-5-(1-phenylethyl)tetrahydrofuran (III-13). The 
coupling of (Z)-2-methylhept-5-en-2-ol (0.025 g, 0.20 mmol) with bromobenzene 
(0.041 mL, 0.4 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.033 g (84%) of the title compound as an orange oil. This 
material was obtained as a 9:1 mixture of diastereomers as judged by 1H NMR 
analysis. Data are for the major isomer. 1H NMR (400 MHz, CDCl3) δ 7.32–7.27 
(m, 3 H), 7.23–7.20 (m, 2 H), 4.08–4.02 (m, 1 H), 2.74 (p, J = 7.1 Hz, 1 H), 1.76–
1.69 (m, 1 H), 1.66–1.54 (m, 3 H), 1.35 (d, J = 7.2 Hz, 3 H), 1.25 (s, 3 H), 1.22 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 144.6, 128.1, 128.0, 126.2, 83.4, 80.6, 46.0, 
38.2, 30.0, 29.1, 28.2, 18.8; IR (film, cm–1) 2968, 1063; MS(ESI): 227.1408 
(227.1412 calcd for C14H20O, M + Na+). 
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(1’R*,5S*)-2,2-Dimethyl-5-(1-phenylethyl)tetrahydrofuran (III-14). The 
coupling of (E)-2-methylhept-5-en-2-ol (0.05 g, 0.39 mmol) with bromobenzene 
(0.082 mL, 0.78 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.079 g (86%) of the title compound as an orange oil. This 
material was obtained as a 20:1 mixture of diastereomers as judged by 1H NMR 
analysis. 1H NMR (400 MHz, CDCl3) δ 7.33–7.25 (m, 4 H), 7.24–7.17 (m, 1 H), 
4.19–4.13 (m, 1 H), 2.96–2.88 (m, 1 H), 1.90–1.81 (m, 1 H), 1.78–1.71 (m, 1 H), 
1.70–1.61 (m, 1 H), 1.69–1.51 (m, 1 H), 1.30 (d, J = 7.2 Hz, 3 H), 1.25 (s, 3 H), 
1.21 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 144.1, 128.2, 128.0, 126.1, 82.6, 
80.5, 44.0, 38.5, 28.7, 28.3, 28.0, 19.2; IR (film, cm–1) 2968, 1046; MS(ESI): 
227.1408 (227.1412 calcd for C14H20O, M + Na+). 
 
(1’R*,5S*)-2,2-Dimethyl-5-phenyl[(o-tolyl)methyl]tetrahydrofuran (III-27). 
The coupling of (E)-2-methyl-6-phenylhex-5-en-2-ol (0.025 g, 0.13 mmol) with 1-
bromo-2-methylbenzene (0.031 mL, 0.26 mmol) was conducted following 
General Procedure 4. This procedure afforded 0.037 g (95%) of the title 
compound as a yellow oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.51 
(d, J = 7.6 Hz, 1 H), 7.27–7.16 (m, 6 H), 7.15–7.07 (m, 2 H), 4.72–4.66 (m, 1 H), 
4.18 (d, J = 7.6 Hz, 1 H), 2.20 (s, 3 H), 1.91–1.81 (m, 1 H), 1.79–1.73 (m, 1 H), 
1.72–1.63 (m, 1 H), 1.57–1.49 (m, 1 H), 1.25 (s, 3 H), 1.20 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 141.9, 140.8, 136.8, 130.5, 129.2, 128.0, 127.3, 126.1, 126.0, 
125.7, 80.7, 80.3, 53.0, 38.4, 30.9, 29.0, 28.1, 20.1; IR (film, cm–1) 2967, 1489; 
MS(ESI): 303.1722 (303.1725 calcd for C20H24O, M + Na+). 
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(1’R*,5S*)-2,2-Dimethyl-5-{phenyl[4-
(trifluoromethyl)phenyl]methyl}tetrahydrofuran (III-28). The coupling of (E)-2-
methyl-6-phenylhex-5-en-2-ol (0.05 g, 0.26 mmol) with 1-bromo-4- 
(trifluoromethyl)benzene (0.074 mL, 0.52 mmol) was conducted following 
General Procedure 4. This procedure afforded 0.077 g (87%) of the title 
compound as a clear oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.56 
(d, J = 8.3 Hz, 2 H), 7.50 (d, J = 8.3 Hz, 2 H), 7.34-7.22 (m, 5 H), 4.77– 4.71 (m, 
1 H), 4.02 (d, J = 8.2 Hz, 1 H), 1.95–1.88 (m, 1 H), 1.78–1.64 (m, 3 H), 1.30 (s, 3 
H), 1.24 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 147.0, 142.4, 129.3, (q, J = 241.5 
Hz), 128.6, 128.45 (q, J = 32.5 Hz), 128.2, 126.7, 125.1 (q, J = 3.9 Hz), 81.5, 
80.1, 57.3, 38.2, 31.3, 29.1, 28.3; IR (film, cm–1) 2969, 1325; MS(ESI): 357.1438 
(357.1442 calcd for C20H21F3O, M + Na+). 
 
(1’S*,5S*)-2,2-Dimethyl-5-{phenyl[4-
(trifluoromethyl)phenyl]methyl}tetrahydrofuran (III-29). The coupling of (Z)-2-
methyl-6-phenylhex-5-en-2-ol (0.025 g, 0.13 mmol) with 1-bromo-4- 
(trifluoromethyl)benzene (0.037 mL, 0.26 mmol) was conducted following 
General Procedure 4. This procedure afforded 0.035 g (80%) of the title 
compound as a clear oil. This material was obtained as a 9:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.50 
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(d, J = 8.4 Hz, 2 H), 7.38 (d, J = 8.4 Hz, 2 H), 7.31–7.23 (m, 4 H), 7.21–7.16 (m, 
4.68 (q, J = 7.2 Hz, 1 H), 4.02 (d, J = 7.2 Hz, 1 H), 1.92–1.84 (m, 1 H), 1.70–1.59 
(m, 2 H), 1.56–1.46 (m, 1 H), 1.24 (s, 3 H), 1.14 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 147.4, 141.5, 129.1 (q, J = 262.7 Hz), 128.6, 128.3 (q, J = 36.0 Hz), 
128.2, 126.5, 125.2 (q, J = 3.8 Hz), 81.3, 79.7, 56.6, 38.2, 30.9, 29.1, 28.9, 28.2, 
28.1; IR (film, cm–1) 2973, 1328; MS(ESI): 357.1431 (357.1442 calcd for 
C20H21F3O, M + Na+). 
 
(1’R*,5S*)-2,2-Dimethyl-5-{naphthalen-2-yl[4-(trifluoromethyl)phenyl]methyl} 
tetrahydrofuran (III-30). The coupling of (E)-2-methyl-6-[4-
(trifluoromethyl)phenyl]hex-5-en-2-ol (0.03 g, 0.12 mmol) with 2-
bromonaphthalene (0.048 g, 0.23 mmol) was conducted following General 
Procedure 4. This procedure afforded 0.037 g (84%) of the title compound as a 
clear oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis, but contained ca 2% of an unidentified impurity. 1H 
NMR (400 MHz, CDCl3) δ 7.84–7.78 (m, 3 H), 7.75 (d, J = 8.5 Hz, 1 H), 7.54 (d, J 
= 8.5 Hz, 2 H), 7.49–7.39 (m, 5 H), 4.83 (q, J = 6.3 Hz, 1 H), 4.22 (d, J = 6.3 Hz, 
1 H), 2.01–1.93 (m, 1 H), 1.78–1.67 (m, 2 H), 1.59–1.52 (m, 1 H), 1.29 (s, 3 H), 
1.18 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 147.0, 139.0, 133.4, 132.3, 130.1, 
129.2 (q, J = 52.0 Hz), 127.9, 127.8 (q, J = 225.2), 127.7, 127.6, 127.5, 125.9, 
125.6, 125.2 (q, J = 3.8 Hz), 81.4, 79.7, 56.7, 38.2, 31.0, 28.9, 28.1; IR (film, cm–
1) 2969, 1325; MS(ESI): 407.1600 (407.1599 calcd for C24H23F3O, M + Na+). 
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(1’S*,5R*)-2,2-Dimethyl-5-{2-phenyl-1-[4-
(trifluoromethyl)phenyl]allyl}tetrahydrofuran (III-31). The coupling of (E)-2-
methyl-6-[4-(trifluoromethyl)phenyl]hex-5-en-2-ol (0.03 g, 0.12 mmol) with α-
bromostyrene (0.035 mL, 0.23 mmol) was conducted following General 
Procedure 4. This procedure afforded 0.025 g (62%) of the title compound as an 
amber oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.1 Hz, 2 
H), 7.35 (d, J = 8.1 Hz, 2 H), 7.29–7.27 (m, 2 H), 7.24– 7.18 (m, 3 H), 5.55 (s, 1 
H), 5.45 (s, 1 H), 4.55 (q, J = 7.3 Hz, 1 H), 4.02 (d, J = 7.3 Hz, 1 H), 1.81–1.74 
(m, 1 H), 1.69–1.60 (m, 2 H), 1.50–1.44 (m, 1 H), 1.28 (s, 3 H), 1.23 (s, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 148.5, 133.9, 129.3, 128.1 (q, J = 253.1 Hz), 128.9, 
127.4, 127.2 (q, J = 65 Hz), 126.8, 124.9 (q, J = 3.8 Hz), 114.7, 79.7, 69.0, 55.7, 
38.3, 30.3, 28.9, 28.0, 19.3; IR (film, cm–1) 2968, 1324; MS(EI): 360.1709 
(360.1701 calcd for C22H23F3O, M+). 
 
(1’S*,5S*)-2,2-Dimethyl-5-{naphthalen-2-yl[4-
(trifluoromethyl)phenyl]methyl} tetrahydrofuran (III-32). The coupling of (Z)-
2-methyl-6-[4-(trifluoromethyl)phenyl]hex-5-en-2-ol (0.03 g, 0.12 mmol) with 2-
bromonaphthalene (0.048 g, 0.23 mmol) was conducted following General 
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Procedure 4. This procedure afforded 0.042 g (94%) of the title compound as a 
clear oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.83–7.77 (m, 2 H), 
7.76 (d, J = 8.3 Hz, 2 H), 7.55–7.50 (m, 3 H), 7.50–7.43 (m, 3 H), 7.31 (dd, J = 
1.9, 8.3 Hz, 1 H), 4.85–4.80 (m, 1 H), 4.15 (d, J = 8.1 Hz, 1 H), 1.94–1.86 (m, 1 
H), 1.80–1.62 (m, 3 H), 1.30 (s, 3 H), 1.24 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 
146.8, 139.9, 133.4, 132.3, 129.3 (q, J = 49.6 Hz), 128.3, 127.8 (q, J = 230.1 Hz), 
127.6, 127.1, 126.9, 126.2, 125.8, 125.1 (q, J = 3.7 Hz), 81.6, 80.0, 57.3, 38.3, 
31.4, 29.2, 19.0, 18.9 (one carbon signal is absent due to incidental equivalence; 
IR (film, cm–1) 2969, 1326; MS(ESI): 407.1597 (407.1599 calcd for C24H23F3O, M 
+ Na+). 
 
(1’R*,5S*)-5-(3,5-Dichlorophenyl)(4-methoxyphenyl)methyl-2,2-
dimethyltetrahydrofuran (III-33). The coupling of (E)-6-(4-methoxyphenyl)-2-
methylhex-5-en-2-ol (0.02 g, 0.09 mmol) with 1-bromo-3,5 dichlorobenzene 
(0.041 g, 0.18 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.017 g (52%) of the title compound as a clear oil. This 
material was obtained as a >20:1 mixture of diastereomers as judged by 1H NMR 
analysis. 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 1.7 Hz, 2 H), 7.12 (t, J = 2.4 
Hz, 1 H), 7.11–7.07 (m, 2 H), 6.81– 6.76 (m, 2 H), 4.53 (q, J = 7.2 Hz, 1 H), 3.77–
3.73 (m, 4 H), 1.88–1.76 (m, 1 H), 1.67–1.52 (m, 3 H), 1.21 (s, 3 H), 1.15 (s, 3 
H); 13C NMR (100 MHz, CDCl3) δ 158.3, 146.4, 134.3, 134.0, 129.4,127.5, 126.2, 
113.9, 81.5, 80.0, 56.0, 55.2, 38.1, 31.2, 29.0, 28.1; IR (film, cm–1) 2968, 1511; 
MS(ESI): 387.0906 (387.0895 calcd for C20H22Cl2O2 M + Na+). 
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(1’S*,5S*)-5-(3,5-Dichlorophenyl)(4-methoxyphenyl)methyl-2,2-
dimethyltetrahydrofuran (III-34). The coupling of (Z)-6-(4-methoxyphenyl)-2-
methylhex-5-en-2-ol (0.027 g, 0.123 mmol) with 1-bromo-3,5 dichlorobenzene 
(0.055 g, 0.24 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.037 g (69%) of the title compound as a clear oil. This 
material was obtained as a >20:1 mixture of diastereomers as judged by 1H NMR 
analysis. 1H NMR (400 MHz, CDCl3) δ 7.17–7.11 (m, 5 H), 6.82–6.78 (m, 2 H), 
4.53 (q, J = 7.4 Hz, 1 H), 3.83 (d, J = 7.4 Hz, 1 H), 3.74 (s, 3 H), 1.93–1.82 (m, 1 
H), 1.67–1.54 (m, 2 H), 1.49–1.38 (m, 1 H), 1.20 (s, 3 H), 1.11 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 158.2, 147.0, 134.5, 132.8, 130.0, 127.2, 126.3, 113.6, 81.3, 
79.6, 55.3, 55.1, 38.1, 30.7, 28.8, 28.0; IR (film, cm–1) 2969, 1512; MS(ESI): 
387.1600 (387.0901 calcd for C20H22Cl2O2, M + Na+). 
 
(1’R*,5S*)-5-[Cyclohexyl(m-tolyl)methyl]-2,2-dimethyltetrahydrofuran (III-
35). The coupling of (E)-6-cyclohexyl-2-methylhex-5-en-2-ol (0.025 g, 0.127 
mmol) with 3-bromotoluene (0.031 mL, 0.26 mmol) was conducted following 
General Procedure 4. This procedure afforded 0.034 g (94%) of the title 
compound as a clear oil. This material was obtained as a >20:1 mixture of 
diastereomers as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.08 
(t, J = 7.4 Hz, 1 H), 7.05–7.03 (m, 1 H), 7.00–6.93 (m, 2 H), 4.42–4.36 (m, 1 H), 
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2.28 (s, 3 H), 2.18–2.12 (m, 1 H), 2.11–2.03 (m, 1 H), 1.85–1.66 (m, 3 H), 1.60–
1.42 (m, 4 H), 1.38–1.26 (m, 3 H), 1.17–1.04 (m, 8 H), 0.98–0.87 (m, 1 H), 0.72–
0.60 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 141.3, 136.5, 131.1, 127.5, 127.0, 
126.5, 80.2, 77.3, 56.3, 39.3, 38.1, 32.2, 31.4, 29.8, 28.4, 27.8, 26.7, 26.3, 26.2, 
21.5; IR (film, cm–1) 2923, 1738; MS(ESI): 309.2193 (309.2194 calcd for 
C20H30O, M + Na+). 
 
(1’S*,5S*)-5-[Cyclohexyl(m-tolyl)methyl]-2,2-dimethyltetrahydrofuran (III-
36). The coupling of (Z)-6-cyclohexyl-2-methylhex-5-en-2-ol (0.05 g, 0.26 mmol) 
with 3-bromotoluene (0.062 mL, 0.5o mmol) was conducted following General 
Procedure 4. This procedure afforded 0.016 g (22%) of the title compound as an 
amber oil. This material was obtained as a 2:1 mixture of diastereomers as 
judged by 1H NMR analysis, and was contaminated with ca. 15% of an 
unidentified side product. Carbon NMR data are not reported due to the 
complexity of the mixture. 1H NMR (400 MHz, CDCl3) δ 7.15–7.00 (m, 2 H), 6.96–
6.85 (m, 2 H), 4.38–4.33 (m, 1 H), 2.88–2.79 (m, 1 H), 2.24 (s, 3 H), 2.20–2.14 
(m, 2 H), 2.14–2.05 (m, 2 H), 1.74–1.59 (m, 3 H), 1.59–1.45 (m, 2 H), 1.31–1.21 
(m, 6 H), 1.14–1.00 (m, 6 H); IR (film, cm–1) 2921, 1446; MS(ESI): 309.2196 
(309.2194 calcd for C20H30O, M + Na+). 
 
(1’R*,5S*)-5-[1-(3-Methoxyphenyl)decyl]-2,2-dimethyltetrahydrofuran (III-
37). The coupling of (E)-2-methylpentadec-5-en-2-ol (0.025 g, 0.104 mmol) with 
3-bromoanisole (0.026 mL, 0.21 mmol) was conducted following General 
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Procedure 4. This procedure afforded 0.036 g (92%) of the title compound as a 
clear oil. This material was obtained as a >20:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.20 (t, J = 8.3 Hz, 1 
H), 6.85–6.81 (m, 2 H), 6.77–6.74 (m, 1 H), 4.18–4.13 (m, 1 H), 3.81 (s, 3 H), 
2.68–2.62 (m, 1 H), 1.90–1.82 (m, 1 H), 1.76–1.64 (m, 3 H), 1.63–1.56 (m, 1 H), 
1.47–1.41 (m, 1 H), 1.34–1.10 (m, 20 H), 0.88 (t, J = 6.8 Hz, 3 H); 13C NMR (100 
MHz, CDCl3) δ 159.2, 114.1, 128.7, 121.8, 115.0, 111.2, 82.0, 80.4, 55.1, 50.5, 
38.4, 31.9, 31.3, 29.8, 29.6, 29.5, 29.3, 28.9, 28.7, 28.0, 27.7, 22.7, 14.1; IR (film, 
cm–1) 2968, 1512; MS(ESI): 369.2757 (369.2770 calcd for C23H38O2, M + Na+). 
 
(1’S*,5S*)-5-[1-(3-Methoxyphenyl)decyl]-2,2-dimethyltetrahydrofuran (III-
38). The coupling of (Z)-2-methylpentadec-5-en-2-ol (0.029 g, 0.120 mmol) with 
3-bromoanisole (0.030 mL, 0.24 mmol) was conducted following General 
Procedure 4. This procedure afforded 0.018 g (43%) of the title compound as an 
orange oil. This material was obtained as a 4:1 mixture of diastereomers as 
judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.18 (t, J = 7.8 Hz, 1 
H), 6.76–6.68 (m, 3 H), 4.05–3.97 (m, 1 H), 3.81–3.76 (m, 4 H), 2.52–2.44 (m, 1 
H), 2.03–1.91 (m, 1 H), 1.70–1.45 (m, 6 H), 1.26–1.15 (m, 18 H), 0.89–0.83 (m, 3 
H); 13C NMR (100 MHz, CDCl3) δ 159.4, 144.6, 128.9, 121.0, 114.5, 111.0, 82.8, 
80.8, 55.1, 52.6, 38.2, 32.8, 31.9, 30.3, 29.7, 29.6, 29.5, 29.3, 29.2, 28.3, 27.5, 
22.6, 14.1; IR (film, cm–1) 2924, 1456; MS(ESI): 369.2769 (369.2770 calcd for 
C23H38O2, M + Na+). 
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(1’R*,5S*)-2-[(5,5-Dimethyltetrahydrofuran-2-yl)(6-methoxynaphthalen-2-
yl)methyl]-1,3-dioxolane (III-39). The coupling of (E)-6-(1,3-dioxolan-2-yl)-2-
methylhex-5-en-2-ol (0.025 g, 0.13 mmol) with 2-bromo-6-methoxy-naphthalene 
(0.064 g, 0.27 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.023 g (50%) of the title compound as an orange solid. m.p. 
92 °C. This material was obtained as a >20:1 mixture of diastereomers as judged 
by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.73–7.64 (m, 3 H), 7.47 (dd, 
J = 2.2, 8.3 Hz, 1 H), 7.11–7.07 (m, 2 H), 5.40 (d, J = 8.6 Hz, 1 H), 4.62–4.56 (m, 
1 H), 3.98–3.84 (m, 6 H), 3.82–3.72 (m, 1 H), 2.88 (dd, J = 2.2, 8.3 Hz, 1 H), 
2.04–1.92 (m, 1 H), 1.65–1.56 (m, 1 H), 1.55–1.46 (m, 1 H), 1.18 (s, 3 H), 1.171–
1.10 (m, 1 H), 1.06 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.3, 133.7, 132.7, 
129.4, 129.2, 129.0, 128.7, 126.0, 118.5, 105.5, 105.2, 81.2, 77.8, 65.1, 55.3, 
54.6, 38.0, 29.7, 28.4, 27.8, 19.1; IR (film, cm–1) 2965, 1646, 1540; MS(ES): 
365.1718 (365.1729 calcd for C21H26O4, M + Na+). 
 
(1’R*,2S*)-2-[(Biphenyl-3-yl)-2-(-1-oxaspiro[4.5]decan-2-yl)ethoxy](tert-
butyl) dimethylsilane (III-40). The coupling of (E)-1-(4-(tert-
butyldimethylsilyloxy)but-2-enyl)cyclohexanol (0.028 g, 0.10 mmol) with 3-bromo-
biphenyl (0.046 mL, 0.20 mmol) was conducted following General Procedure 4. 
This procedure afforded 0.040 g (90%) of the title compound as a clear oil. This 
material was obtained as a 12:1 mixture of diastereomers as judged by 1H NMR 
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analysis. 1H NMR (400 MHz, CDCl3) δ 7.59–7.55 (m, 2 H), 7.53–7.50 (m, 1 H), 
7.44–7.37 (m, 3 H), 7.33–7.24 (m, 3 H), 4.40–4.34 (m, 1 H), 4.03 (dd, J = 7.8, 9.8 
Hz, 1 H), 3.83 (dd, J = 6.1, 12.2 Hz, 1 H), 2.89–2.78 (m, 1 H), 1.88–1.80 (m, 1 H), 
1.66–1.50 (m, 6 H), 1.46–1.35 (m, 3 H), 1.34–1.20 (m, 4 H), 0.83 (s, 9 H), 0.00 
(s, 3 H), -0.05 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 141.6, 140.8, 140.3, 128.8, 
128.6, 128.5, 127.9, 127.1, 126.9, 125.1, 82.0, 77.3, 65.2, 52.8, 38.1, 37.4, 29.1, 
25.9, 25.8, 24.0, 23.7, 18.3, –5.4, –5.5; IR (film, cm–1) 2928, 1093; MS(ESI): 
473.2862 (473.2852 calcd for C29H42O2Si, M + Na+). 
 
(E)-(1’R*,4S*,5S*)-2,2,4-Trimethyl-5-(-4-phenylbut-3-en-2-
yl)tetrahydrofuran (III-42). The coupling of (E)-2,4-dimethylhept-5-en-2-ol10 
(0.025 g, 0.18 mmol) with β-bromostyrene (0.045 mL, 0.35 mmol) was conducted 
following General Procedure 4. This procedure afforded 0.043 g (92%) of the title 
compound as an orange oil. This was obtained as a 12:1 mixture of 
diastereomers, as judged by 1H NMR analysis. Characterization data were 
identical to those previously reported in the literature. 
 
(1’R*,2S*,5S*)-2-Methyl-2-phenyl-5-{1-[4-
(trifluoromethyl)phenyl]ethyl}tetrahydrofuran (III-46). The coupling of (E)-2-
phenylhept-5-en-2-ol (0.03 g, 0.16 mmol) with 4-bromobenzotriflouride (0.044 
mL, 0.32 mmol) was conducted following General Procedure 4. This procedure 
afforded 0.05 g (93%) of the title compound as a clear oil. This material was 
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obtained as a 20:1 mixture of diastereomers as judged by 1H NMR analysis. 1H 
NMR (400 MHz, CDCl3) δ 7.60 (s, 1 H), 7.47 (d, J = 7.2 Hz, 2 H), 7.42–7.37 (m, 1 
H), 7.31–7.24 (m, 4 H), 7.20– 7.14 (m, 1 H), 4.14–4.07 (m, 1 H), 3.00–2.91 (m, 1 
H), 2.18–2.09 (m, 1 H), 1.85–1.74 (m, 2 H), 1.70–1.58 (m, 1 H), 1.38 (s, 3 H), 
1.35 (d, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 148.6, 145.1, 132.0 (q, J 
= 32.6 Hz), 128.3, 128.1 (q, J = 252.4 Hz), 125.0 (q, J = 3.7 Hz), 124.6, 123.0, 
84.4, 82.3, 67.0, 44.5, 39.1, 29.3, 18.0; IR (film) 2957, 1327; MS(ESI): 357.1434 
(357.1442 calcd for C20H21F3O, M + Na+). 
 
(1’S*,2S*,5S*)-2-methyl-2-phenyl-5-{1-[4-
(trifluoromethyl)phenyl]ethyl}tetrahydrofuran (III-47). The coupling of (Z)-2-
phenylhept-5-en-2-ol (0.03 g, 0.16 mmol) with 4-bromo-benzotriflouride (0.044 
mL, 0.32 mmol) was conducted following General Procedure 4. This procedure 
afforded 0.05 g (94%) of the title compound as a clear oil. This material was 
obtained as a 7:1 mixture of diastereomers as judged by 1H NMR analysis. 1H 
NMR (400 MHz, CDCl3) δ 7.58 (s, 1 H), 7.54–7.47 (m, 2 H), 7.46–7.41 (m, 3 H), 
7.38–7.33, (m, 2 H), 7.28–7.22 (m, 1 H), 4.13 (q, J = 6.8 Hz, 1 H), 3.03 (p, J = 7.1 
Hz, 1 H), 2.17–2.11 (m, 1 H), 1.86–1.79 (m, 1 H), 1.70–1.59 (m, 2 H), 1.48 (s, 3 
H), 1.47 (d, J = 7.1 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 148.6, 145.2, 131.4 
(q, J = 31.5 Hz), 128.7, 128.8 (q, J = 225.0 Hz), 125.0 (q, J = 3.9 Hz), 124.7, 
123.1, 84.7, 82.9, 45.0, 39.1, 30.6, 29.3, 18.1; IR (film, cm–1) 2971, 1326; 
MS(ESI): 357.1456 (357.1442 calcd for C20H21F3O, M + Na+). 
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(1’R*,3S*,2S*)-Phenyl-{4-[1-(3,5,5-trimethyltetrahydrofuran-2-
yl)ethyl]phenyl}methanone (III-48). The coupling of (E)-2,4-dimethylhept-5-en-
2-ol (0.03 g, 0.21 mmol) with 4-bromo-benzophenone (0.11 g, 0.42 mmol) was 
conducted following General Procedure 4. This procedure afforded 0.059 g 
(86%) of the title compound as a clear oil. This material was obtained as a 20:1 
mixture of diastereomers as judged by 1H NMR analysis material. 1H NMR (400 
MHz, CDCl3) δ 7.79–7.75 (m, 2 H), 7.74–7.70 (m, 2 H), 7.58–7.52 (m, 1 H), 7.48–
7.42 (m, 2 H), 7.40–7.36 (m, 2 H), 3.66–3.62 (m, 1 H), 2.99–2.91 (m, 1 H), 1.80–
1.72 (m, 2 H), 1.42–1.36 (m, 4 H), 1.24 (s, 3 H), 0.95 (s, 3 H), 0.91 (d, J = 6.1 Hz, 
3 H); 13C NMR (100 MHz, CDCl3) δ 148.7, 137.9, 135.4, 132.0, 129.9, 129.7, 
128.9, 128.1, 88.8, 79.2, 48.1, 48.0, 42.2, 36.2, 29.4, 29.2, 18.5, 16.8; IR (film, 
cm–1) 2930, 1653; MS(ESI): 345.1826 (345.1830 calcd for C22H26O2, M + Na+). 
 
(1’R*,3S*,5S*)-2,2,3-Trimethyl-5-(1-p-tolylethyl)tetrahydrofuran (III-49). The 
coupling of (E)-2,4-dimethylhept-5-en-2-ol (0.025 g, 0.18 mmol) with 4-
bromotoluene (0.043 mL, 0.35 mmol) was conducted following General 
Procedure 4. This procedure afforded 0.033 g (85%) of the title compound as a 
clear oil. This material was obtained as a 4:1 mixture of diastereomers (epimeric 
at C3) as judged by 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 7.13–7.04 
(m, 4 H), 3.98 (p, J = 5.9 Hz, 1 H), 2.86–2.76 (m, 1 H), 2.28 (s, 3 H), 1.98–1.89 
(m, 1 H), 1.58–1.50 (m, 1H), 1.46–1.36 (m, 1 H), 1.19 (d, J = 7.0 Hz, 3 H), 1.16 
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(s, 3 H), 0.93 (s, 3 H), 0.87 (d, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
135.6, 135.4, 129.5, 128.7, 85.4, 79.3, 48.2, 40.2, 38.6, 29.6, 29.4, 21.0, 18.9, 
16.7; IR (film, cm–1) 2967, 1064; MS(ESI): 241.1565 (241.1568 calcd for 
C16H24O, M + Na+). 
 
(1’R*,3S*,5S*)-3,5,5-Trimethyltetrahydrofuran-2-yl(ethyl)pyridine (III-50). 
The coupling of (E)-2,4-dimethylhept-5-en-2-ol (0.02 g, 0.14 mmol) with 4-
bromopyridine HCl (0.55 g, 0.28 mmol) was conducted following General 
Procedure 4 except using 4 equiv of NaOtBu. This procedure afforded 22 mg 
(71%) of the title compound as an amber oil. This was obtained as a 15:1 mixture 
of diastereomers (epimeric at C3) as judged by 1H NMR analysis material. 1H 
NMR (400 MHz, CDCl3) δ 8.40 (d, J = 5.3 Hz, 2 H), 7.17–7.15 (m, 2 H), 3.57 (dd, 
J = 3.7, 9.0 Hz, 1 H), 2.84–2.76 (m, 1 H), 1.77–1.63 (m, 2 H), 1.40–1.35 (m, 1 H), 
1.32 (d, J = 7.3 Hz, 3 H), 1.20 (s, 3 H), 0.91 (s, 3 H), 0.88 (d, J = 6.4 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) δ 149.1, 149.0, 124.4, 88.2, 79.2, 47.9, 41.8, 36.3, 29.3, 
29.2, 18.1, 16.7; IR (film, cm–1) 2965, 1598; MS(ESI): 220.1707 (220.1701 calcd 
for C14H21NO, M + H+). 
 
(Z)-5-benzylidene-2,2-dimethyltetrahydrofuran (III-72). The coupling of 6-
methoxy-2-methylhex-5-en-2-ol (0.02 g, 0.14 mmol) with bromobenze (0.029 mL, 
0.28 mmol) was conducted following General Procedure 4. The yield of the 
reaction was not determined. 1H NMR (400 MHz, CDCl3) δ 7.59-7.51 (m, 2 H), 
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7.44 (m, 1 H), 7.32-7.24 (m, 1 H), 5.24 (t, J = 3.9 Hz, 1 H), 2.21-2.15 (m, 2 H), 
1.65 (t, J = 6.6 Hz, 2 H), 1.31 (s, 6 H). 
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Chapter 4: Stereoselective Synthesis of Substituted 1,3-
Oxazolidines via Pd-Catalyzed Carboamination 
Reactions of O-Vinyl-1, 2-Amino Alcohols 
 
4.1 Introduction   
Substituted 1,3-oxazolidines are displayed in many biologically active 
compounds1 and are also broadly employed in asymmetric synthesis as chiral 
auxiliaries, or as chiral ligands for transition metal catalysts.2 The classical 
approach to 2,4- and 2,5-disubstituted 1,3-oxazolidines involves condensation of 
an aldehyde with an amino alcohol, and alternative routes that involve carbon- 
heteroatom bond-forming cycloaddition,3 conjugate addition,4 or aza-Wacker type 
reactions5 have also been explored. However, most methods for the preparation 
of 1,3-oxazolidines effect the construction of the C-N and the C-O bond during 
the ring-forming event. Transformations that generate both a carbon-heteroatom 
bond and a carbon-carbon bond during oxazolidine formation are relatively rare 
and are typically not amenable to the stereo-controlled preparation of 2,4- or 2,5-
disubstituted products.6 
 
Scheme 4-1. Carboamination Strategy for Stereoselective Oxazolidine Synthesis 
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We sought to develop a new method for the preparation of 1,3-oxazolidines 
(e.g., IV-4) via Pd-catalyzed carboamination reactions between aryl or alkenyl 
bromides and enol ethers (IV-1) derived from readily available 1,2-amino 
alcohols (Scheme 4-1). This approach has significant potential utility, as the 
reactions should proceed with kinetic control of stereochemistry and provide 
enantiomerically pure products with good levels of diastereoselectivity.7,8 
However, in order to accomplish this goal, it was necessary to overcome two key 
obstacles. The transformations were expected to proceed via intramolecular syn-
aminopalladation of intermediate IV-2,9 but enol ethers (or similarly electron-rich 
alkenes) have not previously been employed in Pd-catalyzed carboaminations 
between unsaturated amines and aryl/alkenyl halides.10 No studies have 
demonstrated that such highly electron-rich alkenes can undergo syn-migratory 
insertion into Pd-N bonds of LnPd(R1)(NR2) complexes.11 Moreover, mechanistic 
experiments by Stahl indicate that the transition state for syn-aminopalladation 
exhibits characteristics of a N-nucleophile/alkene electrophile combination,12 
which suggests that insertions of electron-rich alkenes could have relatively high 
barriers.13 In addition to the challenges associated with syn-amino-palladation of 
an electron-rich alkene, the reductive elimination of intermediate IV-3 was also 
expected to be difficult. The two inductively electron-withdrawing heteroatoms on 
the carbon beta to Pd will slow the rate of C-C bond formation from IV-314. Thus, 
competing β-hydride elimination15 to generate IV-6 or β-alkoxide elimination16 to 
form IV-5 could be problematic.  
4.2 Optimization of the Reaction Conditions  
In preliminary feasibility studies, we elected to examine the reactivity of 
bromobenzene with the simple, geometrically constrained enol ether IV-7, which 
was synthesized by boc-protecting the amino group of 2-aminophenol and 
subsequent conversion of the phenol to the vinyl ether using 2,4,6-
trivinylcyclotriboroxane-pyridine complex and a stoichiometric amount of copper 
acetate, as shown in Scheme 4-2.  
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Scheme 4-2. Synthesis of the Substrate Used in Optimization Studies 
Given the anticipated challenges described above, we focused our catalyst 
optimization studies on two classes of ligands: (a) bis-phosphine ligands with 
relatively wide bite angles; and (b) bulky monodentate phosphine ligands (Table 
4-1). These classes of ligands have been shown to promote rapid C-C bond- 
forming reductive elimination,17 and prior studies suggested they could also 
potentially facilitate the key amino-palladation step.18 A preliminary survey of 
catalysts composed of Pd2(dba)3 and a wide bite angle ligand indicated that the 
yield of IV-8 increased with increasing bite angle, and promising results were 
obtained with Xantphos (58% yield).19 However, our experiments with 
monodentate phosphines showed the monodentate S-Phos ligand was superior 
to Xantphos,20 as the 1, 3-oxazolidine product IV-8 was isolated in 70% yield 
when this phosphine was employed.  
 
Table 4-1. Catalyst Optimization Studiesa 
N
H
OH
O
BOB
O B
pyr
Cu(OAc)2BOC +
NH2
OH BOC2O
NEt3
85%
N
H
O
BOC
VI-7
48%
H
N
O
Boc
O
N
Boc
Ph
2 mol % Pd2(dba)3
2–4 mol % Ligand
entry ligand yieldb
1
2
3
4
5
6
dppb 0%
Ru-Phos 20%
Xantphos 58%
Dpe-Phos 13%
P(o-tol)3 0%
S-Phos 70%c
IV-7 IV-8
NaOtBu, Toluene, 95 oC
+ Ph–Br
a Conditions: 1.0 equiv of 7, 2.0 equiv of PhBr, 2.0 equiv of NaOtBu, 2 mol % 
Pd2(dba)3, 2-4 mol % ligand, Toluene, 95 C. b Yields were determined by 1H 
NMR analysis of crude reaction mixtures using phenanthrene as an internal 
standard. c Isolated yield (average of two experiments).
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4.3 Exploration of Substrate Scope  
Having discovered a suitable catalyst system for enol ether carboamination, we 
sought to probe the scope of this new method. A variety of substrates were 
synthesized via O-vinylation of the corresponding amino alcohols via Pd- or Ir-
catalyzed vinyl transfer, as shown in Scheme 4-3.21 
 
Scheme 4-3. Substrate Synthesis 
As shown in Table 4-2, substrates bearing substituents adjacent to the oxygen 
or nitrogen atom were transformed to 2,5-cis- or 2,4-cis-disubstituted-1,3-
oxazolidines in good yield (entries 4-14). The products were typically generated 
with 8-17:1 dr (crude). Additionally, in many cases diastereomers could be 
partially separated by chromatography, and upon isolation the desired products 
were obtained with up to >20:1 dr. Disubstituted substrate IV-(−)-15 was 
converted to trisubstituted products IV-(−)-30 and IV-(−)-31 with good 
R
OH BOC2O
NH2
R
R
OH
NHBOC
R
Pd(TFA)2
1,10-phenanothroline
O
OR
Na2CO3
O
O
[Ir(COD)Cl]2 R
O
NHBOC
R
(+)-IV-12
O
NH
Boc
Et
O
NH
Boc
(±)-IV-10
O
NH
Boc
Ph
(±)-IV-11
O
NH
Boc
Bn
IV-9 (+)-IV-13
(–)-IV-15
O
NH
Boc
Bn
O
NH
Boc
Ph
Ph
O
NH
Boc
Ph
(–)-IV-14
BOC Protection: NA
Pd-Catalyzed Method: 55%
55%
38%
62%
57%
BOC Protection: 73%
Ir-Catalyzed Method: 76%
99%
87%
75%
99%
64%
99%
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stereocontrol (entries 15-16).22 The transformations were effective with a wide 
range of aryl bromides, and alkenyl halides were also successfully used as 
coupling partners (entries 3 and 13). 
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O
N
Boc
Et
15:1
(15:1)
O
N
Boc
69%
OMe
58%
(+)-IV-12 (+)-IV-23
substrate product drb yieldcentry
1
2
O
NH
Boc
O
NH
Boc
Et
O
N
Boc
63%
O
N
Boc
57%3
4
O
NH
Boc
IV-17
IV-18
O
N
Boc
Ph
83%12:1
(9:1)
Ph
O
N
Boc
Ph
OMe
>20:1
(14:1)
89%
(±)-IV-10 (±)-IV-19
(±)-IV-20
5
6
O
NH
Boc
Ph
(±)-IV-10
O
N
Boc
Bn
69%12:1
(12:1)
N
O
N
Boc
Bn
>20:1
(9:1)
83%
(±)-IV-11
7
8
O
NH
Boc
Bn
(±)-IV-11
(±)-IV-21
(±)-IV-22
IV-7
IV-9
IV-9
IV-16
OMe
Ph
O
NH
Boc
+ R1 BrR NaOtBu, Toluene, 95 °C
2 mol % Pd2(dba)3, 4 mol % S-Phos
O
N
Boc
R1
R
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Table 4-2. Stereoselective Synthesis of Substituted Oxazolidinesa 
O
N
Boc
Bn
67%
O
N
Boc
Ph
Ph
16:1
(16:1)
O
N
Boc
Et
19:1
(9:1)
tBu
 >20:1
  (8:1)
O
N
Boc
Bn
Cl 17:1(17:1)
62%
76%
O
N
Boc
Ph
Ph
CF3
17:1
(15:1)
70%
(+)-IV-13
(–)-IV-15
(+)-IV-24
(+)-IV-25
(+)-IV-26
(–)-IV-30
(–)-IV-31
63%(+)-IV-12
(+)-IV-13
(–)-IV-15
9
10
11
12
15
16
O
NH
Boc
Bn
O
NH
Boc
Ph
Ph
O
N
Boc
Ph
72%
C(O)Ph
11:1
(8:1)
O
N
Boc
Ph
18:1
(9:1)
53%
(+)-IV-27
(±)-IV-29
(±)-IV-14
13
14
O
NH
Boc
Ph
(–)-IV-14
Cl
substrate product drb yieldcentry
O
N
Boc
Ph
9:1
(9:1)
58%
(–)-IV-28
(–)-IV-14
C8H17
a Conditions: 1.0 equiv of amine, 2.0 equiv of R1Br, 2.0 equiv of NaOtBu, 2 
mol % Pd2(dba)3, 4 mol % S-Phos, Toluene, 95 C. b Diastereomeric ratios 
were determined by 1H NMR analysis of the pure, isolated material. 
Numbers in parentheses are diastereomeric ratios observed by NMR 
analysis of crude reaction mixtures. c Isolated yields (average of two or 
more experiments).
  
114 
4.4 Stereochemical Model  
A model that accounts for the relative stereochemistry of the products is 
illustrated in Figure 4-1. Transformations of substrates IV-12-IV-14 proceed via 
transition state IV-32, in which the substituent adjacent to the nitrogen atom is 
oriented in an axial position to minimize A1,3 strain in alternative transition state 
IV-33. Reactions of IV-10-IV-11 undergo cyclization via transition state IV-34, in 
which the substituent adjacent to the oxygen atom is equatorial to avoid 1,3-
diaxial interactions that would be present in transition state IV-35. The nature of 
the aryl or alkenyl halide appears to have a small effect on diastereoselectivity, 
but no clear trend is apparent. 
 
Figure 4-1. Stereochemical Model 
4.5 Conclusions  
H
O
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R1Boc
O
N
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O
N
Boc
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L
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R
H
R
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O
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L
H
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O
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R
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disfavored
O
N
Pd
Boc
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L
H
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O
N
Boc
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In summary, we have developed a concise approach to the synthesis of 
enantiomerically pure 2,4- and 2,5-disubstituted 1,3-oxazolidines. The 
heterocyclic products are generated in only three steps from commercially 
available amino alcohols in good yield and diastereoselectivity. This 
transformation provides access to compounds that are difficult to prepare in a 
stereocontrolled manner with existing methods. These transformations also 
illustrate the viability of enol ethers as participants in alkene carboamination 
processes and highlight the efficacy of S-Phos in promoting challenging sp3-sp3 
C-C bond-forming reductive elimination from Pd(II). 
4.6 Experimental  
 
Preparation of Substrates 
General Procedure 1: Synthesis of vinyl ethers via Pd-catalyzed 
vinylation.23 An oven-dried flask equipped with a magnetic stirbar was cooled 
under a stream of nitrogen and charged with the appropriate Boc-protected 
amino alcohol (1 equiv), palladium trifluoroacetate (1 mol %), 1,10 
phenanthroline (1 mol %), triethylamine (0.1 equiv) and n-butyl vinyl ether (0.25 
M). The resulting solution was heated to 75 °C for 12 h, then was cooled to rt. 
Brine (5 mL) and EtOAc (5 mL) were added, and the mixture was transferred to a 
separatory funnel. The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by flash chromatography on silica gel using 10:1 hexanes:ethyl acetate 
that contained 1% triethylamine (by volume) as the eluent. 
General Procedure 2: Iridium-catalyzed synthesis of vinyl ethers.24 A 
flame-dried round-bottomed flask equipped with a magnetic stirbar, a reflux 
condenser, and a rubber septum was cooled under a stream of nitrogen and 
charged with di-µ-chloro-bis(1,5-cyclooctadiene)diiridium (I), [Ir(cod)Cl]2, (0.01 
equiv) and sodium carbonate (0.6 equiv). The appropriate Boc-protected amino 
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alcohol (1 equiv), vinyl acetate (2 equiv), and toluene (1 M) were added, and the 
resulting mixture was heated to reflux for 12 h. The mixture was cooled to rt, 
brine (5 mL) and EtOAc (5 mL) were added, and the mixture was transferred to a 
separatory funnel. The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated in vacuo. The crude material was 
purified by flash chromatography on silica gel using 10:1 hexanes:ethyl acetate 
that contained 1% triethylamine (by volume) as the eluent. 
 
tert-Butyl [2-(vinyloxy)phenyl]carbamate (IV-7).25 An oven-dried flask was 
cooled under a stream of nitrogen and charged with Cu(OAc)2 (1 equiv) and 
CH2Cl2 (0.1 M). The resulting mixture was stirred at rt for 10 min then 2,4,6-
trivinylcyclotriboroxane-pyridine (1 equiv), tert-butyl (2-hydroxyphenyl)carbamate 
(1 equiv), and pyridine (10 equiv) were added. The resulting mixture was stirred 
at rt for 24 h, then was passed through an alumina column eluting with CH2Cl2. 
The resulting solution was concentrated in vacuo to afford the title compound as 
an orange oil that was used without additional purification. 1H NMR (400 MHz, 
CDCl3) δ 8.10 (d, J = 7.6 Hz, 1 H), 7.09–7.02 (m, 1 H), 6.99–6.90 (m, 2 H), 6.56 
(dd, J = 6.1, 13.7 Hz, 1 H), 4.79 (dd, J = 1.8, 15.3 Hz, 1 H), 4.49 (dd, J = 1.8, 6.1 
Hz, 1 H), 1.52 (s, 9 H) [missing NH peak]; 13C NMR (100 MHz, CDCl3) δ 152.6, 
148.0, 144.6, 129.2, 123.9, 122.4, 118.9, 115.9, 95.9, 80.6, 28.3; IR (film, cm–1) 
3442, 2978, 1733; MS(EI): 235.1208 (235.1214 calcd for C13H17NO3, M+). 
 
O
NH
Boc
IV-7
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tert-Butyl [2-(vinyloxy)ethyl]carbamate (IV-9). General Procedure 1 was 
used for conversion of tert-butyl (2-hydroxyethyl)carbamate (0.2 mL, 1.23 mmol) 
to the title compound. This procedure afforded 0.64 g (55%) of the title 
compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 6.40 (dd, J = 6.7, 14.3 
Hz, 1 H), 4.87 (s, br, 1 H), 4.16 (dd, J = 2.4, 14.5 Hz, 1 H), 3.99 (dd, J = 2.4, 6.9 
Hz, 1 H), 3.70 (t, J= 6.4 Hz, 2 H), 3.41–3.34 (m, 2 H), 1.41 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 155.8, 151.4, 87.0, 79.4, 67.0, 39.8, 28.3; IR (film, cm–1) 
3341, 2976, 1699; MS(ESI): 210.1095 (210.1101 calcd for C9H17NO3, M + H+). 
 
(±)-tert-Butyl [2-phenyl-2-(vinyloxy)ethyl]carbamate (IV-10). General 
Procedure 1 was used for the conversion of tert-butyl (2-hydroxy-2-
phenylethyl)carbamate (0.5 g, 2.1 mmol) to the title compound. This procedure 
afforded 0.20 g (38%) of the title compound as a white solid, mp = 76 oC. 1H 
NMR (400 MHz, CDCl3) δ 7.38–7.24 (m, 5 H), 6.31 (dd, J = 6.7, 14.2 Hz, 1 H), 
4.97–4.80 (m, 2 H), 4.24 (d, J = 14.2 Hz, 1 H), 4.00 (dd, J = 1.6, 6.6 Hz, 1 H), 
3.60–3.46 (m, 1 H), 3.32–3.23 (m, 1 H), 1.45 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 155.8, 150.4, 138.6, 128.6, 128.0, 126.2, 90.0, 80.3, 79.5, 46.7, 28.4; 
IR (film, cm–1) 3392, 2978, 1683; MS(ESI): MS(ESI): 286.1410 (286.1414 calcd 
for C16H23NO3 M + Na+). 
O
NH
Boc
IV-9
O
NH
Boc
Ph
IV-10
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(±)-tert-Butyl [3-phenyl-2-(vinyloxy)propyl]carbamate (IV-11). General 
Procedure 2 was used for the conversion of tert-butyl (2-hydroxy-3-
phenylpropyl)carbamate (0.4 g, 1.5 mmol) to the title compound. This procedure 
afforded 0.32 g (76%) of the title compound as a white solid, mp = 62 oC. 1H 
NMR (400 MHz, CDCl3) δ 7.31–7.24 (m, 2 H), 7.23–7.16 (m, 3 H), 6.47 (dd, J = 
6.8, 14.5 Hz, 1 H), 4.80 (s, br, 1 H), 4.13 (dd, J = 2.2, 14.3 Hz, 1 H), 4.08–3.98 
(m, 2 H), 3.63–3.54 (m, 2 H), 2.96–2.80 (m, 2 H), 1.41 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 155.22, 151.4, 137.8, 129.4, 128.5, 126.5, 87.0, 79.4, 67.6, 51.0, 
37.7, 28.5; IR (film, cm–1) 3395, 1686, 1164; MS(ESI): 300.1573 (300.1570 calcd 
for C16H23NO3 M + Na+). 
 
(+)-(R)-tert-Butyl [1-(vinyloxy)butan-2-yl]carbamate (IV-12). General 
Procedure 1 was used for the conversion of (R)-tert-butyl (1-hydroxybutan-2-
yl)carbamate (1.0 g, 5.28 mmol) to the title compound. This procedure afforded 
0.99 g (87%) of the title compound as a colorless oil [a]D23 = +28.5 (c 18.53, 
CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 6.47 (dd, J = 6.8, 14.4 Hz, 1 H), 4.67 (s, 
br, 1 H), 4.18 (dd, J = 2.0, 14.2 Hz, 1 H), 4.0 (dd, J = 2.2, 6.8 Hz, 1 H), 3.76–3.63 
(m, 3 H), 1.66–1.58 (m, 1 H), 1.56–1.48 (m, 1 H), 1.45 (s, 9 H), 0.94 (t, J = 7.3 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 155.6, 151.7, 86.7, 69.1, 51.2, 28.4, 24.9, 
10.5 (one carbon signal is missing due to incidental equivalence); IR (film, cm–1) 
3440, 2970, 1686; MS(ESI): 238.1412 (238.1414 calcd for C11H21NO3, M + Na+). 
 
IV-11
O
NH
Boc
Bn
O
NH
Boc
Et
IV-12
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(+)-(R)-tert-Butyl [1-phenyl-3-(vinyloxy)propan-2-yl]carbamate (IV-13). 
General Procedure 1 was used for the conversion of (R)-tert-butyl (1-hydroxy-3-
phenylpropan-2-yl)carbamate (0.5 g, 1.99 mmol) to the title compound. This 
procedure afforded 0.54 g (99%) of the title compound as a white solid, mp = 62 
oC, [a]D23 = +20.7 (c 18.06, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.30–7.24 (m, 
2 H), 7.22–7.15 (m, 3 H), 6.47 (dd, J = 6.8, 14.2 Hz, 1 H), 4.86 (s, br, 1 H), 4.13 
(dd, J = 2.1, 14.2 Hz, 1 H), 4.08–3.96 (m, 2 H), 3.63–3.54 (m, 2 H), 2.93–2.80 (m, 
2 H), 1.41 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.2, 151.4, 137.8, 129.4, 
128.4, 126.4, 87.0, 79.3, 67.7, 51.0, 37.7, 28.3.; IR (film, cm–1) 3359, 2922, 1687; 
MS(ESI): 300.1567 (300.1570 calcd for C16H23NO3, M + Na+). 
 
(–)-(R)-tert-Butyl [1-phenyl-2-(vinyloxy)ethyl]carbamate (IV-14). General 
Procedure 1 was used for the conversion of (R)-tert-butyl (2-hydroxy-1-
phenylethyl)carbamate (0.4 g, 1.68 mmol) to the title compound. This procedure 
afforded 0.23 g (52%) of the title compound as a white solid, mp = 72 oC, [a]D23 = 
–18.1 (c 2.02, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.38–7.32 (m, 3 H), 7.31–
7.27 (m, 2 H), 6.46 (dd, J = 6.8, 14.2 Hz, 1 H), 5.20 (s, 1 H), 4.96 (s, 1H), 4.21 
(dd, J = 2.2, 14.4 Hz, 1 H), 4.04 (dd, J = 2.2, 6.8 Hz, 1 H), 3.98–3.92 (m, 1 H), 
3.91–3.85 (m, 1 H), 1.45 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.3, 151.3, 
139.8, 128.5, 127.6, 126.7, 87.2, 79.8, 70.3, 53.7, 28.4; IR (film, cm–1) 3390, 
2978, 1682; MS(ESI): 286.1414 (286.1414 calcd for C16H23NO3 M + Na+). 
O
NH
Boc
Bn
IV-13
O
NH
Boc
Ph
IV-14
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(±)-tert-Butyl [1-phenyl-2-(vinyloxy)ethyl]carbamate (IV-14). General 
Procedure 1 was used for the conversion of tert-butyl (2-hydroxy-1-
phenylethyl)carbamate (1.5 g, 6.32 mmol) to the title compound. This procedure 
afforded 0.95 g (57%) of the title compound as a white solid, mp = 72 oC. 1H 
NMR (400 MHz, CDCl3) δ 7.38–7.32 (m, 3 H), 7.31–7.27 (m, 2 H), 6.46 (dd, J = 
6.8, 14.2 Hz, 1 H), 5.20 (s, 1 H), 4.96 (s, 1H), 4.21 (dd, J = 2.2, 14.4 Hz, 1 H), 
4.04 (dd, J = 2.2, 6.8 Hz, 1 H), 3.98–3.92 (m, 1 H), 3.91–3.85 (m, 1 H), 1.45 (s, 9 
H); 13C NMR (100 MHz, CDCl3) δ 155.3, 151.3, 139.8, 128.5, 127.6, 126.7, 87.2, 
79.8, 70.3, 53.7, 28.4; IR (film, cm–1) 3390, 2978, 1682; MS(ESI): 286.1412 
(286.1414 calcd for C16H23NO3 M + Na+). 
 
(–)-(1R,2S)-tert-Butyl [1,2-diphenyl-2-(vinyloxy)ethyl]carbamate (IV-15). 
General Procedure 2 was used for the conversion of (1R,2S)-tert-butyl (2-
hydroxy-1,2-diphenylethyl)carbamate (0.5 g, 1.99 mmol) to the title compound. 
This procedure afforded 0.54 g (99%) of the title compound as a white solid, mp 
= 62 oC, [a]D23 = –32.3 (c 2.33, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.24–7.16 
(m, 6 H), 7.03–6.98 (m, 2 H), 6.97–6.92 (m, 2 H), 6.35 (dd, J = 6.6, 14.2 Hz, 1 H), 
5.40 (s, br, 1 H), 5.19 (s, br, 1 H), 4.96 (s, br, 1 H), 4.24 (d, J = 14.2 Hz, 1 H), 
4.03 (dd, J = 1.7, 6.6 Hz. 1 H), 1.42 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 155.0, 
150.4, 137.1, 128.2, 128.0, 127.7, 127.5, 127.4, 126.8, 126.6, 90.1, 83.0, 79.7, 
59.4, 28.4; IR (film, cm–1) 3388, 2979, 1681, 1171; MS(ESI): 362.1727 (362.1727 
calcd for C21H25NO3, M + Na+). 
O
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Synthesis of Substituted 1,3-Oxazolidines via Pd-Catalyzed Alkene 
Carboamination 
General Procedure 4: Palladium-Catalyzed Carboamination Reactions for 
the Formation of Oxazolidines. An oven or flame-dried Schlenk tube was 
cooled under a stream of nitrogen and charged with Pd2(dba)3 (2 mol% complex, 
4 mol % Pd), S-Phos (4 mol %), NaOtBu (2.0 equiv), and the aryl bromide (2.0 
equiv). The tube was purged with nitrogen and the amine substrate (1.0 equiv), 
and toluene (0.25 M in substrate) were added. The mixture was heated to 98 °C 
with stirring until the starting material had been consumed as judged by GC or 1H 
NMR analysis. The mixture was cooled to room temperature, quenched with 
saturated aqueous NH4Cl (2 mL), and diluted with ethyl acetate (10 mL). The 
layers were separated and the aqueous layer was extracted with ethyl acetate (3 
X 10 mL). The combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was then purified 
by flash chromatography on silica gel.  
 
(±)-tert-Butyl 2-benzylbenzo[d]oxazole-3(2H)-carboxylate (IV-8). The 
coupling of tert-butyl [2-(vinyloxy)phenyl]carbamate (20 mg, 0.09 mmol) with 
bromobenzene (0.27 µL, 0.17 mmol) was conducted following General 
Procedure 4. This procedure afforded 19.5 mg (74%) of the title compound as an 
orange oil. 1H NMR (400 MHz, C7D8, 100 oC) δ 7.45 (s, 1 H), 7.17–7.13 (m, 2 H), 
7.07–7.02 (m, 3 H), 7.00–6.94 (m, 2 H), 6.70–6.62 (m, 1 H), 6.59–6.55 (m, 1 H), 
3.11 (dd, J = 2.7, 14.1 Hz, 1 H), 2.99 (dd, J = 6.4, 14.1 Hz, 1 H), 1.40 (s, 9 H); 
13C NMR (100 MHz, CDCl3) δ 150.1, 135.0, 131.6, 131.5, 129.9, 128.6, 128.4, 
128.3, 127.0, 126.8, 123.3, 120.9, 114.1, 113.8, 108.7, 94.7, 82.4, 41.4, 40.6, 
28.3 (doubling of 5 peaks was observed due to the interconversion of rotamers); 
O
N
Boc
Ph
IV-8
  
122 
IR (film, cm–1) 2978, 1702, 1480; MS(ESI): 334.1416  (334.1414 calcd for 
C20H23NO4, M + Na+). 
 
(±)-tert-Butyl 2-(4-methoxybenzyl)benzo[d]oxazole-3(2H)-carboxylate (IV-
16). The coupling of tert-butyl [2-(vinyloxy)phenyl]carbamate (20 mg, 0.09 mmol) 
with 4-bromoanisole (21 µL, 0.17 mmol) was conducted following General 
Procedure 4. This procedure afforded 20 mg (71%) of the title compound as a 
yellow oil. 1H NMR (400 MHz, C7D8, 90 oC) δ 7.49 (s, 1 H), 7.10–7.05 (m, 1 H), 
6.99–6.95 (m, 1 H), 6.67–6.64 (m, 5 H), 6.14–6.08 (m, 1 H), 3.33 (s, 3 H), 3.13–
3.06 (s, 1 H), 2.02–1.93 (s, 1 H), 1.40 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 
158.6, 150.1, 130.9, 127.0, 126.5, 123.2, 121.0, 114.0, 113.8, 108.7, 94.8, 82.4, 
55.2, 40.4, 39.6, 29.7, 28.3 (doubling of 1 peak was observed due to the 
interconversion of rotamers); IR (film, cm–1) 2974, 1702, 1480, 1248, 1063; 
MS(ESI): 364.1519  (364.1519 calcd for C19H21NO3, M + Na+). 
 
(±)-tert-Butyl 2-(naphthalen-2-ylmethyl)oxazolidine-3-carboxylate (IV-17). 
The coupling of tert-butyl [2-(vinyloxy)ethyl]carbamate (30 mg, 0.16 mmol) with 2-
bromonaphthalene (66 mg, 0.32 mmol) was conducted following General 
Procedure 4. This procedure afforded 50 mg (70%) of the title compound as a 
yellow oil. 1H NMR (400 MHz, C7D8, 100 oC) δ 7.67–7.64 (m, 1 H), 7.63–7.54 (m, 
2 H), 7.39–7.33 (m, 1 H), 7.25–7.17 (m, 1 H), 7.09–7.05 (m, 1 H), 7.00–6.95 (m, 
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1 H), 4.39–4.33 (m, 1 H), 3.55–3.45 (m, 1 H), 3.41–3.28 (m, 2 H), 3.25–3.17 (m, 
1 H), 3.16–3.07 (m, 1 H), 2.79–2.69 (m, 1 H), 1.41 (m, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 152.9, 134.2, 133.5, 132.3, 128.6, 127.6, 127.5, 125.8, 125.4, 89.3, 
80.4, 65.6, 44.5, 40.8, 28.4 (2 carbon signals are missing due to incidental 
equivalence); IR (film, cm–1) 2967, 2928, 1699; MS(ESI): 336.1568 (336.1570 
calcd for C19H23NO3, M + Na+). 
 
(±)-(E)-tert-Butyl 2-cinnamyloxazolidine-3-carboxylate (IV-18). The coupling 
of tert-butyl [2-(vinyloxy)ethyl]carbamate (20 mg, 0.11 mmol) with (E)-b-
bromostyrene (28 µL, 0.22 mmol) was conducted following General Procedure 4. 
This procedure afforded 20 mg (65%) of the title compound as an orange oil. 1H 
NMR (400 MHz, C7D8, 100 oC) δ 7.22–7.18 (m, 1 H), 7.10–7.04 (m, 3 H). 7.01–
7.94 (m, 1 H), 6.44 (d, J = 15.9 Hz, 1 H), 6.23–6.14 (m, 1 H), 5.20–5.14 (m, 1 H), 
3.68–3.60 (m, 1 H), 3.47–3.35 (m, 2 H), 3.10–3.00 (m, 1 H), 2.71–2.64 (m, 1 H), 
2.62–2.55 (m, 1 H), 1.40 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 152.9, 137.9, 
137.4, 133.2, 131.5, 128.9, 128.7, 128.5, 128.1, 127.1, 126.7, 126.1, 124.2, 
123.9, 88.5, 80.2, 65.7, 44.7, 38.0, 28.4 (doubling of 7 peaks was observed due 
to the interconversion of rotamers); IR (film, cm–1) 2976, 1699, 1457; MS(EI): 
290.1761  (290.1756 calcd for C17H23NO3, M + H+). 
 
(±)-(2R*,5S*)-tert-Butyl 2-([1,1'-biphenyl]-4-ylmethyl)-5-phenyloxazolidine-
3-carboxylate (IV-19). The coupling of (±)-tert-butyl [2-phenyl-2-
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(vinyloxy)ethyl]carbamate (20 mg, 0.08 mmol) with 2-bromobiphenyl (35 mg, 0.15 
mmol) was conducted following General Procedure 4. This procedure afforded 
21 mg (68%) of the title compound as an orange oil. This material was formed as 
a 9:1 mixture of diastereomers as judged by 1H NMR analysis of the crude 
product; the isolated product was obtained in 12:1 dr following purification. Data 
are for the major isomer. 1H NMR (400 MHz, C6D6, 70 oC) δ 7.43–7.38 (m, 4 H), 
7.37–7.33 (m, 2 H), 7.18–7.12 (m, 2 H), 7.07–7.03 (m, 4 H), 7.02–6.97 (m, 2 H), 
5.48–5.42 (m, 1 H), 4.46–4.40 (m, 1 H), 3.92–3.80 (m, 1 H), 3.30–3.16 (m, 2 H), 
2.74 (t, J = 10.2 Hz, 1 H), 1.45–1.42 (m, 9 H); 13C NMR (100 MHz, CDCl3) δ 
152.7, 141.1, 139.5, 137.4, 135.4, 130.9, 129.7, 129.0, 128.7, 128.6, 128.4, 
128.3, 128.1, 127.4, 127.3, 127.1, 127.0, 126.9, 126.6, 126.4, 126.2, 90.0, 89.3, 
80.3, 78.9, 52.3, 40.6, 39.2, 28.5, 28.4, 28.0, 27.9 (doubling of 13 peaks was 
observed due to the interconversion of rotamers); IR (film, cm–1) 2918, 1699, 
1366; MS(ESI): 416.2214 (416.2220 calcd for C27H29NO3, M + H+). 
 
(±)-(2R*,5S*)-tert-Butyl 2-(3-methoxybenzyl)-5-phenyloxazolidine-3-
carboxylate (IV-20). The coupling of (±)-tert-butyl [2-phenyl-2-
(vinyloxy)ethyl]carbamate (20 mg, 0.07 mmol) with 3-bromo-anisole (28 µL, 0.15 
mmol) was conducted following General Procedure 4. This procedure afforded 
025 mg (89%) of the title compound as an amber oil. This material was formed 
as a 14:1 mixture of diastereomers as judged by 1H NMR analysis of the crude 
product; the isolated product was obtained in >20:1 dr following purification. Data 
are for the major isomer. 1H NMR (400 MHz, C6D6, 70 oC) δ 7.07–6.88 (m, 8 H), 
6.68 (d, J = 8.2 Hz, 1 H), 5.45–5.40 (m, 1 H), 4.44–4.37 (m, 1 H), 3.83 (s, 1 H), 
3.35 (s, 3 H), 3.25–3.16 (m, 2 H), 2.68 (t, J = 10.0 Hz, 1 H), 1.42 (s, 9 H); 13C 
NMR (100 MHz, CDCl3) δ 159.3, 152.6, 137.7, 137.4, 129.0, 128.4, 128.3, 126.6, 
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122.8, 115.9, 112.3, 89.2, 80.1, 78.7, 55.1, 40.9, 39.8, 28.4; IR (film, cm–1) 2930, 
1696, 1367; MS(ESI): 370.2016 (370.2013 calcd for C23H29NO3 M + H+). 
 
(±)-(2R*,5S*)-tert-Butyl 5-benzyl-2-(pyridin-3-ylmethyl)oxazolidine-3-
carboxylate (IV-21). The coupling of (±)-tert-butyl [3-phenyl-2-
(vinyloxy)propyl]carbamate (20 mg, 0.07 mmol) with 3-bromopyridine (15 mg, 
0.14 mmol) was conducted following General Procedure 4. This procedure 
afforded 25 mg (63%) of the title compound as an orange oil. This material was 
formed as a 12:1 mixture of diastereomers as judged by 1H NMR analysis of the 
crude product; the isolated product was obtained in 12:1 dr following purification. 
Data are for the major isomer. 1H NMR (400 MHz, C7D8, 90 oC) δ 8.65 (s, 1 H), 
8.42 (d, J = 3.6 Hz, 1 H), 7.35 (d, J = 7.4 Hz, 1 H), 7.11–7.04 (m, 2 H), 7.02–7.91 
(m, 3 H), 6.85–6.79 (m, 1 H), 5.11–5.06 (m, 1 H), 3.87 (s, 1 H), 3.54 (d, J = 8.8 
Hz, 1 H), 3.34–3.26 (m, 1 H), 3.07–2.99 (m, 1 H), 2.97–2.89 (m, 1 H), 2.74 (d, J = 
12.9 Hz, 1 H), 1.96 (t, J = 11.6 Hz, 1 H), 1.40 (s, 9 H); 13C NMR (100 MHz, 
CDCl3) δ 153.0, 151.6, 148.0, 138.0, 131.9, 129.2, 128.5, 128.4, 126.5, 123.0, 
80.1, 69.2, 58.4, 39.3, 28.6, 28.4 (one carbon signal is missing due to incidental 
equivalence); IR (film, cm–1) 3028, 2929, 1699, 1367; MS(ESI): 355.2019 
(355.2016 calcd for C21H26N2O3,M+H+). 
 
(±)-(2R*,5S*)-tert-Butyl 5-benzyl-2-(4-methylbenzyl)oxazolidine-3-
carboxylate (IV-22). The coupling of (±)-tert-butyl [3-phenyl-2-
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(vinyloxy)propyl]carbamate (20 mg, 0.07 mmol) with 4-bromotoluene (24 µL, 0.14 
mmol) was conducted following General Procedure 4. This procedure afforded 
20 mg (74%) of the title compound as an amber oil. This material was formed as 
a 9:1 mixture of diastereomers as judged by 1H NMR analysis of the crude 
product; the isolated product was obtained in >20:1 dr following purification. Data 
are for the major isomer. 1H NMR (400 MHz, C7D8, 90 oC) δ 7.21–7.16 (m, 2 H), 
7.07–7.00 (m, 4 H), 6.98–6.92 (m, 3 H), 5.20–5.15 (m, 1 H), 3.90 (s, 1 H), 3.59–
3.53 (m, 1 H), 3.36–3.30 (m, 1 H), 3.15 (d, J = 14.1 Hz, 1 H), 3.02–2.92 (m, 1 H), 
2.82 (d, J = 12.9 Hz, 1 H), 2.12–2.09 (m, 3 H), 2.08–2.02 (m, 1 H), 1.39 (m, 9 H); 
13C NMR (100 MHz, CDCl3) δ 153.1, 138.3, 136.1, 133.5, 130.2, 129.4, 128.8, 
128.5, 127.3, 126.4, 126.3, 91.1, 90.5, 69.3, 69.0, 58.4, 39.4, 29.7, 28.4, 21.1 
(doubling of 3 peaks was observed due to the interconversion of rotamers); IR 
(film, cm–1) 2973, 1699, 1366; MS(EI): 390.2037 (390.2040 calcd for C23H29NO3, 
M + Na+). 
 
(+)-(2R,4R)-tert-Butyl 4-ethyl-2-[(6-methoxynaphthalen-2-
yl)methyl]oxazolidine-3-carboxylate (IV-23). The coupling of (R)-tert-butyl [1-
(vinyloxy)butan-2-yl]carbamate (20 mg, 0.09 mmol) with 2-bromo-6-
methoxynaphthalene (44 mg, 0.18 mmol) was conducted following General 
Procedure 4. This procedure afforded 20 mg (58%) of the title compound as an 
amber oil, [a]D23 = +48.5 (c 1.59, CH2Cl2). This material was formed as a 15:1 
mixture of diastereomers as judged by 1H NMR analysis of the crude product; the 
isolated product was obtained in 15:1 dr following purification. Data are for the 
major isomer. 1H NMR (400 MHz, C7D8, 100 oC) δ 7.64 (s, 1 H), 7.55–7.47 (m, 2 
H), 7.41 (d, J = 8.6 Hz, 1 H), 7.07–7.02 (m, 1 H), 6.99–6.93 (m, 1 H), 5.31–5.26 
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(m, 1 H), 3.67–3.68 (m, 1 H), 3.53–3.44 (m, 5 H), 3.33 (d, J = 14.1 Hz, 1 H), 3.15 
(dd, J = 6.1, 13.7 Hz, 1 H), 1.47–1.31 (m, 10 H), 1.12–0.99 (m, 1 H), 0.67–0.61 
(m, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.3, 153.6, 133.4, 132.0, 129.1, 128.9, 
128.4, 126.4, 118.6, 105.6, 90.5, 70.1, 58.2, 55.2, 28.4, 28.3, 26.8, 10.6 (2 
carbon signals are missing due to incidental equivalence); IR (film, cm–1) 3368, 
2976, 1699; MS(ESI): 372.2173 (372.2169 calcd for C22H29NO4, M + H+). 
 
(+)-(2R,4R)-tert-Butyl 4-ethyl-2-(3-methylbenzyl)oxazolidine-3-carboxylate 
(IV-24). The coupling of (R)-tert-butyl [1-(vinyloxy)butan-2-yl]carbamate (20 mg, 
0.09 mmol) with 3-bromotoluene (31 µL, 0.18 mmol) was conducted following 
General Procedure 4. This procedure afforded 21 mg (74%) of the title 
compound as a yellow oil, [a]D23 = +45.0 (c 3.65, CH2Cl2). This material was 
formed as a 9:1 mixture of diastereomers as judged by 1H NMR analysis of the 
crude product; the isolated product was obtained in 19:1 dr following purification. 
Data are for the major isomer. 1H NMR (400 MHz, C7D8, 100 oC) δ 7.12–7.02 (m, 
2 H), 6.99–6.94 (m, 1 H), 6.91–6.85 (m, 1 H), 5.24–5.18 (m, 1 H), 3.61 (s, 1 H), 
3.50–3.38 (m, 2 H), 3.17 (d, J = 13.3 Hz, 1 H), 2.97 (dd, J = 5.9, 13.3 Hz, 1 H), 
2.16 (s, 3 H), 2.09 (s, 1 H), 1.40 (s, 9 H), 1.14–1.02 (s, 1 H), 0.68 (t, J = 7.2 Hz, 3 
H);13C NMR (100 MHz, CDCl3) δ 153.6, 137.6, 136.7, 130.8, 128.0, 127.2, 90.4, 
80.0, 70.0, 58.1, 41.5, 28.5, 26.8, 21.3, 10.6, (1 carbon signal is missing due to 
incidental equivalence); IR (film, cm–1) 2972, 1699, 1366; MS(ESI): 328.1883 
(328.1883 calcd for C18H27NO3, M + Na+). 
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(+)-(2R,4R)-tert-Butyl 4-benzyl-2-[4-(tert-butyl)benzyl]oxazolidine-3-
carboxylate (IV-25). The coupling of (R)-tert-butyl [1-phenyl-3-(vinyloxy)propan-
2-yl]carbamate (25 mg, 0.12 mmol) with 4-bromo-tert-butylbenzene (49 µL, 0.23 
mmol) was conducted following General Procedure 4. This procedure afforded 
25 mg (89%) of the title compound as a yellow oil, [a]D23 = +26.5 (c 4.69, CH2Cl2). 
This material was formed as an 8:1 mixture of diastereomers as judged by 1H 
NMR analysis of the crude product; the isolated product was obtained in >20:1 dr 
following purification. Data are for the major isomer. 1H NMR (400 MHz, C6D6, 70 
oC) δ 7.32–7.28 (m, 2 H), 7.27–7.22 (m, 2 H), 7.07–7.00 (m, 2 H), 6.99–6.92 (m, 
3 H), 5.27–5.22 (m, 1 H), 3.98–3.86 (m, 1 H), 3.57–3.51 (m, 1 H), 3.31–3.16 (m, 
2 H), 3.11–2.96 (m, 1 H), 2.89–2.78 (m, 1 H), 2.00 (t, J = 10.8 Hz, 1 H), 1.40 (s, 9 
H), 1.16 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 153.1, 149.4, 138.3, 133.6, 130.0, 
129.3, 128.5, 126.4, 125.0, 106.1, 90.5, 80.2, 69.4, 58.1, 47.4, 39.2, 34.4, 31.4, 
31.2, 28.5, doubling of 2 peaks was observed due to the interconversion of 
rotamers; IR (film, cm–1) 2966, 1696, 1367; MS(EI): 410.2695 (410.2695 calcd for 
C26H35NO3, M + H+). 
 
(+)-(2R,4R)-tert-Butyl 4-benzyl-2-(2-chlorobenzyl)oxazolidine-3-
carboxylate (IV-26). The coupling of (R)-tert-butyl [1-phenyl-3-(vinyloxy)propan-
2-yl]carbamate (25 mg, 0.12 mmol) with 2-bromochlorobenzene (44 µL, 0.23 
mmol) was conducted following General Procedure 4. This procedure afforded 
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22 mg (75%) of the title compound as a yellow oil, [a]D23 = +30.0 (c 4.68, CH2Cl2). 
This material was formed as a 17:1 mixture of diastereomers as judged by 1H 
NMR analysis of the crude product; the isolated product was obtained in 17:1 dr 
following purification. Data are for the major isomer. 1H NMR (400 MHz, C6D6, 70 
oC) δ 7.22 (d, J = 6.7 Hz, 1 H), 7.17 (d, J = 7.6 Hz, 1 H), 7.07–6.95 (m, 5 H), 
6.90–6.82 (m, 1 H), 6.78–6.71 (m, 1 H), 5.41–5.35 (m, 1 H), 3.98 (s, 1 H), 3.61–
3.54 (m, 1 H), 3.45–3.36 (m, 1 H), 3.35–3.26 (m, 1 H), 3.10–2.92 (m, 2 H), 2.36–
2.25 (m, 1 H), 1.37 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 153.3, 138.1, 134.6, 
132.5, 129.4, 128.5, 128.1, 127.7, 126.5, 88.9, 80.1, 69.2, 58.2, 39.6, 38.6, 37.5, 
28.6, 28.5 (2 peaks are missing due to incidental equivalence, and doubling of 2 
peaks was observed due to the interconversion of rotamers); IR (film, cm–1) 
3062, 2977, 1699, 1397; MS(ESI): 410.1487 (410.1493 calcd for C22H26ClNO3, M 
+ Na+). 
 
(+)-(2R,4R)-tert-Butyl 2-(4-benzoylbenzyl)-4-phenyloxazolidine-3-
carboxylate (IV-27). The coupling of (R)-tert-butyl [1-phenyl-2-
(vinyloxy)ethyl]carbamate (20 mg, 0.08 mmol) with 4-bromobenzophenone (40 
mg, 0.12 mmol) was conducted following General Procedure 4. This procedure 
afforded 27 mg (80%) of the title compound as a yellow oil, [a]D23 = +27.1 (c 2.06, 
CH2Cl2).This material was formed as an 8:1 mixture of diastereomers as judged 
by 1H NMR analysis of the crude product; the isolated product was obtained in 
11:1 dr following purification. The enantiopurity was judged to be >99% ee by 
chiral HPLC analysis (chiralcel AD column, 1% isopropanol/hexanes, 0.5% 
triethylamine, 1.0 mL/min, RT = 17.39 min and 23.48 min).  Data are for the 
major isomer. 1H NMR (400 MHz, C6D6, 70 oC) δ 7.71–7.75 (m, 4 H), 7.28–7.23 
(m, 2 H), 7.08–6.95 (m, 8 H), 5.35–5.30 (m, 1 H), 4.62 (s, br, 1 H), 3.70–3.64 (m, 
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2 H), 3.40 (d, J = 13.6 Hz, 1 H), 3.10 (dd, J = 7.3, 13.5 Hz, 1 H), 1.34–1.24 (m, 9 
H); 13C NMR (100 MHz, CDCl3) δ 218.2, 153.6, 141.9, 137.8, 136.0, 132.2, 
128.7, 128.4, 128.3, 128.2, 127.8, 127.4, 126.5, 126.3, 91.0, 73.1, 66.6, 60.5, 
46.2, 40.6, 28.3 (doubling of 1 peak was observed due to the interconversion of 
rotamers); IR (film, cm–1) 2928, 1696, 1366; MS(ESI): 444.2168 (444.2169 calcd 
for C28H29NO4, M + H+). 
 
(–)-(E)-(2R,4R)-tert-butyl 4-phenyl-2-(undec-2-en-1-yl)oxazolidine-3-
carboxylate (IV-28). The coupling of (R)-tert-butyl (1-phenyl-2-
(vinyloxy)ethyl)carbamate (0.025 g, 0.095 mmol) with (E)-1-bromodec-1-ene 
(0.042, 0.19 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.021 g (58%) of the title compound as a yellow oil. This 
material was obtained as a 9:1 mixture of diastereomers as judged by 1H NMR 
analysis. Data are for the major isomer. [a]D23 = –10.0 (c 1.94, CH2Cl2). 1H NMR 
(400 MHz, C7D8, 100 oC) δ 7.38–7.34 (m, 2 H), 7.26–7.19 (m, 1 H), 7.17–7.11 
(m, 1 H), 7.09–7.04 (m, 1 H), 5.73–5.45 (m, 2 H), 5.37–5.32 (m, 1 H), 4.84–4.78 
(m, 1 H), 3.97–3.85 (m, 2 H), 2.97–2.88 (m, 1 H), 2.71–2.62 (m, 1 H), 2.21–2.16 
(m, 2 H), 1.40–1.21 (m, 23 H), 1.11–0.99 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 
155.6, 143.9, 134.8, 134.4, 130.3, 128.3, 127.3, 126.4, 124.2, 110.8, 90.8, 72.9, 
60.5, 55.4, 37.9, 33.2, 32.7, 31.9, 29.5, 29.3, 29.2, 29.1, 28.2, 14.1, 3.9 (doubling 
of 4 peaks was observed due to the interconversion of rotamers); IR (film, cm–1) 
2926, 1704, 1451; MS(ESI): 402.3010 (402.3003 calcd for C25H39NO3, M + H+). 
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(±)-(2R*,4R*)-tert-Butyl 2-(4-chlorobenzyl)-4-phenyloxazolidine-3-
carboxylate (IV-29). The coupling of (±)-tert-butyl [1-phenyl-2-
(vinyloxy)ethyl]carbamate (20 mg, 0.08 mmol) with 1-bromo-4-chlorobenzene (29 
mg, 0.15 mmol) was conducted following General Procedure 4. This procedure 
afforded 15 mg (53%) of the title compound as an orange oil. This material was 
formed as a 9:1 mixture of diastereomers as judged by 1H NMR analysis of the 
crude product; the isolated product was obtained in 18:1 dr following purification. 
Data are for the major isomer. 1H NMR (400 MHz, C7D8, 100 oC) δ 7.13–7.96 (m, 
9 H), 5.22 (d, J = 6.8 Hz, 1 H), 4.66–4.59 (m, 1 H), 3.75–3.68 (m, 2 H), 3.25 (d, J 
= 14.1 Hz, 1 H), 3.03 (dd, J = 7.1, 13.9 Hz, 1 H), 1.29 (s, 9 H); 13C NMR (100 
MHz, CDCl3) δ 153.6, 140.8, 135.3, 131.3, 128.8, 128.4, 127.8, 127.4, 127.3, 
126.6, 126.3, 113.7, 91.1, 80.7, 73.2, 60.5, 39.7, 28.3, 27.9 (doubling of 4 peaks 
was observed due to the interconversion of rotamers); IR (film, cm–1) 2976, 2930, 
1699, 1396; MS(ESI): 396.1322  (396.1337 calcd for C21H24ClNO3, M + Na+). 
 
(–)-(4R,5S)-tert-Butyl 2-(2-methylbenzyl)-4,5-diphenyloxazolidine-3-
carboxylate (IV-30). The coupling of (–)-(1R,2S)-tert-butyl [1,2-diphenyl-2-
(vinyloxy)ethyl]carbamate (25 mg, 0.07 mmol) with 2-bromotoluene (25 µL, 0.14 
mmol) was conducted following General Procedure 4. This procedure afforded 
25 mg (74%) of the title compound as an orange oil, m.p. = 51 oC, [a]D23 = –88.4 
(c 1.69, CH2Cl2). This material was formed as a 16:1 mixture of diastereomers as 
judged by 1H NMR analysis of the crude product; the isolated product was 
obtained in 18:1 dr following purification. Data are for the major isomer. 1H NMR 
(400 MHz, C6D6, 70 oC) δ 7.56 (d, J = 6.4 Hz, 1 H), 7.10–7.02 (m, 3 H), 6.93–
6.84 (m, 8 H), 6.83–6.78 (m, 2 H), 5.39–5.34 (m, 1 H), 4.98 (s, 1 H), 4.79–4.74 
(m, 1 H), 3.96 (d, J = 15.2 Hz, 1 H), 3.43–3.36 (m, 1 H), 2.49 (s, 3 H), 1.34 (s, 9 
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H); 13C NMR (100 MHz, CDCl3) δ 153.8, 138.3, 137.4, 135.6, 135.4, 131.2, 
130.3, 127.7, 127.6, 127.5, 126.9, 126.8, 126.7, 126.6, 125.9, 90.4, 82.7, 80.1, 
65.3, 39.6, 28.4, 20.2; IR (film, cm–1) 2977, 1697, 1367; MS(ESI): 428.2217  
(428.2220 calcd for C28H30NO3, M+). 
 
(–)-(4R,5S)-tert-Butyl 4,5-diphenyl-2-[4-
(trifluoromethyl)benzyl]oxazolidine-3-carboxylate (IV-31). The coupling of 
(1R,2S)-tert-butyl [1,2-diphenyl-2-(vinyloxy)ethyl]carbamate (25 mg, 0.07 mmol) 
with 1-bromo-4-(trifluoromethyl)benzene (33 mg, 0.14 mmol) was conducted 
following General Procedure 4. This procedure afforded 23 mg (64%) of the title 
compound as an orange oil, [a]D23 = –42.1 (c 2.23, CH2Cl2). This material was 
formed as a 15:1 mixture of diastereomers as judged by 1H NMR analysis of the 
crude product; the isolated product was obtained in 17:1 dr following purification. 
Data are for the major isomer. 1H NMR (400 MHz, C6D6, 70 oC) δ 7.36 (s, 3 H), 
6.90–6.74 (m, 9 H), 6.20 (d, J = 6.7 Hz, 2 H), 5.21 (d, J = 6.8 Hz, 1 H), 4.87 (d, J 
= 5.1 Hz, 1 H), 4.76 (d, J = 6.7 Hz, 1 H), 3.67 (d, J = 13.9 Hz, 1 H), 3.38 (dd, J = 
6.7, 13.7 Hz, 1 H), 1.29 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 153.6, 140.8, 
137.9, 135.3, 130.8 (q, J = 276.3 Hz), 129.3 (q, J = 31.8 Hz), 127.7, 127.6, 127.3, 
126.8, 126.6, 126.4, 125.7, 125.2, 123.0, 89.7, 82.8, 82.7, 81.3, 80.6, 65.1, 39.8, 
28.3, 28.8 (doubling of 3 peaks was observed due to the interconversion of 
rotamers); IR (film, cm–1) 2979, 1700, 1324; MS(ES): 428.1456 (428.1468 calcd 
for C24H20F3NO3, M + H+). 
 
Assignment of Stereochemistry 
O
N
Boc
Ph
Ph
CF3
IV-31
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The relative stereochemistry of (+)-IV-23 was assigned by single crystal x-ray 
analysis as shown below. The relative stereochemistry of other 2,4-disbustituted 
products was assigned based on analogy to (+)-IV-23. 
 
 
The stereochemistry of (±)-IV-19 was assigned by single crystal x-ray analysis 
as shown below. The relative stereochemistry of other 2,5-disbustituted products 
was assigned based on analogy to (±)-IV-19. 
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Chapter 5: Synthesis of Chromans via Palladium-
Catalyzed Carboetherification 
 
5.1 Introduction  
Chromans and other benzo-fused oxygen heterocycles are displayed in a 
number of biologically active natural products,1 including α-tocopherol2 and 
polyalthidin. In addition, 2-benzylchroman derivatives such as englitazone (V-1, 
antidiabetic activity) and molecules with general structure V-2 (beta-secretase 
inhibitory activities)3 have been explored as pharmaceutical leads (Figure 5-1).  
 
Figure 5-1. Biologically Active 2-Benzylchroman Derivatives 
 Over the past several years we have developed a new approach to the 
construction of substituted tetrahydrofurans via palladium-catalyzed 
carboetherification reactions between aryl or alkenyl halides and alcohols bearing 
pendant alkenes.4,5,6 For example, treatment of alcohol V-3 with 4-
bromobiphenyl, NaOtBu, and a catalyst composed of Pd2(dba)3/Dpe-Phos 
provided V-4 in 70% yield with >20:1 dr (Scheme 5-1). We envisioned this 
method could provide a concise and convergent approach to benzofurans or 
chromans7,8 from simple starting materials (phenols bearing pendant alkenes)9.  
However, although the Pd-catalyzed carboetherification reactions were quite 
effective for the generation of tetrahydrofurans, our efforts to employ Pd-
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catalyzed carboetherification reactions for the synthesis of 6-membered 
heterocycles (e.g., tetrahydropyrans) failed to afford satisfactory results.10 In 
addition, the scope of our carboetherification method appeared to be limited to 
aliphatic alcohol substrates, as efforts to couple 2-allylphenol V-5 with 
bromobenzene failed to generate the desired substituted benzofuran product.11 
Instead, the formation of 2-(prop-1-en-1-yl)phenol V-6 via double bond 
isomerization was observed.  
 
 
Scheme 5-1. Palladium-Catalyzed Carboetherification Reactions of Alcohols vs. 
Phenols 
 We have previously illustrated that the mechanism of Pd-catalyzed 
carboetherification reactions, such as those shown in Scheme 5-1, involves 
suprafacial insertion of the substrate alkene into the Pd–O bond of an 
intermediate palladium alkoxide complex. Recent mechanistic studies conducted 
by our group and others have shown that the rate of alkene insertion into Pd-
heteroatom bonds is highly dependent on the nucleophilicity of the heteroatom, 
and the insertion likely occurs from an intermediate Pd-complex that bears a 
single phosphine ligand.12  These results suggest that two factors may be 
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responsible for the poor reactivity of phenols such as V-5 in Pd/Dpe-Phos-
catalyzed carboetherifications: (a) the relatively low nucleophilicity of phenols as 
compared to aliphatic alcohols; and (b) use of the chelating bis-phosphine Dpe-
Phos, which may disfavor generation of the reactive monophosphine 
intermediate. These factors apparently slow the catalytic reaction to the point that 
alkene isomerization of V-5 to V-6 occurs more rapidly than the desired 
transformation. 
 
5.2 Optimization Studies   
The hypothesis outlined above suggests that use of catalysts bearing 
monodentate phosphine ligands may provide improved results in 
carboetherification reactions of phenol derivatives, as these ligands could 
potentially facilitate the key alkene insertion step. In addition, we also anticipated 
that the conversion of 2-(but-3-en-1-yl)phenol (V-11) to chroman V-12 (Table 5-1) 
may be more straightforward than the analogous transformation of 2-allylphenol 
(V-5) to a benzofuran derivative, as V-11 should be much less prone to base-
mediated alkene isomerization than V-5. Thus, we synthesized V-11 from p-
anisaldehyde using the literature procedure16 shown in Scheme 5-2 and 
examined the coupling of V-11 with bromobenzene using the biaryl 
monophosphine ligand S-Phos. We had previously found this ligand provided 
good results in other challenging carboetherification reactions, and we were 
gratified to discover these conditions afforded the desired product V-12 in 86% 
isolated yield. A quick survey of related biaryl phosphines did not lead to any 
further improvement (entries 2-5), and Dpe-Phos produced V-12 in only 30% 
yield (entry 6).  
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Scheme 5-2. Synthesis of Substrate V-11, V-14, and V-47 
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H
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NaBH4
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OH
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SOCl2
Pyr
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V-7 V-8 V-9
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Table 5-1. Optimization of Ligand for the Coupling of V-11 with Bromobenzenea 
5.3 Substrate Scope 
In order to examine the scope of the phenol carboetherification reactions, a 
number of substrates that differed in their substitution patterns were synthesized 
and subjected to the optimized reaction conditions. Namely, V-14 was 
synthesized according to a literature procedure analogous to that shown in 
Scheme 5-2,17 and V-19 was prepared through an aldol reaction, selective 
reduction of the alkene, conversion of the ketone to the corresponding alkene via 
cat. Pd2(dba)3
cat. ligand
NaOtBu, Toluene, 110 °C
OH
PhBr
O
Ph
Entry Ligand Yieldb
1
2
3
4
5
6
S-Phos
RuPhos
Me-Phos
Dave-Phos
Brett-Phos
Dpe-Phos
 84% (75%)
76%
31%
12%
47%
30%
a Conditions: 1.0 equiv V-11, 2.0 equiv PhBr, 2.0 equiv NaO tBu, 2 mol % Pd 2(dba)3, 4 mol % 
ligand, toluene (0.25 M), 110 °C. b Yields were determined by 1H NMR analysis of crude reaction 
mixtures using phenanthrene as an internal standard. The yield in parentheses is an isolated yield 
of pure product.
V-12
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Cy2P
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OiPr
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iPr
iPr
MeO
Cy2PMeO
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Ph2P PPh2
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addition of Tebbe’s Reagent and subsequent cleavage of the arylmethyl ether to 
the phenol, as shown in Scheme 5-3. 
 
Scheme 5-3. Synthesis of Substrate V-19 
As shown in Table 5-2, substrates V-11, V-14, and V-19 were converted to 2-
substituted- or 2,2-disubstituted chromans in moderate to good yield (entries 1–
9). In addition, cyclopentane- and cyclohexane-derived substrates V-22–V-25 
were prepared in accordance with the method shown in Scheme 5-4, which 
features a hydrazone alkylation, Wittig reaction and arylmethyl ether cleavage, 
and were transformed to tricyclic products V-39–V-41 with high 
diastereoselectivity (entries 10–12). 
 
Scheme 5-4. Synthesis of Substrate V-22 and V-25 
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However, stereocontrol was poor in the reaction of 4-bromo-tert-butylbenzene 
and V-30, which was synthesized via Heck reaction, Wittig olefination and 
arylmethyl ether cleavage (Scheme 5-5). V-42 was produced in 2:1 dr, and a 
significant amount (ca. 25%) of an inseparable unidentified low molecular weight 
side product was also formed (entry 13). Although these new reaction conditions 
were generally effective for the preparation of chromans, efforts to transform V-5 
to substituted benzofuran V-43 were still only modestly successful; the desired 
product was generated in 37% yield (entry 14). 
 
Scheme 5-5. Synthesis of Substrate V-30 
 A range of different electrophiles were examined in the carboetherification 
reactions of V-11, V-14, and V-19. As shown in Table 5-2, aryl halides bearing 
chloride, fluoride, methoxy and diaryl ketone functionality were successfully 
converted to the desired products. Alkenyl halides were also effective coupling 
partners in these reactions (entries 6–7), and the coupling of V-14 with the 
heteroaryl halide 3-bromopyridine also proceeded smoothly (entry 4). However, 
the scope of carboetherification reactions involving V-22 and V-25 was not as 
broad, and use of aryl halides that were relatively electron rich or electron 
deficient led to poor reactivity or low yields.  
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a Conditions: 1.0 equiv phenol substrate, 2.0 equiv R–Br, 2.0 equiv NaOtBu, 2 mol % Pd2(dba)3, 4 mol % S-Phos, toluene (0.25 M), 110 °C. b 
Isolated yield (average of two experiments). c The two inseparable stereoisomeric products were isolated in 63% yield and ca. 75% purity. The 
remaining 25% of the mixture was primarily composed of an unidentifed low molecular weight side product that appears to be derived from the 
phenol substrate.
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Table 5-2. Pd-Catalyzed Carboetherification Reactions of Phenols Bearing 
Pendant Alkenesa 
 
Scheme 5-6. Palladium-Catalyzed Carboetherification Reactions of Substituted 
Phenols 
Substrates V-45 and V-47, which possess an additional substituent and an 
internal alkene, respectively, were synthesized according to literature procedures 
and were subjected to the optimized conditions. However, complex mixtures of 
regio- and stereoisomers were obtained with substrate V-45, and decomposition 
occurred with substrate V-47, as shown in Scheme 5-6. 
5.4 Progress Towards the Development of Enantioselective Conditions 
Having successfully developed a new synthesis of racemic chroman 
derivatives, we sought to explore the enantioselective construction of these 
compounds through the use of chiral ligands for the palladium catalyst. In prior 
studies we found that the chiral phosphoramidite Siphos-PE13 provides 
satisfactory results in asymmetric carboamination reactions that afford pyrrolidine 
derivatives.14 Unfortunately, this ligand gave poor results (37% yield, 13% ee) in 
the reaction of V-11 with 4-bromobenzophenone. Although we have not yet 
developed an efficient asymmetric variant of these transformations, after further 
exploration we have discovered two promising leads. As shown in Table 5-3, 
ligand V-48 provides good yield and moderate enantioselectivity for the 
conversion of V-11 to V-32, whereas ligand V-4915 provides V-32 in 76% ee 
OH
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(although the chemical yield is low). Asymmetric transformations of methyl 
substituted substrate V-14 are more challenging, as use of ligand V-48 led to 
formation of V-34 in only 7% ee, and use of ligand V-49 failed to generate the 
desired product. Nonetheless, this collection of results illustrates the potential 
feasibility of enantioselective construction of chroman derivatives via Pd-
catalyzed carboetherification reactions, although further optimization is obviously 
needed.  
 
Table 5-3. Efforts Toward the Development of Enantioselective Conditions 
5.5 Conclusions 
In conclusion, we have developed a new method for the construction of 2-
substituted chroman derivatives via Pd-catalyzed carboetherification reactions. 
These transformations employ simple substrates, and provide access to a 
number of different derivatives in a straightforward manner. In addition these are 
the first examples of Pd-catalyzed alkene carboetherification reactions between 
aryl bromides and alkenyl phenols, and are also rare cases in which six-
OH
R
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NaOtBu, Toluene, 110 °C
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a Conditions: 1.0 equiv 7 or 9, 2.0 equiv ArBr, 2.0 equiv NaOtBu, 2 mol % Pd2(dba)3, 
8 mol % ligand, toluene (0.25 M), 110 °C. b Isolated yield (average of two
experiments). c Determined by chiral HPLC analysis.
V-48
V-49
V-11
V-14
V-32
V-34
a Conditions: 1.0 equiv V-11 or V-14, 2.0 equiv ArBr, 2.0 equiv NaOtBu, 2 mol % Pd2(dba)3, 8 
mol % ligand, toluene (0.25 M), 110 oC. b Isolated yield (average of two experiments). C 
Determined by chiral HPLC analysis.
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membered oxygen heterocycles are generated via 1,2-alkene 
carboheterofunctionalization processes. Future studies will be directed towards 
the development of improved catalysts for enantioselective variants of these 
transformations. 
 
5.6 Experimental 
General. All reactions were carried out under a nitrogen atmosphere in oven or 
flame dried glassware. Tris(dibenzylideneacetone)dipalladium (0) and all 
phosphine ligands were purchased from Strem Chemical Co. and used without 
further purification. All aryl bromides were obtained from commercial sources 
(Aldrich Chemical Co. or Acros Chemical Co.) and were used as obtained. 2-
(But-3-en-1-yl)phenol,16  2-(3-methylbut-3-en-1-yl)phenol,1 2-allylphenol, 3-(2-
methoxyphenyl)-1-phenylpropan-1-one,17  2-cyclopentylidene-1,1-
dimethylhydrazine,18 1-(bromomethyl)-2-methoxybenzene,19  2-cyclohexylidene-
1,1-dimethylhydrazine, and [2-(bromomethyl)phenoxy](tert-butyl)dimethylsilane,20 
were prepared according to literature procedures. Toluene and THF were purified 
using a GlassContour solvent purification system. Yields refer to isolated yields 
of compounds estimated to be ≥95% pure as determined by 1H NMR. The yields 
reported in the supporting information describe the result of a single experiment, 
whereas the yields reported in Tables 5-2–5-3 are average yields of two or more 
experiments. Thus, the yields reported in the supporting information may differ 
from those shown in Tables 5-2–5-3. 
 
Synthesis of Substrates 
General Procedure 1: Alkylation of hydrazones.21  An oven-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with the appropriate hydrazone (1 equiv) and THF (1 M). The resulting 
solution was cooled to 0 °C and a solution of n-BuLi (1 equiv, 1.6 M in hexanes) 
was added dropwise. The reaction mixture was stirred at 0 °C for 1 hr, then the 
alkyl halide (1 equiv) was added dropwise as a 1 M solution in THF, and the 
  
147 
reaction mixture was warmed to rt. The mixture was stirred at rt until GC analysis 
indicated that the starting materials were fully consumed, then 1 M HCl was 
added (10 mL), and the reaction was stirred for 4 hr at rt. Brine (5 mL) and EtOAc 
(5 mL) were added, and the mixture was transferred to a separatory funnel. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 20 
mL). The combined organic layers were dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel. 
 
General Procedure 2: Methylenation of ketones.22  A flame-dried round-
bottomed flask equipped with a magnetic stirbar and a rubber septum was cooled 
under a stream of nitrogen and charged with methyltriphenylphosphonium 
bromide (1 equiv) and THF (1 M). The reaction mixture was cooled to –78 oC and 
a solution of NaHMDS was added dropwise (1 equiv, 2 M in THF). The resulting 
mixture was stirred at –78 oC for 2 h then the ketone substrate (1 equiv) was 
added dropwise as a 1 M solution in THF and the reaction mixture was heated to 
40 oC until the starting material had been completely consumed as judged by tlc 
analysis. The mixture was cooled to rt, brine (5 mL) and EtOAc (5 mL) were 
added, and the mixture was transferred to a separatory funnel. The layers were 
separated and the aqueous layer was extracted with EtOAc (2 x 20 mL). The 
combined organic layers were dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography 
on silica gel. 
 
General Procedure 3: Deprotection of aryl(methyl)ethers. A flame-dried 
round-bottomed flask equipped with a magnetic stirbar, reflux condenser and a 
rubber septum was cooled under a stream of nitrogen and charged with NaH (4 
equiv) and DMF (2 M). The reaction mixture was cooled to 0 oC and a 2 M 
solution of ethanethiol (2.6 equiv) in DMF was added dropwise. The resulting 
mixture was stirred at rt for 30 min, then the methyl ether substrate (1 equiv) was 
added and the reaction mixture was heated to 160 oC until the starting material 
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had been completely consumed as judged by tlc analysis. The reaction mixture 
was then cooled to rt and 1 M HCl (5 mL) and EtOAc (5 mL) were added. The 
mixture was transferred to a separatory funnel and the layers were separated. 
The aqueous layer was extracted with EtOAc (2 x 20 mL), and the combined 
organic layers were dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by flash chromatography on silica gel. 
 
1-Methoxy-2-(3-phenylbut-3-en-1-yl)benzene (V-18). General Procedure 2 
was used for the conversion of 3-(2-methoxyphenyl)-1-phenylpropan-1-one (1.77 
g, 7.36 mmol) to the title compound. This procedure afforded 0.98 g (56%) of the 
title compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 
Hz, 2 H), 7.33 (t, J = 7.0 Hz, 2 H), 7.26 (d, J = 7.0 Hz, 1 H), 7.20–7.14 (m, 1 H), 
7.09 (dd, J = 1.6, 7.2 Hz, 1 H), 6.89–6.81 (m, 1 H), 5.30 (s, 1 H), 5.06 (s, 1 H), 
3.81 (s, 3 H), 2.76 (s, 4 H); 13C NMR (100 MHz, CDCl3) δ 157.5, 148.3, 141.2, 
130.4, 129.9, 128.3, 127.3, 127.1, 126.1, 120.3, 112.2, 110.2, 55.2, 35.5, 29.7; 
IR (film, cm–1) 2929, 1495, 1243; MS(ESI): 241.1228 (241.1223 calcd for 
C17H18O, M + H+). 
 
2-(3-Phenylbut-3-en-1-yl)phenol (V-19). General Procedure 3 was used for 
the conversion of 1-methoxy-2-(3-phenylbut-3-en-1-yl)benzene (1.1 g, 4.6 mmol) 
to the title compound. This procedure afforded 0.66 g (63%) of the title 
compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.8 Hz, 2 H), 
7.43 (t, J = 7.3 Hz, 2 H), 7.40–7.34 (m, 1 H), 7.20–7.14 (m, 2 H), 6.96 (t, J = 7.6 
Hz, 1 H), 6.79 (d, J = 7.8 Hz, 1 H), 5.42 (s, 1 H), 5.18 (s, 1 H), 4.86 (s, 1 H), 
2.94–2.84 (m, 4 H); 13C NMR (100 MHz, CDCl3) δ 153.5, 148.0, 141.0, 130.4, 
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128.5, 128.0, 127.6, 127.4, 126.2, 120.9, 115.4, 112.8, 35.5, 29.3; IR (film, cm–1) 
3411, 3030, 1454; MS(EI): 224.1208 (224.1201 calcd for C16H16O, M+).  
 
2-(2-Methoxybenzyl)cyclopentanone (V-20). General Procedure 1 was used 
for the conversion of 2-cyclopentylidene-1,1-dimethylhydrazine (1.0 g, 7.9 mmol) 
and 1-(bromomethyl)-2-methoxybenzene (1.24 g, 7.9 mmol) to the title 
compound. This procedure afforded 1.0 g (62%) of the title compound as a clear 
oil. 1H NMR (400 MHz, CDCl3) δ 7.21 (dd, J = 1.7, 7.8 Hz, 1 H), 7.12 (dd, J = 1.7, 
7.3 Hz, 1 H), 6.88 (t, J = 7.6 Hz, 1 H), 6.85 (d, J = 8.0 Hz, 1 H), 3.82 (s, 3 H), 
3.28–3.20 (m, 1 H), 2.51–2.42 (m, 2 H), 2.37–2.29 (m, 1 H), 2.19–2.10 (m, 1 H), 
2.04–1.92 (m, 2 H), 1.79–1.66 (m, 1 H), 1.60–1.50 (m, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 220.7, 157.6, 130.5, 128.5, 127.4, 120.3, 110.2, 55.2, 49.6, 38.1, 30.2, 
29.3, 20.6; IR (film, cm–1) 2928, 1699, 1456; MS(EI): 204.1148 (204.1150 calcd 
for C13H16O2, M+).  
 
1-Methoxy-2-[(2-methylenecyclopentyl)methyl]benzene (V-21). General 
Procedure 2 was used for the conversion of 2-(2-methoxybenzyl)cyclopentanone 
(0.7 g, 3.5 mmol) to the title compound. This procedure afforded 0.64 g (93%) of 
the title compound as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.32–7.23 (m, 
2 H), 6.99 (t, J = 7.3 Hz, 1 H), 6.94 (d, J = 8.3 Hz, 1 H), 5.05 (s, 1 H), 4.97 (s, 1 
H), 3.91 (s, 3 H), 3.12 (dd, J = 5.1, 13.2 Hz, 1 H), 2.87–2.80 (m, 1 H), 2.60 (dd, J 
= 9.8, 13.2 Hz, 1 H), 2.53–2.47 (m, 2 H), 1.88–1.76 (m, 2 H), 1.68–1.56 (m, 1 H), 
1.51–1.43 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 157.7, 156.7, 130.7, 130.0, 
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127.1, 120.3, 110.2, 104.6, 55.2, 44.2, 35.3, 33.3, 32.8, 24.1; IR (film, cm–1) 
2928, 1490, 1261; MS(EI): 302.0274 (302.2066 calcd for C14H18O, M+).  
 
2-[(2-Methylenecyclopentyl)methyl]phenol (V-22). An oven-dried flask 
equipped with a magnetic stirbar and a reflux condenser was cooled under a 
stream of nitrogen and charged with 1-methoxy-2-[(2-
methylenecyclopentyl)methyl]benzene (0.1 g, 0.46 mmol). L-selectride (3 equiv, 
1 M in THF) was added, and the reaction mixture was stirred at rt for 3 d. After 
the starting material had been completely consumed, 1 M HCl (5 mL) and EtOAc 
(5 mL) were added, and the mixture was transferred to a separatory funnel. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 20 
mL). The combined organic layers were dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel to afford 0.75 g (75%) of the title compound as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 7.15–7.07 (m, 2 H), 6.88 (t, J = 7.4 Hz, 1 
H), 6.78 (d, J = 7.8 Hz, 1 H), 4.97 (s, 1 H), 4.91 (s, 1 H), 2.95 (dd, J = 5.4, 13.6 
Hz, 1 H), 2.78–2.70 (m, 1 H), 2.57 (dd, J = 8.9, 13.6 Hz, 1 H), 2.41–2.34 (m, 2 H), 
1.79–1.65 (m, 3 H), 1.57–1.49 (m, 1 H), 1.45–1.30 (m, 1 H); 13C NMR (100 MHz, 
CDCl3) δ 157.2, 153.7, 131.2, 127.3, 120.6, 115.5, 105.0, 44.0, 35.1, 33.3, 32.4, 
24.1, one peak is missing due to incidental equivalence; IR (film, cm–1) 3435, 
2928, 1456; MS(EI): 188.1201 (188.1197 calcd for C13H16O, M+).  
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2-[2-(tert-Butyldimethylsiloxy)benzyl]cyclohexanone. General Procedure 1 
was used for the conversion of 2-cyclohexylidene-1,1-dimethylhydrazine (0.23 g, 
1.66 mmol) and 2-(bromomethylphenoxy)(tert-butyl)dimethylsilane (0.5 g, 1.66 
mmol) to the title compound. This procedure afforded 0.36 g (68%) of the title 
compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.13–7.04 (m, 2 H), 6.86 
(dt, J = 1.2, 7.4 Hz, 1 H), 6.77 (dd, J = 0.2, 8.0 Hz, 1 H), 3.21 (dd, J = 4.5, 9.2 Hz, 
1 H), 2.71–2.61 (m, 1 H), 2.45–2.23 (m, 3 H), 2.10–1.94 (m, 2 H), 1.85–1.77 (m, 
1 H), 1.73–1.49 (m, 3 H), 1.41–1.21 (m, 2 H), 0.98 (s, 9 H), 0.24 (s, 3 H), 0.21 (s, 
3 H); 13C NMR (100 MHz, CDCl3) δ 212.9, 153.8, 131.6, 130.8, 127.0, 120.8, 
118.3, 50.7, 42.2, 33.6, 30.7, 28.2, 25.7, 25.2, 18.2, 0.2, 0.0; IR (film, cm–1) 2931, 
1711, 1253; MS(ESI): 319.2088 (319.2088 calcd for C19H30O2Si, M + H+). 
 
tert-Butyldimethyl{2-[(2-methylenecyclohexyl)methyl]phenoxy}silane (V-
24). General Procedure 2 was used for the conversion of 2-[2-(tert-
butyldimethylsiloxy)benzyl]cyclohexanone (1.4 g, 4.41 mmol) to the title 
compound. This procedure afforded 0.86 g (64%) of the title compound as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 6.90–6.84 (m, 2 H), 6.68–6.62 (m, 1 H), 
6.59 (d, J = 7.8 Hz, 1 H), 4.48 (s, 1 H), 4.41 (s, 1 H), 2.78 (dd, J = 5.4, 13.4 Hz, 1 
H), 2.32 (dd, J = 6.2, 13.2 Hz, 1 H), 2.21–2.10 (m, 2 H), 1.86–1.78 (m, 1 H), 
1.55–1.41 (m, 3 H), 1.30–1.22 (m, 1 H), 1.17–1.05 (m, 1 H), 1.00–0.92 (m, 1 H), 
0.81 (s, 9 H), 0.05 (s, 3 H), 0.02 (s, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.7, 
157.0, 135.6, 135.1, 130.6, 124.6, 122.3, 109.2, 46.7, 39.6, 37.4, 35.5, 29.7, 
29.6, 28.9, 22.1, 0.2, 0.0; IR (film, cm–1) 2930, 1598, 1252; MS(EI): 316.2225 
(316.2222 calcd for C20H32OSi, M+).  
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2-[(2-Methylenecyclohexyl)methyl]phenol (V-25). An oven-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with tert-butyldimethyl{2-[(2-methylenecyclohexyl)methyl]phenoxy}silane 
(0.57 g, 1.8 mmol). The flask was cooled to 0 oC and TBAF (3 equiv, 1 M in THF) 
was added. The resulting mixture was warmed to rt and was stirred for 2 h until 
the starting material had been completely consumed as judged by tlc analysis. A 
solution of 1 M HCl (5 mL) and EtOAc (5 mL) were added, and the resulting 
mixture was transferred to a separatory funnel. The layers were separated and 
the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic 
layers were dried over anhydrous MgSO4, filtered, and concentrated in vacuo. 
The crude material was purified by flash chromatography on silica gel 0.37 g 
(73%) of the title compound as a clear oil.  1H NMR (400 MHz, CDCl3) δ 7.10–
7.05 (m, 2 H), 6.85 (dt, J = 1.0, 8.2 Hz, 1 H), 6.79–6.76 (m, 1 H), 5.51 (s, 1 H), 
4.70 (s, 1 H), 4.64 (s, 1 H), 2.97 (dd, J = 5.3, 13.4 Hz, 1 H), 2.58 (dd, J = 9.3, 
13.7 Hz, 1 H), 2.42–2.31 (m, 2 H), 2.10–2.05 (m, 1 H), 1.75–1.61 (m, 3 H), 1.54–
1.34 (m, 2 H), 1.28–1.17 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 153.9, 153.1, 
131.2, 127.2, 127.1, 120.4, 115.3, 105.6, 43.0, 35.4, 33.1, 33.0, 28.7, 24.7.; IR 
(film, cm–1) 3435, 1507, 1229; MS(ESI): 203.1427 (203.1430 calcd for C14H18O, 
M + H+). 
 
3-(2-Methoxyphenyl)butanal (V-28). An oven-dried flask equipped with a 
magnetic stirbar was cooled under a stream of nitrogen and charged with sodium 
bicarbonate (0.89 g, 10.7 mmol), palladium acetate (0.0192 g, 0.09 mmol) and 
tetrabutylammonium chloride (1.19 g, 4.3 mmol). DMF (10 mL), 2-iodoanisole 
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(1.0 g, 4.27 mmol), and 2-methylprop-2-en-1-ol (0.46 mL, 6.4 mmol) were added, 
and the reaction mixture was heated to 85 oC. Palladium acetate was added 
again (0.0192 g, 0.09 mmol) after 12 h, and the reaction was stirred for another 
12 h. When the reaction was complete, sat’d NH4Cl (5 mL) and ether (5 mL) were 
added, and the resulting mixture was transferred to a separatory funnel. The 
layers were separated and the aqueous layer was extracted with ether (2 x 20 
mL). The combined organic layers were dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel 0.61 g (85%) of the title compound as a clear oil.  
1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1 H), 7.20 (dt, J = 1.8, 8.9 Hz, 1 H), 7.10 
(dd, J = 1.4, 7.4 Hz, 1 H), 6.88 (dt, J = 1.0, 7.4 Hz, 1 H), 6.84 (d, J = 6.8 Hz, 1 H), 
3.78 (s, 3 H), 3.07 (dd, J = 6.4, 13.1 Hz, 1 H), 2.71 (ds, J = 1.6, 7.0 Hz, 1 H), 2.63 
(dd, J = 7.4, 13.1 Hz, 1 H), 1.04 (d, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3) δ 
204.8, 157.4, 130.9, 127.8, 127.0, 120.4, 110.3, 55.1, 46.4, 31.7, 13.3; IR (film, 
cm–1) 2963, 1718, 1245; MS(EI): 178.0994 (178.0994 calcd for C11H14O2, M+). 
 
1-Methoxy-2-(pent-4-en-2-yl)benzene (V-29). General Procedure 2 was used 
for the conversion of 3-(2-methoxyphenyl)butanal (0.47 g, 2.62 mmol) to the title 
compound. This procedure afforded 0.43 g (93%) of the title compound as a 
clear oil.  1H NMR (400 MHz, CDCl3) δ 7.44–7.41 (m, 1 H), 7.20 (dt, J = 1.8, 8.0 
Hz, 1 H), 7.19 (dd, J = 1.6, 7.2 Hz, 1 H), 7.00–6.91 (m, 1 H), 5.98–5.88 (m, 1 H), 
5.07–4.98 (m, 2 H), 3.88 (s, 3 H), 2.84–2.76 (m, 1 H), 2.70–2.58 (m, 2 H), 1.10 
(d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 157.8, 144.6, 131.0, 129.3, 
128.6, 127.1, 120.2, 112.2, 55.2, 37.8, 37.5, 19.6.; IR (film, cm–1) 2962, 1495, 
1243; MS(EI): 176.1201 (176.1201 calcd for C12H16O, M+). 
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2-(Pent-4-en-2-yl)phenol (V-13). General Procedure 3 was used for the 
conversion of 1-methoxy-2-(pent-4-en-2-yl)benzene (V-30) (0.16 g, 0.91 mmol) to 
the title compound. This procedure afforded 0.10 g (75%) of the title compound 
as a clear oil.  1H NMR (400 MHz, CDCl3) δ 7.10–7.04 (m, 2 H), 6.87–6.82 (m, 1 
H), 6.74 (d, J = 8.7 Hz, 1 H), 5.89–5.75 (m, 1 H), 5.00–4.90 (m, 2 H), 4.78 (s, 1 
H), 2.69–2.60 (m, 1 H), 2.59–2.48 (m, 2 H), 1.02 (d, J = 6.4 Hz, 3 H).; 13C NMR 
(100 MHz, CDCl3) δ 153.8, 144.2, 131.5, 127.3, 127.1, 120.6, 115.6, 113.0, 38.0, 
37.4, 19.6.; IR (film, cm–1) 3367, 2974, 1456; MS(EI): 162.1042 (162.1045 calcd 
for C11H14O, M+). 
 
Synthesis of Benzopyrans via Pd-Catalyzed Alkene Carboetherification 
General Procedure 4: Palladium-Catalyzed Carboetherification Reactions. 
An oven or flame-dried Schlenk tube was cooled under a stream of nitrogen and 
charged with Pd2(dba)3 (2 mol% complex, 4 mol % Pd), S-Phos (4 mol %), 
NaOtBu (2.0 equiv), and the aryl bromide (2.0 equiv). The tube was purged with 
nitrogen and the alcohol substrate (1.0 equiv), and toluene (0.25 M substrate 
concentration) were added. The mixture was heated to 110 °C with stirring until 
the starting material had been consumed as judged by GC or 1H NMR analysis. 
The mixture was cooled to room temperature, quenched with saturated aqueous 
NH4Cl (2 mL), and diluted with ethyl acetate (10 mL). The layers were separated 
and the aqueous layer was extracted with ethyl acetate (3 X 10 mL). The 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel.  
 
(±)-2-Benzylchroman (V-12). The coupling of 2-(but-3-en-1-yl)phenol (30 mg, 
0.20 mmol) with bromobenzene (0.43 µL, 0.40 mmol) was conducted following 
General Procedure 4. This procedure afforded 37.4 mg (83%) of the title 
compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.33–7.19 (m, 5 H), 
O
V-12
  
155 
7.09–6.97 (m, 2 H), 6.83–6.75 (m, 2 H), 4.23–4.15 (m, 1 H), 3.12 (dd, J = 7.6, 
13.6 Hz, 1 H), 2.85 (dd, J = 7.0, 13.6 Hz, 1 H), 2.78–2.68 (m, 2 H), 2.00–1.91 (m, 
1 H), 1.74–1.62 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 154.8, 137.8, 129.6, 
129.5, 128.3, 127.1, 126.4, 121.9, 120.0, 116.7, 76.5, 41.8, 26.5, 24.5; IR (film, 
cm–1) 2924, 1456, 1236; MS(EI): 224.1207  (224.1201 calcd for C16H16O, M+).  
 
(±)-2-(4-Methoxybenzyl)chroman (V-31). The coupling of 2-(but-3-en-1-
yl)phenol (25 mg, 0.17 mmol) with 4-bromoanisole (40 µL, 0.34 mmol) was 
conducted following General Procedure 4. This procedure afforded 28 mg (66%) 
of the title compound as an orange oil. 1H NMR (400 MHz, CDCl3) δ 7.20–7.15 
(m, 2 H), 7.06 (t, J = 7.4 Hz, 1 H), 7.01 (d, J = 7.0 Hz, 1 H), 6.86–6.75 (m, 4 H), 
4.19–4.11 (m, 1 H), 3.78 (s, 3 H), 3.07 (dd, J = 6.1, 13.9 Hz, 1 H), 2.83–2.70 (m, 
3 H), 2.00–1.92 (m, 1 H), 1.73–1.63 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 
132.2, 130.5, 129.9, 129.5, 127.2, 120.0, 116.7, 115.7, 113.8, 76.7, 55.4, 55.2, 
40.9, 26.4, 24.6; IR (film, cm–1) 2929, 1488, 1247; MS(EI): 254.1307 (254.1313 
calcd for C16H16O, M+).  
 
(±)-[4-(Chroman-2-ylmethyl)phenyl](phenyl)methanone (V-32). The 
coupling of 2-(but-3-en-1-yl)phenol (20 mg, 0.13 mmol) with 4-
bromobenzophenone (70 mg, 0.26 mmol) was conducted following General 
Procedure 4. This procedure afforded 24.7 mg (56%) of the title compound as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.84–7.78 (m, 4 H), 7.63–7.58 (m, 1 H), 
7.51 (t, J = 7.8 Hz, 2 H), 7.42 (d, J = 8.0 Hz, 2 H), 7.11 (t, J = 7.3 Hz, 1 H), 7.06 
(d, J = 7.6 Hz, 1 H), 6.88–6.81 (m, 2 H), 4.33–4.27 (m, 1 H), 3.21 (dd, J = 6.6, 
13.9 Hz, 1 H), 3.01 (dd, J = 6.1, 13.7 Hz, 1 H), 2.90–2.75 (m, 2 H), 2.07–2.00 (m, 
1 H), 1.83–1.73 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 196.5, 154.6, 143.0, 
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137.8, 135.8, 132.3, 130.2, 130.0, 129.5, 128.3, 127.3, 121.8, 120.2, 116.8, 76.0,  
41.8, 26.8, 24.5, 18.5; IR (film, cm–1) 2918, 1616, 1457; MS(ESI): 329.1537  
(329.1536 calcd for C23H20O2, [M+H]+).  
 
(+)-[4-(Chroman-2-ylmethyl)phenyl](phenyl)methanone ((+)-V-32). The 
coupling of 2-(but-3-en-1-yl)phenol (25 mg, 0.17 mmol) with 4-
bromobenzophenone (88 mg, 0.33 mmol) was conducted following General 
Procedure 4 except using V-48 as a ligand. This procedure afforded 0.044 mg 
(70%) of the title compound as a yellow oil, [α]D23 = +4.2 (c 0.40, CH2Cl2). The 
enantiopurity was determined to be 30% ee by chiral HPLC analysis [OJH 0.46 
cm x 25 cm, 10% isopropanol/hexanes, 2 mL/min, RT = 11.5 and 13.1 min]. 
Spectroscopic data were identical to those above for (±)-V-32. 
 
(+)-[4-(Chroman-2-ylmethyl)phenyl](phenyl)methanone ((+)-V-32). The 
coupling of 2-(but-3-en-1-yl)phenol (20 mg, 0.13 mmol) with 4-
bromobenzophenone (70 mg, 0.026 mmol) was conducted following General 
Procedure 4 except using V-49 as ligand. This procedure afforded 0.06 mg 
(14%) of the title compound as a yellow oil, [α]D23 = +11.2 (c 0.02, CH2Cl2). The 
enantiopurity was determined to be 76% ee by chiral HPLC analysis [OJH 0.46 
cm x 25 cm, 10% isopropanol/hexanes, 2 mL/min, RT = 11.5 and 13.1 min]. 
Spectroscopic data were identical to those above for (±)-V-32. 
 
 
(±)-3-[(2-Methylchroman-2-yl)methyl]pyridine (V-33). The coupling of 2-(3-
methylbut-3-en-1-yl)phenol (20 mg, 0.12 mmol) with 3-bromopyridine (23.7 µL, 
0.24 mmol) was conducted following General Procedure 4. This procedure 
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afforded 24 mg (81%) of the title compound as an amber oil. 1H NMR (400 MHz, 
CDCl3) δ 7.16–7.07 (m, 4 H), 6.88–6.84 (m, 2 H), 6.80–6.77 (m, 2 H), 2.94 (d, J = 
13.6 Hz, 1 H), 2.89–2.78 (m, 3 H), 1.87–1.74 (m, 2 H), 1.24 (s, 3 H); 13C NMR 
(100 MHz, CDCl3) δ 154.5, 131.5, 129.9, 129.5, 127.3, 119.7, 119.5, 117.4, 76.3, 
45.1, 30.8, 25.7, 24.3, 22.1, 18.4, 18.2; IR (film, cm–1) 2928, 1581, 1455, 1243; 
MS(ESI): 240.1386 (240.1383 calcd for C16H17NO, M + H+). 
 
(±)-{4-[(2-Methylchroman-2-yl)methyl]phenyl}(phenyl)methanone (V-34). 
The coupling of 2-(3-methylbut-3-en-1-yl)phenol (20.0 mg, 0.12 mmol) with 4-
bromobenzophenone (70.0 mg, 0.24 mmol) was conducted following General 
Procedure 4. This procedure afforded 35.0 mg (83%) of the title compound as an 
orange oil. 1H NMR (400 MHz, CDCl3) δ 7.81–7.77 (m, 2 H), 7.75–7.71 (m, 2 H), 
7.60–7.53 (m, 1 H), 7.49–7.44 (m, 2 H), 7.36–7.32 (m, 2 H), 7.13–7.04 (m, 2 H), 
6.86-6.81 (m, 2 H), 3.07 (d, J = 13.3 Hz, 1 H), 2.90 (d, J = 13.5 Hz, 1 H), 2.82 (t, 
J = 6.6 Hz, 2 H), 1.83 (t, J = 6.8 Hz, 2 H), 1.26 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 196.5, 153.6, 142.4, 137.8, 135.7, 132.3, 130.6, 130.0, 129.9, 129.6, 
128.2, 127.4, 120.8, 119.9, 117.3, 75.9, 45.7, 31.2, 24.5, 22.1; IR (film, cm–1) 
2927, 1653, 1278; MS(EI): 343.1697  (343.1693 calcd for C24H22O2, [M+H]+). 
 
(–)-{4-[(2-Methylchroman-2-yl)methyl]phenyl}(phenyl)methanone (–)-V-34). 
The coupling of 2-(3-methylbut-3-en-1-yl)phenol (20 mg, 0.12 mmol) with 4-
bromobenzophenone (64 mg, 0.24 mmol) was conducted following General 
Procedure 4 except using V-48 as ligand. This procedure afforded 13 mg (30%) 
of the title compound as an orange oil. [α]D23 = –4.1 (c 0.11, CH2Cl2). The 
enantiopurity was determined to be 7% ee by chiral HPLC analysis [OJH 0.46 cm 
O
OV-34
O
O(–)-V-34
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x 25 cm, 10% isopropanol/hexanes, 1 mL/min, RT = 13.2 and 15.2 min]. 
Spectroscopic data were identical to those above for (±)-V-34. 
 
  (±)-2-Cinnamyl-2-methylchroman (V-35). The coupling of 2-(3-methylbut-3-
en-1-yl)phenol (20 mg, 0.12 mmol) with (E)-β-bromostyrene (30 µL, 0.24 mmol) 
was conducted following General Procedure 4. This procedure afforded 28 mg 
(88%) of the title compound as an orange oil. 1H NMR (400 MHz, CDCl3) δ 7.38–
7.27 (m, 4 H), 7.26–7.18 (m, 2 H), 7.13–7.02 (m, 2 H), 6.86–6.79 (m, 1 H), 6.45 
(d, J = 15.8 Hz, 1 H), 6.33–6.24 (m, 1 H), 2.79 (t, J = 6.8 Hz, 2 H), 2.56–2.50 (m, 
2 H), 1.94–1.85 (m, 1 H), 1.83–1.74 (m, 1 H), 1.33 (s, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 153.8, 137.4, 133.2, 129.4, 128.5, 127.3, 127.2, 126.1, 125.2, 121.0, 
119.8, 117.3, 76.1, 43.4, 30.8, 24.6, 22.1.); IR (film, cm–1) 2929, 1581, 1453; 
MS(EI): 264.1512  (264.1514 calcd for C19H20O, M+). 
 
(±)-(E)-2-Methyl-2-(undec-2-en-1-yl)chroman (V-36). The coupling of 2-(3-
methylbut-3-en-1-yl)phenol (20 mg, 0.12 mmol) with (E)-1-bromodec-1-ene (30 
µL, 0.54 mmol) was conducted following General Procedure 4. This procedure 
afforded 37.0 mg (80%) of the title compound as an amber oil. 1H NMR (400 
MHz, CDCl3) δ 7.09–6.99 (m, 2 H), 6.81–6.73 (m, 2 H), 5.56–5.36 (m, 2 H), 2.76–
2.68 (m, 2 H), 2.37–2.25 (m, 2 H), 1.99 (p, J = 6.9 Hz, 2 H), 1.87–1.64 (m, 2 H), 
1.35–1.17 (m, 16 H), 0.85 (t, J = 6.6 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
153.9, 134.5, 133.0, 129.4, 127.2, 123.7, 121.1, 117.2, 76.0, 42.8, 37.3, 32.6, 
31.8, 30.6, 30.4, 29.4, 29.3, 27.4, 24.4, 22.6, 14.1; IR (film, cm–1) 2926, 1653, 
1456; MS(EI): 300.2453  (300.2453 calcd for C21H32O, M+). 
O Ph
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(±)-2-(3-Methylbenzyl)-2-phenylchroman (V-37). The coupling of 2-(3-
phenylbut-3-en-1-yl)phenol (25 mg, 0.11 mmol) with m-bromotoluene (24 µL, 
0.22 mmol) was conducted following General Procedure 4. This procedure 
afforded 35 mg (57%) of the title compound as an amber oil. 1H NMR (400 MHz, 
CDCl3) δ 7.31–7.23 (m, 4 H), 7.17–7.08 (m, 3 H), 7.04–6.98 (m, 2 H), 6.92–6.88 
(m, 3 H), 6.79 (dt, J = 1.2, 7.3 Hz, 1 H), 3.22 (d, J = 13.4 Hz, 1 H), 3.10 (d, J = 
13.4 Hz, 1 H), 2.63–2.56 (m, 1 H), 2.49–2.38 (m, 2 H), 2.28 (s, 3 H), 2.08-2.00 
(m, 1 H); 13C NMR (100 MHz, CDCl3) δ 154.1, 143.8, 137.0, 136.3, 131.8, 129.3, 
128.3, 128.1, 128.0, 127.5, 127.3, 127.0, 126.7, 125.8, 121.9, 120.0, 80.7, 50.0, 
29.6, 22.3, 21.4; IR (film, cm–1) 3058, 2927, 1237; MS(ESI): 315.1747 (315.1743 
calcd for C23H22O, M + H+). 
 
(±)-2-[4-(tert-Butyl)benzyl]-2-phenylchroman (V-38). The coupling of 2-(3-
phenylbut-3-en-1-yl)phenol (25 mg, 0.11 mmol) with 4-bromo-tert-butylbenzene 
(35 µL, 0.22 mmol) was conducted following General Procedure 4. This 
procedure afforded 24.3 mg (61%) of the title compound as an amber oil. 1H 
NMR (400 MHz, CDCl3) δ 7.31–7.17 (m, 7 H), 7.15–7.09 (m, 1 H), 7.07–7.01 (m, 
3 H), 6.89–6.85 (m, 1 H), 6.76 (dt, J = 1.2, 7.4 Hz, 1 H), 3.22 (d, J = 13.7 Hz, 1 
H), 3.06 (d, J = 13.7 Hz, 1 H), 2.60–2.51 (m, 1 H), 2.46–2.35 (m, 2 H), 2.04–1.95 
(m, 1 H), 1.29 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 154.1, 149.0, 144.0, 133.4, 
130.5, 129.3, 128.1, 127.2, 126.7, 125.7, 124.6, 121.8, 119.8, 117.0, 80.8, 49.6, 
34.3, 31.4, 29.3, 22.3; IR (film, cm–1) 2962, 1490, 1237; MS(ESI): 209.0963 
(209.0966 calcd for C26H28O, [M – C11H15]+). 
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(±)-(3aS*,9aR*)-3a-(Naphthalen-2-ylmethyl)-1,2,3,3a,9,9a-
hexahydrocyclopenta[b]chromene (V-39). The coupling of 2-[(2-
methylenecyclopentyl)methyl]phenol (25 mg, 0.13 mmol) with 2-
bromonaphthalene (55 mg, 0.26 mmol) was conducted following General 
Procedure 4. This procedure afforded 25.6 mg (61%) of the title compound as an 
orange oil. 1H NMR (400 MHz, CDCl3) δ 7.81–7.71 (m, 3 H), 7.61 (s, 1 H), 7.46–
7.39 (m, 2 H), 7.36–7.32 (m, 1 H), 7.15 (t, J = 7.6 Hz, 1 H), 7.10 (d, J = 7.0 Hz, 1 
H), 6.90–6.83 (m, 2 H), 3.18 (d, J = 13.7 Hz, 1 H), 3.04 (dd, J = 6.5, 17.0 Hz, 1 
H), 2.83 (d, J = 13.7 Hz, 1 H), 2.68 (d, J = 16.4 Hz, 1 H), 2.21–2.12 (m, 1 H), 
1.88–1.64 (m, 4 H), 1.62–1.42 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 153.3, 
135.6, 133.3, 132.2, 130.0, 128.9, 128.6, 127.6, 127.4, 127.3, 125.8, 125.3, 
120.2, 120.0, 117.5, 86.1, 69.0, 42.1, 39.9, 36.8, 29.0, 25.4, 20.4; IR (film, cm–1) 
2916, 1456, 1231; MS(EI): 314.1666 (314.1671 calcd for C23H22O,M+).  
 
(±)-(4aS*,9aR*)-4a-(4-Chlorobenzyl)-2,3,4,4a,9,9a-hexahydro-1H-xanthene 
(V-40). The coupling of 2-[(2-methylenecyclohexyl)methyl]phenol (20 mg, 0.10 
mmol) with 4-bromochlorobenzene (37.8 mg, 0.20 mmol) was conducted 
following General Procedure 4. This procedure afforded 23 mg (76%) of the title 
compound as an orange oil. 1H NMR (400 MHz, CDCl3) δ 7.22–7.19 (m, 2 H), 
7.14 (t, J = 7.4 Hz, 1 H), 7.07 (d, J = 7.6 Hz, 1 H), 7.04–6.99 (m, 2 H), 6.89–6.82 
(m, 2 H), 3.23 (dd, J = 6.3, 16.8 Hz, 1 H), 3.08 (d, J = 13.8 Hz, 1 H), 2.47 (d, J = 
O
V-39
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13.7 Hz, 1 H), 2.41 (d, J = 17.0 Hz, 1 H), 1.81–1.72 (m, 1 H), 1.68–1.59 (m, 3 H), 
1.51–1.41 (m, 2 H), 1.39–1.16 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 135.6, 
132.1, 131.9, 131.8, 130.1, 127.9, 127.4, 120.0, 117.3, 76.4, 42.6, 42.1, 36.0, 
34.6, 29.2, 28.6, 25.2, 21.2; IR (film, cm–1) 2920, 1456, 1247; MS(EI): 312.1281 
(312.1278 calcd for C20H21ClO, M+). 
 
(±)-(4aS*,9aR*)-4a-(4-Fluorobenzyl)-2,3,4,4a,9,9a-hexahydro-1H-xanthene 
(V-41). The coupling of 2-[(2-methylenecyclohexyl)methyl]phenol (20 mg, 0.10 
mmol) with 4-bromofluorobenzene (22 µL, 0.20 mmol) was conducted following 
General Procedure 4. This procedure afforded 21 mg (72%) of the title 
compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.14 (t, J = 7.6 Hz, 1 
H), 7.10–7.01 (m, 3 H), 6.96–6.90 (m, 2 H), 6.89–6.83 (m, 2 H), 3.24 (dd, J = 6.4, 
16.8 Hz, 1 H), 3.08 (d, J = 13.9 Hz, 1 H), 2.48 (d, J = 13.9 Hz, 1 H), 2.41 (d, J = 
16.8 Hz, 1 H), 1.81–1.73 (m,1 H), 1.68–1.60 (m, 2 H), 1.51–1.42 (m, 3 H), 1.39–
1.30 (m, 1 H), 1.30–1.19 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 162.8, 152.8, 
132.7, 131.9, 131.8 (q, J = 254.8 Hz), 129.7, 120.1, 119.9,117.3, 114.7 (q, J = 
21.0 Hz), 76.5, 42.4, 36.0, 34.6, 28.7, 25.8, 25.2, 21.2; IR (film, cm–1) 2952, 
1736, 1249; MS(EI): 296.1579 (296.1576 calcd for C20H21FO, M+).  
 
(±)-2-[4-(tert-Butyl)benzyl]-3-methylchroman (V-42). The coupling of 2-(2-
methylbut-3-en-1-yl)phenol (30 mg, 0.19 mmol) with 4-bromo-tert-butyl benzene 
(60 µL, 0.37 mmol) was conducted following General Procedure 4. This 
procedure afforded 0.036 mg (65%) of the title compound as an amber oil. 1H 
NMR (400 MHz, CDCl3) δ 7.37–7.31 (m, 6.60 H), 7.29–7.24 (m, 3.78 H), 7.23–
O
F
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7.19 (m, 1.43 H), 7.13–7.07 (m, 1.90 H), 7.06–7.01 (m, 2.33 H), 6.88–6.76 (m, 
4.10 H), 4.71 (d, J = 10.9 Hz, 0.10 H), 4.47 (t, J = 6.4 Hz, 0.55 H), 4.25 (dt, J = 
2.2, 8.2 Hz, 0.49 H), 4.18–4.14 (m, 0.63 H), 4.01 (dt, J = 4.3, 7.4 Hz, 1 H), 3.07–
2.98 (m, 1.75 H), 2.96–2.76 (m, 3.56 H), 2.53–2.41 (m, 2.43 H), 2.16–2.08 (m, 
0.57 H), 1.98–1.86 (m, 1.73 H), 1.36–1.27 (m, 27.84 H), 1.12–1.08 (m, 4.72 H), 
1.06 (d, J = 6.8 Hz, 1.52 H), 1.01–0.98 (m, 0.36 H).; 13C NMR (100 MHz, CDCl3) 
δ 154.0, 153.5, 149.1, 148.9, 139.3, 137.9, 135.2, 135.1, 130.1, 129.6, 129.4, 
129.3, 129.1, 128.9, 127.1, 127.0, 125.3, 125.2, 125.1, 121.5, 121.4, 121.1, 
120.2, 120.0, 119.9, 116.9, 116.6, 82.7, 81.2, 79.4, 51.7, 38.4, 37.1, 34.4, 34.3, 
32.9, 31.9, 31.4, 31.3, 31.1, 29.6, 28.2, 27.7, 18.3, 18.1, 13.1; IR (film, cm–1) 
2962, 1249; MS(EI): 294.1991 (294.1984 calcd for C21H26O, M+).  
 
(±)-2-Benzyl-2,3-dihydrobenzofuran (V-43). The coupling of 2-allylphenol (20 
mg, 0.15 mmol) with bromobenzene (0.31 µL, 0.30 mmol) was conducted 
following General Procedure 4. This procedure afforded 13.5 mg (43%) of the 
title compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.38–7.20 (m, 5 H), 
7.14–7.07 (m, 2 H), 6.84–6.75 (m, 2 H), 5.04–4.96 (m, 1 H), 3.24–3.14 (m, 2 H), 
2.98–2.89 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 137.4, 129.4, 128.5, 128.0, 
126.5, 125.0, 120.2, 109.4, 83.5, 41.9, 34.9, 2 signals missing due to incidental 
equivalence; IR (film, cm–1) 2920, 1653, 1456; MS(EI): 210.1049  (210.1045 
calcd for C15H14O, M+).  
 
Assignment of Stereochemistry 
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The relative stereochemistry of V-39 was assigned on the basis of signals 
observed in 1H NMR nOe experiments. Relevant nOe data is shown below.  
 
The relative stereochemistry of V-41 was assigned on the basis of signals 
observed in 1H NMR nOe experiments. Relevant nOe data is shown below. The 
stereochemistry of compound V-40 was assigned based on analogy to V-41. 
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Chapter 6: Synthesis of Benzoxepines via Palladium-
Catalyzed Carboetherification Reactions 
 
6.1 Introduction 
Benzoxepines are benzo-fused 7-membered ring heterocycles found in a 
variety of biologically active natural products such as randulanin A (VI-1) and 
heliannuol D (VI-2), which are illustrated in Figure 6-1.1,2 Thus, the synthesis of 
benzoxepines is an important objective for organic and medicinal chemists,3 and 
many methods have been applied for their synthesis, including Bayliss-Hilman 
reactions4, Pd-catalyzed reactions,5 and Grubb’s catalysis.6 Nevertheless, a 
concise method that can be used to rapidly synthesize a variety of different 
analogs would be a useful tool. For this purpose, we desired to apply our Pd-
catalyzed carboetherification methodology, which has been used for the 
synthesis of various oxygenated heterocycles such as tetrahydrofurans and 
benzopyrans, for the production of benzoxepines.7  However, palladium-
catalyzed carboetherification reactions have never been employed to produce 7-
membered rings. 
 
 
Figure 6.1. Biologically Active Benzoxepines 
6.2 Reaction Optimization 
To identify optimal conditions for the synthesis of benzoxepines via palladium-
catalyzed carboetherification reactions, substrate VI-3 was prepared in 4 steps 
O
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according to a literature procedure8 and was coupled to bromobenzene in the 
presence of a variety of different catalyst systems, including those based on 
bidentate and monodentate phosphine ligands, as shown in Table VI-1. A 
catalyst system composed of Pd2(dba)3/Ru-Phos gave the best results, and the 
desired product was obtained in 65% isolated yield (84% H-NMR yield). 
  
Table 6.1. Catalyst System Optimization 
6.3 Substrates Bearing 1,1-Disubstituted and Internal Alkenes  
With the optimized conditions in hand, we elected to examine the substrate 
scope of the reaction. To this end, compound VI-5, which possesses a 1,1-
disubstituted alkene, was synthesized according to a previously described 
procedure9 and subjected to the optimized reaction conditions.  Unfortunately, in 
the presence of several different catalyst systems, including the optimized 
catalyst, the desired product was not obtained (Table 6-2), and only various 
amounts of starting material or complex mixtures were observed. 
PhBr, NaOtBu
Pd2(dba)3, Ligand
OH
O
VI-3 VI-4
Ligand H-NMR Yield
Xantphos 0%
Dpe-Phos 0%
dppb 0%
BrettPhos 0%
S-Phos 65%
RuPhos 84%
a Conditions: 1.0 equiv of VI-3 2.0 equiv of PhBr, 2.0 equiv 
of NaOtBu, 2 mol % of Pd2(dba)3, 4 mol % of ligand, 
toluene, 110 °C.
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Table 6.2. Efforts Toward the Pd-Catalyzed Carboetherification of 1,1-
Disubstituted Alkene Substrates 
 In addition, compound VI-12, which possesses an internal alkene, was 
synthesized according to the method outlined in Scheme 6-1. Namely, the 
hydrazone of 2-methoxyacetophenone was produced, monoalkylated with (E)-1-
bromobut-2-ene and transformed to the corresponding ketone in 50% overall 
yield. Subsequently, the ketone was reduced to the alcohol, which was further 
reduced using ZnI2 and NaBH3CN. Lastly, the methoxy aryl ether was 
deprotected to the corresponding phenol to obtain VI-12 in 82% yield. Similar to 
the results obtained with VI-6, which contains a 1,1-disubstituted alkene, only 
starting material and decomposition were observed, as shown in Table 6-3. 
OH
O
VI-5 VI-6
Ligand Result
Xantphos complex mixture
Dpe-Phos complex mixture
dppb complex mixture
BrettPhos 50% SM
S-Phos 66% SM
RuPhos 68% SM
a Conditions: 1.0 equiv of VI-6, 2.0 equiv of PhBr, 2.0 equiv 
of NaOtBu, 2 mol % of Pd2(dba)3, 4 mol % of ligand, xylene, 
140 °C.
PMe3HBF4
NiXantphos
dppf
84% SM
decomposition
decomposition
PhBr, NaOtBu
Pd2(dba)3, Ligand
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Scheme 6-1. Synthesis of Substrate VI-12 
 
Table 6.3. Efforts Toward the Pd-Catalyzed Carboetherification of Substrates 
Bearing an Internal Alkene 
6.4 Synthesis of 2,3-, 2,4- and 2,5-Disubstituted Benzoxepines  
O
O
VI-7
H2N
N N
O
VI-8
N
1. nBuLi
2. Br
3. H3O+
O
O
VI-9
NaBH4
MeOH
OH
O
VI-10
O
VI-11
ZnI2
NaBH3CN
NaH
SH OH
VI-12
89%
56%
82%
47% 82%
OH
O
VI-12 VI-13
Ligand Result
Xantphos 88% SM
Dpe-Phos 64% SM
dppb 80% SM
BrettPhos 90% SM
S-Phos 82% SM
RuPhos 84% SM
a Conditions: 1.0 equiv of VI-12 2.0 equiv of PhBr, 2.0 
equiv of NaOtBu, 2 mol % of Pd2(dba)3, 4 mol % of ligand, 
xylene, 140 °C.
PMe3HBF4
NiXantphos
dppf
40% SM
decomposition
decomposition
PhBr, NaOtBu
Pd2(dba)3, Ligand
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To determine the diastereoselectivity of the reaction for the formation of 2,3-, 
2,4-, and 2,5-disubstituted benzoxepines, substrates bearing different 
substituents along the backbone were evaluated. For instance, to evaluate the 
synthesis of 2,3-disubstituted benzoxepines, VI-16 was prepared according to 
the route shown in Scheme 6-2, which is similar to that shown in Scheme 6-1. 
Upon subjection to the optimized reaction conditions, VI-17 was obtained as 1:1 
mixture of diastereomers in 72% yield. 
 
 
Scheme 6-2. Synthesis and Pd-Catalyzed Carboetherification Reaction of 
Substrate VI-16  
The formation of 2,4-disubstituted benzoxepines via Pd-catalyzed 
carboetherification was also evaluated. To this end, VI-23 was synthesized 
according to the route shown in Scheme 6-3. However, upon subjection to the 
optimized Pd-catalyzed carboetherification reaction conditions, decomposition 
occurred. 
O
O
VI-7
O
HOMg
Br
VI-1474%
ZnI2
NaBH3CN
NaH
SHO
VI-15
48%
OH
VI-16
80%
p-tBuPhBr
Pd2(dba)3, RuPhos O tBu
VI-1772%, 1:1 dr
NaOtBu
Toluene, 110oC
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Scheme 6-3. Synthesis and Attempted Pd-Catalyzed Carboetherification 
Reaction of Substrate VI-23 
Lastly, the formation of 2,5-disubstituted benzoxepines was assessed. VI-24 
was synthesized using a literature procedure,10 and was transformed into VI-25 
by applying the method shown in Scheme 6-4. Upon subjection to the optimized 
reaction conditions, decomposition was observed, and the desired product was 
not obtained. 
NN
O
O
O
O
OH
O
O
O TFA
H2N
N
1. nBuLi
Br
2. 3 M HCl
NaBH4
ZnI2
NaBH3CN
NaH
SH OH
VI-18 VI-19 VI-20
VI-21 VI-22 VI-23
88% 40%
52% 15% 54%
Pd2(dba)3
NaOtBu
RuPhos
PhBr
Decomposition
OH
VI-23
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Scheme 6-4. Synthesis and Attempted Pd-Catalyzed Carboetherification 
Reaction of Substrate VI-25 
 
6.5 Conclusions 
Although the synthesis of benzoxepines was achieved via palladium-catalyzed 
carboetherification reactions, the scope of the reaction was limited. For the 
synthesis of 2,3-disubstituted benzoxepines, the yield of the reaction was high 
but stereocontrol was poor. Moreover, benzoxepines with other substitution 
patterns  were not produced under the optimized reaction conditions; thus, novel 
catalyst systems must be developed in order to improve the diastereoselectivity 
of the reaction and to expand the substrate scope. Based on our previous results 
with benzopyrans11 and pyrrolidines12, phosphite and phosphoramidite ligands 
should be explored for the synthesis of benzoxepines via palladium-catalyzed 
carboetherification reactions. 
6.6 Experimental 
NN
O
O
O
O
OH
O
O
O TFA
H2N
N
1. nBuLi
Br
2. 3 M HCl
NaBH4
ZnI2
NaBH3CN
NaH
SH OH
VI-18 VI-19 VI-20
VI-21 VI-22 VI-23
88% 40%
52%
15% 54%
Decomposition
OH
VI-23
p-tBuPhBr
Pd2(dba)3, RuPhos
NaOtBu
Toluene, 110oC
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All reactions were carried out under a nitrogen atmosphere in oven or flame 
dried glassware. Tris(dibenzylideneacetone)dipalladium (0) and all phosphine 
ligands were purchased from Strem Chemical Co. and used without further 
purification. All aryl bromides were obtained from commercial sources (Aldrich 
Chemical Co. or Acros Chemical Co.) and were used as obtained. Toluene and 
THF were purified using a GlassContour solvent purification system. Yields refer 
to isolated yields of compounds estimated to be ≥95% pure as determined by 1H 
NMR.  
 
General Procedure 1: Alkylation of hydrazones.13  An oven-dried flask 
equipped with a magnetic stirbar was cooled under a stream of nitrogen and 
charged with the appropriate hydrazone (1 equiv) and THF (1 M). The resulting 
solution was cooled to 0 °C and a solution of n-BuLi (1 equiv, 1.6 M in hexanes) 
was added dropwise. The reaction mixture was stirred at 0 °C for 1 hr, then the 
alkyl halide (1 equiv) was added dropwise as a 1 M solution in THF, and the 
reaction mixture was warmed to rt. The mixture was stirred at rt until GC analysis 
indicated that the starting materials were fully consumed, then 1 M HCl was 
added (10 mL), and the reaction was stirred for 4 hr at rt. Brine (5 mL) and EtOAc 
(5 mL) were added, and the mixture was transferred to a separatory funnel. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 20 
mL). The combined organic layers were dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel. 
General Procedure 2: Reduction of Ketones14 A round bottom flask 
equipped with a magnetic stirbar and a rubber septum was cooled under a 
stream of nitrogen and charged with the ketone substrate (1 equiv) and methanol 
(1 M). The reaction mixture was cooled to 0 oC and a 1 M solution of NaBH4 in 1 
M NaOH (1.0 equiv) was added dropwise. The resulting mixture was stirred at rt 
until the starting material had been completely consumed as judged by tlc 
analysis. A sat’d solution of NaCl (5 mL) and EtOAc (5 mL) were added. The 
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mixture was transferred to a separatory funnel and the layers were separated. 
The aqueous layer was extracted with EtOAc (2 x 20 mL), and the combined 
organic layers were dried over anhydrous MgSO4, filtered, and concentrated in 
vacuo. The crude material was purified by flash chromatography on silica gel. 
General Procedure 3: Removal of Alcohol Group15 A round bottom flask 
equipped with a magnetic stirbar and a rubber septum was cooled under a 
stream of nitrogen and charged with the alcohol substrate (1 equiv) and 
dichloroethane (0.25 M). Next, ZnI2 was added (1.5 equiv), followed by NaBH3CN 
(7.0 equiv). The resulting mixture was stirred at rt until the starting material had 
been completely consumed as judged by tlc analysis. The reaction mixture was 
filtered through celite, and a sat’d solution of NH4Cl (5 mL) and EtOAc (5 mL) 
were added to the filtrate. The mixture was transferred to a separatory funnel and 
the layers were separated. The aqueous layer was extracted with EtOAc (2 x 20 
mL), and the combined organic layers were dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo. The crude material was purified by flash 
chromatography on silica gel. 
General Procedure 4: Removal of Aryl(methyl)ether Protecting Group A 
flame-dried round-bottomed flask equipped with a magnetic stirbar, reflux 
condenser and a rubber septum was cooled under a stream of nitrogen and 
charged with NaH (4 equiv) and DMF (2 M). The reaction mixture was cooled to 
0 oC and a 2 M solution of ethanethiol (2.6 equiv) in DMF was added dropwise. 
The resulting mixture was stirred at rt for 30 min, then the methyl ether substrate 
(1 equiv) was added and the reaction mixture was heated to 160 oC until the 
starting material had been completely consumed as judged by tlc analysis. The 
reaction mixture was then cooled to rt and 1 M HCl (5 mL) and EtOAc (5 mL) 
were added. The mixture was transferred to a separatory funnel and the layers 
were separated. The aqueous layer was extracted with EtOAc (2 x 20 mL), and 
the combined organic layers were dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The crude material was purified by flash chromatography 
on silica gel.  
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(E)-1-(2-methoxyphenyl)hex-4-en-1-one (VI-9). General Procedure 1 was 
used for the conversion of (E)-2-(1-(2-methoxyphenyl)ethylidene)-1,1-
dimethylhydrazine16 (5.0 g, 26.0 mmol) to the title compound. This procedure 
afforded 3.0 g (56%) of the title compound as a clear oil. 1H NMR (400 MHz, 
CDCl3) δ 7.66 (dd, J = 1.7, 7.6 Hz, 1 H), 7.46–7.41 (m, 1 H), 7.01–6.93 (m, 2 H), 
5.49–5.46 (m, 2 H), 3.89 (s, 3 H), 3.02 (t, J = 7.3 Hz, 2 H), 2.39–2.34 (m, 2 H), 
1.66–1.63 (m, 3 H); 13C NMR (100 MHz, CDCl3) δ 202.3, 158.4, 133.3, 133.2, 
130.2, 130.1, 125.4, 120.6, 111.5, 55.4, 43.6, 27.4, 17.9; IR (film, cm–1) 2961, 
1684; MS(ESI): 227.1045 (227.1043 calcd for C13H16O2, M+Na+).  
 
 
(E)-1-(2-methoxyphenyl)hex-4-en-1-ol (VI-10). General Procedure 2 was 
used for the conversion of (E)-1-(2-methoxyphenyl)hex-4-en-1-one (2.68 g, 13.1 
mmol) to the title compound. This procedure afforded 2.21 g (81%) of the title 
compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.34–7.30 (m, 1 H), 7.28–
7.23 (m, 1 H), 6.97 (dt, J = 1.0, 7.6 Hz, 1 H), 6.91–6.87 (m, 1 H), 5.50–5.47 (m, 2 
H), 4.88 (t, J = 6.3 Hz, 1 H), 3.86 (s, 3 H), 2.74 (s, 1 H), 2.21–2.13 (m, 1 H), 
2.11–2.03 (m, 1 H), 1.92–1.78 (m, 2 H), 1.69–1.66 (m, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 156.6, 132.5, 131.0, 128.2, 127.0, 125.1, 120.7, 110.5, 70.5, 55.2, 37.1, 
29.1, 18.0; IR 3403, 2917, 1456 (film, cm–1); MS(ESI): 229.1209 (229.1199 calcd 
for C13H18O2, M+Na+). 
O
O
VI-9
OH
O
VI-10
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(E)-1-(hex-4-en-1-yl)-2-methoxybenzene (VI-11). General Procedure 3 was 
used for the conversion of (E)-1-(2-methoxyphenyl)hex-4-en-1-ol (2.09 g, 10.1 
mmol) to the title compound. This procedure afforded 0.91 g (47%) of the title 
compound as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.28–7.20 (m, 2 H), 6.97 
(t, J = 9.3 Hz, 1 H), 6.92 (d, J = 10.0 Hz, 1 H), 5.58–5.53 (m, 2 H), 3.89 (s, 3 H), 
2.72 (t, J = 9.5 Hz, 2 H), 2.20–2.10 (m, 2 H), 1.79–1.73 (m, 4 H), 1.45–1.36 (m, 1 
H); 13C NMR (100 MHz, CDCl3) δ 157.5, 131.5, 131.1, 129.9, 126.9, 124.8, 
120.4, 110.2, 55.2, 32.6, 29.8, 29.7, 18.0; IR 2920, 1652, 1456 (film, cm–1); 
MS(EI): 191.1357 (191.1358 calcd for C13H18O2, M+). 
 
(E)-2-(hex-4-en-1-yl)phenol (VI-12). General Procedure 3 was used for the 
conversion of (E)-1-(hex-4-en-1-yl)-2-methoxybenzene (0.91 g, 4.7 mmol) to the 
title compound. This procedure afforded 0.69 g (82%) of the title compound as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 7.12–7.03 (m, 2 H), 6.85 (dt, J = 1.0, 7.4 
Hz, 1 H), 6.74 (d, J = 7.8 Hz, 1 H), 5.47–5.43 (m, 2 H), 4.63 (s, 1 H), 2.58 (t, J = 
7.4 Hz, 3 H), 2.07–2.00 (m, 2 H), 1.70–1.62 (m, 4 H); 13C NMR (100 MHz, CDCl3) 
δ 157.5, 131.5, 129.9, 126.9, 124.9, 120.4, 110.2, 55.2, 32.6, 29.9, 29.8, 18.0; IR 
(film, cm–1) 3405, 1652, 1456; MS(EI): 176.1202 (176.1201 calcd for C12H16O, 
M+). 
 
O
VI-11
OH
VI-12
O
HO
VI-14
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2-(2-methoxyphenyl)hex-5-en-2-ol (VI-14). To a suspension of Mg (1.48 g) in 
ether (50 mL) at 0 oC, 4-bromobut-1-ene (5.0 mL) was added. The reaction 
mixture was raised to RT and stirred for 30 min. Upon completion, the solution 
was transferred to a round bottom flask charged with a stir bar and a septum and 
was cooled to 0 oC. A solution of 1-(2-methoxyphenyl)ethanone (6.19 g) in ether 
(50 mL) was added dropwise and the reaction mixture was raised to RT and 
stirred until the starting material was consumed, as judged by TLC analysis. A 1 
M solution of HCl (10 mL) and EtOAc (10 mL) were added. The mixture was 
transferred to a separatory funnel and the layers were separated. The aqueous 
layer was extracted with EtOAc (2 x 20 mL), and the combined organic layers 
were dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The 
crude material was purified by flash chromatography on silica gel. This procedure 
afforded 5.82 g (74%) of the title compound as a clear oil. 1H NMR (400 MHz, 
CDCl3) δ 7.28 (dd, J = 2.1, 9.5 Hz, 1 H), 7.25–7.19 (m, 1 H), 7.00–6.88 (m, 2 H), 
5.84–5.73 (m, 1 H), 4.98–4.82 (m, 2 H), 3.88 (s, 3 H), 2.59 (s, 3 H), 2.10–1.88 
(m, 4 H), 1.57 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 156.8, 139.1, 133.6, 128.1, 
126.7, 120.9, 114.0, 111.3, 75.0, 55.4, 55.3, 41.2, 31.8, 28.9, 27.4; IR (film, cm–
1); 3519, 2841, 1672. MS(EI): 206.1305 (206.1307 calcd for C13H18O2, M+). 
 
1-(hex-5-en-2-yl)-2-methoxybenzene (VI-15). General Procedure 3 was used 
for the conversion of 2-(2-methoxyphenyl)hex-5-en-2-ol (2.0 g, 30.2 mmol) to the 
title compound. This procedure afforded 0.88 g (48%) of the title compound as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ; 7.29-7.22 (m, 2 H), 7.04-6.97 (m, 1 H), 
6.95-6.91 (m, 1 H), 5.96-5.86 (m, 1 H), 5.10-4.99 (m, 2 H), 3.89 (s, 3 H), 3.37-
3.29 (m, 1 H), 2.18-2.02 (m, 2 H), 1.87-1.78 (m, 1 H), 1.76-1.66 (m, 1 H), 1.31 (d, 
J = 7.0 Hz, 3 H). 13C NMR (100 MHz, CDCl3) 157.1, 139.2, 128.9, 126.8, 120.6, 
O
VI-15
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120.5, 114.1, 110.5, 55.3, 36.4, 32.0, 31.6, 22.0, 20.9.IR (film, cm–1) 2959, 1492; 
MS(EI): 190.2864 (190.1353 calcd for C13H18O, M+). 
 
2-(hex-5-en-2-yl)phenol (VI-16). General Procedure 4 was used for the 
conversion of 1-(hex-5-en-2-yl)-2-methoxybenzene (0.77 g, 4.1 mmol) to the title 
compound. This procedure afforded 0.62 g (87%) of the title compound as a 
clear oil. 1H NMR (400 MHz, CDCl3) δ 7.23 (dd, J = 6.1, 7.8 Hz, 1 H), 7.15–7.10 
(m, 1 H), 6.98 (dt, J = 1.0, 7.3 Hz, 1 H), 6.80 (dd, J = 1.2, 8.0 Hz, 1 H), 5.94–5.84 
(m, 1 H), 5.13 (s, 1 H), 5.10–4.99 (m, 2 H), 3.17 (sextet, J = 7.1 Hz, 1 H), 2.13–
2.03 (m, 2 H), 1.87–1.79 (m, 1 H), 1.77–1.69 (m, 1 H), 1.32 (d, J = 6.8 Hz, 3 H).; 
13C NMR (100 MHz, CDCl3) δ 153.0, 139.1, 133.2, 127.2, 126.7, 121.0, 115.5, 
114.5, 36.3, 31.8, 31.7, 20.9. IR (film, cm–1) 3423, 2919, 1456; MS(EI): 176.1195 
(176.1201 calcd for C12H16O, M+). 
 
2-(1-(2-methoxyphenyl)propylidene)-1,1-dimethylhydrazine (VI-19). To a 
round bottom flask equipped with a magnetic stirbar, Dean-Stark trap, reflux 
condenser and a rubber septum, 1-(2-methoxyphenyl)propan-1-one (2.86 g, 17.4 
mmol, 1 equiv),17 trifluoroacetic acid (0.1 mL, 0.87 mmol, 0.05 equiv), 1,1-
dimethylhydrazine (1.25 mL, 20.8 mmol, 1.2 equiv) and benzene (24.8 mL) was 
added. The reaction was heated to reflux until the starting material had been 
completely consumed as judged by tlc analysis. Upon completion, the reaction 
mixture was concentrated in vacuo and used without further purification. This 
OH
VI-16
NN
O
VI-19
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procedure afforded 3.59 g (88%) of the title compound as a 1:1 mixture of E:Z 
isomers. 1H NMR (400 MHz, CDCl3) δ 7.34–7.27 (m, 2 H), 7.23 (dd, J = 1.8, 7.4 
Hz, 1 H), 7.05 (dd, J = 1.7, 7.4 Hz, 1 H), 7.00–6.91 (m, 3 H), 6.87 (d, J =8.2 Hz, 1 
H), 3.82 (s, 3 H), 3.80 (s, 3 H), 2.90–2.81 (m, 2 H), 2.60 (s, 6 H), 2.51 (q, J = 7.6 
Hz, 2 H), 2.43 (s, 6 H), 1.01 (t, J = 7.4 Hz, 3 H), 0.90 (t, J = 7.4 Hz, 3 H).; 13C 
NMR (100 MHz, CDCl3) δ 168.6, 154.4, 152.6, 127.5, 127.4, 127.1, 126.7, 125.4, 
125.3, 118.1, 117.9, 117.8, 108.2, 108.1, 52.8, 52.7, 45.0, 44.4, 29.0, 21.5, 8.6, 
8.5. IR (film, cm–1) 2954, 1678, 1496; MS(EI): 207.1492 (207.1492 calcd for 
C12H18N2O, M+). 
 
1-(2-methoxyphenyl)-2-methylpent-4-en-1-one (VI-20). General Procedure 1 
was used for the conversion of 2-(1-(2-methoxyphenyl)propylidene)-1,1-
dimethylhydrazine (2.0 g, 12.2 mmol) to the title compound. This procedure 
afforded 0.79 g (40%) of the title compound as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.53 (dd, J = 5.9, 7.6 Hz, 1 H), 7.46–7.41 (m, 1 H), 7.02–6.89 (m, 2 H), 
5.82–5.71 (m, 1 H), 5.06–4.96 (m, 2 H), 3.88 (s, 3 H), 2.56–2.48 (m, 1 H), 2.16–
2.07 (m, 1 H), 2.05–1.94 (m, 1 H), 1.11 (d, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 206.9, 157.8, 136.4, 132.8, 130.2, 120.7, 116.3, 111.3, 55.5, 55.4, 45.0, 
37.5, 16.0. IR (film, cm–1) 2916, 1676, 1459; MS(EI): 204.1149 (204.1150 calcd 
for C13H16O2, M+). 
 
O
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1-(2-methoxyphenyl)-2-methylpent-4-en-1-ol (VI-21). General Procedure 2 
was used for the conversion of 1-(2-methoxyphenyl)-2-methylpent-4-en-1-one 
(0.7 g, 3.5 mmol) to the title compound. This procedure afforded 0.37 g (52%) of 
the title compound as a 1:1 mixture of diastereomers (data are for both 
compounds). 1H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 1.5, 7.4 Hz, 1 H), 7.27–
7.23 (m, 2 H), 7.23–7.21 (m, 1 H), 6.98–6.92 (m, 2 H), 6.90–6.85 (m, 2 H), 5.90–
5.73 (m, 2 H), 5.10–4.97 (m, 4 H), 4.75 (t, J = 6.0 Hz, 1 H), 4.56 (t, J = 7.4 Hz, 1 
H), 3.84 (s, 3 H), 3.83 (s, 3 H), 2.65 (d, J = 7.2 Hz, 1 H), 2.57–2.50 (m, 1 H), 2.43 
(d, J = 6.4 Hz, 1 H), 2.17–2.09 (m, 1 H), 2.04–1.96 (m, 3 H), 1.95–1.86 (m, 1 H), 
0.94 (d, J = 6.6 Hz, 3 H), 0.73 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
156.7, 156.4, 137.6, 137.5, 131.5, 131.2, 128.4, 128.2, 128.1, 120.6, 120.5, 
115.9, 115.8, 110.6, 110.4, 75.9, 55.2, 38.9, 38.5, 38.3, 37.9, 31.6, 22.7, 16.1, 
14.4, 14.1. IR (film, cm–1) 3437, 1490; MS(EI): 206.1308 (206.1307 calcd for 
C13H18O2, M+). 
 
1-methoxy-2-(2-methylpent-4-en-1-yl)benzene (VI-22). General Procedure 3 
was used for the conversion of 1-(2-methoxyphenyl)-2-methylpent-4-en-1-ol 
(0.35 g, 1.7 mmol) to the title compound. This procedure afforded 0.05 g (15%) of 
the title compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.18 (t, J = 7.4 
Hz, 1 H), 7.09 (d, J = 7.0 Hz, 1 H), 6.91–6.82 (m, 2 H), 5.90–5.76 (m, 1 H), 5.06–
4.96 (m, 2 H), 3.80 (s, 3 H), 2.66 (dd, J = 5.9, 13.2 Hz, 1 H), 2.40 (dd, J = 7.8, 
13.2 Hz, 1 H), 2.17–2.08 (m, 1 H), 1.98–1.83 (m, 2 H), 0.85 (d, J = 6.2 Hz, 3 H). 
13C NMR (100 MHz, CDCl3) δ 159.1, 137.7, 130.9, 129.8, 126.9, 120.1, 115.5, 
110.2, 55.2, 41.2, 37.3, 33.3, 19.3. IR (film, cm–1) 2965, 1490; MS(EI): 190.1360 
(190.1358 calcd for C13H18O, M+). 
O
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2-(2-methylpent-4-en-1-yl)phenol (VI-23). General Procedure 4 was used for 
the conversion of 1-methoxy-2-(2-methylpent-4-en-1-yl)benzene (0.04 g, 0.2 
mmol) to the title compound. This procedure afforded 0.02 g (54%) of the title 
compound as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.11–7.04 (m, 2 H), 
6.87–6.82 (m, 1 H), 6.76–6.71 (m, 1 H), 5.88–5.76 (m, 1 H), 5.07–4.99 (m, 2 H), 
4.58 (s, 1 H), 2.64 (dd, J = 5.9, 13.7 Hz, 1 H), 2.40–2.33 (m, 1 H), 2.17–2.07 (m, 
1 H), 1.99–1.81 (m, 2 H), 0.88 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 
153.6, 137.4, 131.3, 127.2, 120.6, 116.1, 115.3, 41.1, 36.9, 33.5, 19.4, one peak 
missing due to incidental equivalence. IR (film, cm–1) 3400, 2917, 1616; MS(EI): 
176.1200 (176.1201 calcd for C12H16O, M+). 
 
2-(3-methylpent-4-en-1-yl)phenol (VI-26). General Procedure 3 and 4 was 
used for the conversion of 1-methoxy-2-(3-methylpent-4-en-1-yl)benzene (1.98 g, 
9.5 mmol) to the title compound. This procedure afforded 0.24 g (28%) of the title 
compound as a orange oil. 1H NMR (400 MHz, CDCl3) δ 7.11–7.04 (m, 2 H), 
6.87–6.82 (m, 1 H), 6.76–6.71 (m, 1 H), 5.88–5.76 (m, 1 H), 5.07–4.99 (m, 2 H), 
4.58 (s, 1 H), 2.64 (dd, J = 5.9, 13.7 Hz, 1 H), 2.40–2.33 (m, 1 H), 2.17–2.07 (m, 
1 H), 1.99–1.81 (m, 2 H), 0.88 (d, J = 6.4 Hz, 3 H; 13C NMR (100 MHz, CDCl3) δ 
153.6, 137.4, 131.3, 127.2, 120.6, 116.1, 115.3, 41.1, 36.9, 33.5, 19.4, one peak 
missing due to incidental equivalence. IR (film, cm–1) 3423, 2919, 1456; MS(EI): 
176.1200 (176.1201 calcd for C12H16O, M+). 
Synthesis of Benzoxepines via Pd-Catalyzed Alkene Carboetherification 
OH
VI-23
OH
VI-26
  
181 
General Procedure 5: Palladium-Catalyzed Carboetherification Reactions. 
An oven or flame-dried Schlenk tube was cooled under a stream of nitrogen and 
charged with Pd2(dba)3 (2 mol% complex, 4 mol % Pd), Ru-Phos (4 mol %), 
NaOtBu (2.0 equiv), and the aryl bromide (2.0 equiv). The tube was purged with 
nitrogen and the alcohol substrate (1.0 equiv), and toluene (0.25 M substrate 
concentration) were added. The mixture was heated to 110 °C with stirring until 
the starting material had been consumed as judged by GC or 1H NMR analysis. 
The mixture was cooled to room temperature, quenched with saturated aqueous 
NH4Cl (2 mL), and diluted with ethyl acetate (10 mL). The layers were separated 
and the aqueous layer was extracted with ethyl acetate (3 X 10 mL). The 
combined organic layers were dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was then purified by flash 
chromatography on silica gel.  
 
 
2-benzyl-2,3,4,5-tetrahydrobenzo[b]oxepine (VI-4). The coupling of 2-(pent-
4-en-1-yl)phenol (20 mg, 0.12 mmol) with bromobenzene (30 µL, 0.24 mmol) was 
conducted following General Procedure 5. This procedure afforded 20 mg (70%) 
of the title compound as an amber oil. 1H NMR (400 MHz, CDCl3) δ 7.37–7.29 
(m, 4 H), 7.28–7.23 (m, 1 H), 7.11–7.08 (m, 1 H), 7.03 (dt, J =1.9, 7.6 Hz, 1 H), 
6.94 (dt, J = 5.9, 6.1 Hz, 1 H), 6.61 (dd, J = 1.2, 7.8 Hz, 1 H), 3.82–3.76 (m, 1 H), 
3.08 (dd, J = 8.3, 13.7 Hz, 1 H), 2.93 (t, J = 13.1 Hz, 1 H), 2.86 (dd, J = 5.1, 13.9 
Hz, 1 H), 2.74–2.68 (m, 1 H), 2.05–1.98 (m, 2 H), 1.92–1.81 (m, 1 H), 1.54–1.45 
(m, 1 H); 13C NMR (100 MHz, CDCl3) δ 159.3, 139.1, 136.0, 130.0, 129.5, 128.2, 
127.2, 126.2, 123.4, 121.3, 84.3, 43.6, 37.1, 33.7, 26.0.; MS(EI): 238.1361 
(238.1358 calcd for C17H18O, M+). 
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2-(4-(tert-butyl)benzyl)-5-methyl-2,3,4,5-tetrahydrobenzo[b]oxepine (VI-
17). The coupling of 2-(hex-5-en-2-yl)phenol (20 mg, 0.12 mmol) with 4-bromo-
tert-butylbenzene (34 µL, 0.24 mmol) was conducted following General 
Procedure 5. This procedure afforded 25 mg (72%) of the title compound as a 
1:1 mixture of diastereomers (data are for both isomers). 1H NMR (400 MHz, 
CDCl3) δ 7.35-7.31 (m, 2 H), 7.22-7.18 (m, 2 H), 7.17-7.12 (m, 1 H), 7.04-6.98 
(m, 2 H), 6.67-6.61 (m, 1 H), 3.83-3.69 (m, 1 H), 3.16-2.99 (m, 2 H), 2.83-2.76 
(m, 1 H), 1.96-1.72 (m, 2 H), 1.33-1.32 (m, 12 H); 13C NMR (100 MHz, CDCl3) δ 
139.8, 135.8, 129.1, 127.2, 126.9, 126.8, 126.0, 125.0, 123.6, 122.2, 121.5, 84.5, 
83.7, 78.3, 77.3, 76.7, 76.6, 43.1, 42.8, 38.7, 35.9, 34.7, 34.4, 33.9, 31.9, 31.6, 
31.4, 31.2, 20.3, 18.7, 2 peaks missing due to incidental equivalence; IR (film, 
cm–1) 2961, 1485; MS(EI): 308.2103 (308.2140 calcd for C22H18O, M+). 
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